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Abstract 
Diarrhoeal diseases remain the second most common cause of death among children 
under-five globally, following closely behind pneumonia. In developing countries, 
rotavirus and Shigella spp. are thought to be the most important enteropathogens 
causing acute childhood diarrhoea. Systematic data on diarrhoea) diseases, particularly 
Shigella infection, in southern Viet Nam is lacking. An analysis of the historical trends 
in epidemiology, antibiotic susceptibility, and clinical features of Shigella infection and 
contemporary clinical studies of the response to antibiotic treatment in Vietnamese 
children were the central aims of this thesis. 
By analysing Shigella strains isolated from children between 1995 and 2009 I 
documented a transition in the dominant Shigella species causing diarrhoea from 
S. flexneri to S. sonnei, a change previously linked with industrialisation and economic 
development. During the same period there was a sharp increase of nalidixic acid 
resistant Shigella strains from approximately 7% to 70%. In addition, the clinical 
presentation appeared to be more severe and the duration of hospital stays longer. 
During the course of this thesis I also documented for the first time in Viet Nam 
Shigella spp. which harboured the plasmid-transferable drug resistance blaCTX-M 
genes. The occurrence of this plasmid-transferable gene may endanger the use of beta- 
lactams for this infection in the future. In a large randomised controlled trial, 
gatifloxacin, a new 8-methoxy-fluoroquinolone antibiotic proved comparable to 
ciprofloxacin for the treatment of acute dysentery including those caused by multi- 
resistant Shigella. Although gatifloxacin has been associated with dysglycaemic side- 
effects in adults, this adverse effect was not observed in this study. 
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Chapter One: Introduction 
Chapter One 
Introduction 
1.1 Introduction: 
Diarrhoea) diseases are a major public health problem and the second leading cause of 
death in children under five years old (UNICEF/WHO 2009). According to the World 
Health Organization estimations, each year there are approximately two billion cases of 
diarrhoea) disease worldwide leading to 1.5 millions children deaths in the year 2004, in 
which 80% are under two years old (http: //www. who. int/media 
centre/factsheets/fs330/en/print. html accessed July 10,2010). A wide range of pathogens 
including viruses, bacteria, and parasites can cause diarrhoea. However, only a handful of 
organisms are responsible for most cases of acute diarrhoea. Rotavirus is the leading cause 
of acute diarrhoea both in developed and developing countries, and is responsible for about 
40% of all hospital admissions due to diarrhoea among children under five worldwide 
(Weekly Epidemiological Report, vol. 83, no. 47,21 Nov. 2008). Parasites only contribute 
a relatively small part in the aetiology of acute diarrhoea, of which Cryptosporidium is 
most frequently isolated in stools of children with diarrhoea seen at health facilities, 
particularly among HIV-positive children. 
Bacterial pathogens (including Shigella, enteropathogenic E. coli, Campylobacter and 
Salmonella) are the second most important group of pathogens causing acute diarrhoea. Of 
these Shigella spp. is the most frequently bacterial agent isolated from children treated at 
hospital with acute diarrhoea (Hien et al. 2008). A recent review by The World Health 
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Organisation experts estimated that the annual number of Shigella episodes and deaths in 
Asia to be 91 million and 414000 respectively (WHO 2005b). 
Although distributed throughout the world, the prevalence of Shigella infection differs 
from between countries and within countries. It is estimated that the annual incidence rate 
(IR) of shigellosis (cases per 100,000 per year) is 6.5 in the United States, 3.3 in the United 
Kingdom, 5.6 in Australia, 1.8 in France, and 130 in Israel (Kotloff et al. 1999). In Viet 
Nam, between the year 1991 and 2001 the mean annual incidence rate of shigellosis was 
estimated to be 70/100.000 population, much higher than that of typhoid fever (mean IR 
23/100.000 population) and cholera (mean IR 2.7/100.000 population) during the same 
period (Kelly-Hope et al. 2007). 
Shigella infection manifests a wide range of clinical features from mild watery diarrhoea to 
dysentery with mucoid bloody stools accompanied by tenesmus. In some cases severe 
complications such as toxic megacolon, hyperleukocytosis, and haemolytic-uremic 
syndrome may lead to death. In addition, shigellosis is a protein-losing enteropathy which 
may promote malnutrition in children if left untreated. 
The treatment of shigellosis includes using antibiotics, rehydration and nutrition. The use 
of antibiotics to treat shigellosis is increasingly complicated because of the spread of 
develop resistant Shigellae. Despite the long history since the discovery the causative 
agent, the development of a vaccine against shigellosis remains elusive because the 
immunity to Shigella infection is serogroup- and serotype-specific. 
2 
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1.2 The agent: 
Dysentery has been a well-characterized syndrome since antiquity. However the causative 
agent was only discovered in the year 1897 by Kiyoshi Shiga, a Japanese microbiologist, 
for whom the organism was ultimately named (Trofa et al. 1999). The original organism 
described by Dr. Shiga is now known as S. dysenteriae type 1. Over the 4 decades 
following Shiga's original description, three additional Shigella species were described. 
Organisms of the genus Shigella belong to the Enterobacteriaceae family. They are Gram 
negative rod-shaped, non-motile and non-lactose fermenting bacilli (Figure 1.1). 
1.2.1 Shigella serogroups: 
All four species (or sero-groups or subgroup) of the genus Shigella can cause illness in 
human and non-human primates. These are: Subgroup A; Shigella dysenteriae 
(S. dysenteriae) with 15 serotypes in which serotype 1 is the most virulent, 
Subgroup B; S. flexneri contains 6 serotypes, with many subtypes in each serotype, 
Subgroup C: S. boydii with 20 serotypes. Subgroup D: S. sonnei has a single serotype 
(WHO 2005a). 
Serotyping is based on the 0 antigen component of lipo-polysaccharide present on the 
outer membrane of the cell wall. In clinical practice there are a small percentage of 
Shigella strains which cannot be typed by commercial antisera, but may be identified later 
on as new serotypes or subtypes using highly specific monoclonal antisera prepared by 
research laboratories or by molecular techniques. 
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Figure 1.1 Image of a pure culture of Shigella spp. in Gram stain. 
1.2.2 Genetic origin of Shigella: 
The whole genome of all four species of the genus Shigella have been sequenced (Yang et 
al. 2005). Through comparative genomics, the sequence divergence between S.. lexneri and 
E. coli K-12 is approximately 1.5% while between S. flexneri and Salmonella enterica is 
approximately 15%. Comparative genomics indicated that Shigella and Enteroinvasive 
E. coli (EIEC) evolved from multiple E. coli strains by convergent evolution (Lan and 
Reeves 2002). The Shigella bacteria have evolved from commensal E. coli to exhibit a 
pathogenic phenotype by the acquisition of a virulence plasmid and chromosomal 
pathogenicity islands as well as through the loss of other gene loci which are not functional 
intracellularly or impede virulence by genomic compensatory mechanism (Schroeder and 
Hilbi 2008) (Figure 1.2). 
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Figure 1.2 Evolution of Shigella spp. from non-invasive E. co1i ancestors: acquisition of a 
large virulence plasmid and chromosomal pathogenicity islands plus loss of genetic foci, 
which are not functional intracellularly or impede virulence. (Reproduced from Schroeder 
and Hilbi 2008) 
1.3 Epidemiology: 
1.3.1 Disease burden: 
The global burden of Shigella infection has been estimated by analyzing published data 
between 1966 to 1997, and gave estimates of 164.7 million of episodes of Shigella 
infection annually worldwide, of which 163.2 million were in developing countries (with 
1.1 million deaths) and 1.5 million in industrialized countries. A total of 69% of all 
episodes and 61% of all deaths attributable to shigellosis involved children 5 years of age 
or younger (Kotloff et al. 1999). The figures from Kotloff et al's review may not reflect the 
current situation because they have been based upon retrospective studies of relatively old 
data. A newer analysis was based on more recent data of Shigella infection studies in low- 
and medium-Human Development Index (HDI) countries published between 1984 to 2005 
(Ram et al. 2008). From this analysis, the annual incidence varied from 0-6/1000 person- 
year in Thailand to 107/1000 person-years in Egypt. However, because of the large gaps 
in data on the burden of Shigella infections for low human development index countries 
and, more specifically, for sub-Saharan Africa, the estimation may still not reflect the true 
global prevalence of the disease (Ram et al. 2008). 
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A passive surveillance community-based study in six Asian countries has been recently 
completed (von Seidlein et al. 2006). Patients of all ages presenting with diarrhoea or 
dysentery at a participating health care centre or health provider were enrolled in the study. 
Clinical history and physical findings were recorded. Stools were culture for Shigella. The 
results showed that Shigella was the causative agent of 5% of 56,958 diarrhoea episodes 
detected between 2000 and 2004 in the region; the overall incidence of treated shigellosis 
was 2.1 episodes per 1,000 residents per year in all ages and 13.2/1,000/y (equal to 0.013 
episodes of shigellosis per child-year) in children under 60 months old (von Seidlein et al. 
2006). The researchers of this study also used real-time polymerase chain reaction (PCR), 
to amplify the gene encoding the invasion plasmid antigen H (ipaH), which they contend is 
a more sensitive diagnostic technique than classical culture method. PCR detected ipaH in 
33% of a sample of culture-negative stool specimens, suggesting that the classical stool 
culture method may miss a lot of shigellosis cases. Hence the true prevalence of shigellosis 
may be much higher than previously thought. 
Another longitudinal diarrhoeal disease study has been carried out in the Peruvian Amazon 
between 2002 and 2006. This was an active community-based surveillance, in which 
research health workers visited participating families 3-times a week to record the number, 
consistency, and characteristics of stool passed over the 24-hour period, and collected stool 
for culture whenever the definition of diarrhoea cases were met (Kosek et al. 2008). The 
incidence rate for shigellosis was 0.34 episodes per child-year, a 20-fold higher than the 
rate detected by passive surveillance in Asia reported by von Seidlein et al. 
Shigellosis in these communities may have become milder during the study periods 
because there were no shigellosis-related deaths reported in these two community-based 
studies. The trend towards a more benign pattern of shigellosis may be due to the better 
nutritional status of children in economically emerging Asian countries, or earlier access to 
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health service and improvement of primary case management during the surveillance study 
period in Peru (Sansonetti 2006). 
1.3.2 Transmission: 
Shigella infection is by faecal-oral route with a low infectious dose: ingesting as few as 10 
to 100 colony-forming-units of S. dysenteriae type 1 may result in disease in 10% to 20% 
of non-immune subjects (DuPont et al. 1989). Transmission is via direct person-to-person, 
contaminated food or water. Houseflies may transmit infection mechanically in some 
situations where control of houseflies reduces transmission of shigellosis (Cohen et al. 
1991). Shigella transmission also takes place via oral-anal sexual contact particularly in 
men who have sex with men (Marcus et al. 2004). 
In developing countries, epidemics of S. dysenteriae type 1, which produces Shiga toxin 
and typically carries R factors that encode resistance to multiple antibiotics, may occurred 
with considerable morbidity and mortality, particularly in extreme situations such as 
natural disasters or political upheaval leads to mass population displacement and crowding 
in refugees camps (Shears 1996). Endemic shigellosis is largely a paediatric disease, most 
cases occurred in children under 5 years old and the Sfexneri serotypes predominate 
(Kotloff et al. 1999; von Seidlein et al. 2006). 
In developed countries, S. sonnei persists and causes sporadic diarrhoea and occasional 
outbreaks in epidemiological niches (such as mental institution and day-care centres) 
where personal hygiene may be suboptimal (Mohle-Boetani et al. 1995), or in population 
of men who have sex with men, in that case S. flexneri may be the dominant species. 
Recently, outbreaks of shigellosis have occurred in industrialised countries and have been 
found to be linked with consumption of food imported from a developing country (Lewis 
et al. 2009). An international food-borne outbreak of S. sonnei in airlines passengers with 
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47 culture-confirmed shigellosis and 116 probable cases in 4 countries was related to 
consume raw carrot served on-board planes and supplied by one caterer. These outbreaks 
represent a new face of epidemiology of shigellosis in the era of modem air transportation. 
1.3.3 Distribution of Shigella species: 
The distribution of Shigella species varies with location of isolation and changes by time. 
S. dysenteriae type 1, for unknown reasons, is the only Shigella that can cause large 
outbreaks of infection in developing countries and which has been linked with a high 
mortality. Such major epidemics occurred in Central America in the late 1960s 
(Mendizabal-Moms et al. 1971) and South Asia (Pal 1984) in early 1980s and early 2000s 
in Central Africa (Kerneis et al. 2009; Paquet et al. 1995). 
In Britain and Europe during the 1920s S. flexneri and S. sonnei were of equal prevalence, 
but the former gradually faded and after the Second World War S. sonnei accounted for the 
majority of the endemic Shigellosis in these areas. Similar trends have also been observed 
in the United States (Skirrow 1996). In Japan, where the prototype Shigella was first 
described, S. dysenteriae type 1 was the most common species in the latter half of 19`h 
century and early 20th century. But after that most of the Shigella strains isolated in 
hospitalized patients in Tokyo were S. flexneri. The percentage of S. sonnei increased 
gradually from 10% in 1953 to 50% in 1963 (Hiroshi 1964) and now S. sonnei is the most 
prevalent indigenous Shigella species in Japan. Statistics in Korea showed that S. sonnei 
constituted 4.8% of all Shigella isolated in the 1961-1968 period, which increased to 
23.6% in 1980-1987, and then became the most prevalent species in 1991-1997 period 
with 77.1% of all isolates (Je Chul Lee 2006). 
8 
Chapter One: Introduction 
While S. sonnei is the main sero-group of Shigella causing diarrhoea) diseases in 
industrialized countries, in developing countries S. flexneri remains the predominant 
species (Kotloff et al. 1999; Zafar et al. 2009). However, recently S. flexneri has been 
replaced by S. sonnei as the most important sero-group causing shigellosis in some 
"transitional" countries (e. g. Thailand, Turkey, Israel, von Seidlein et al. 2006, 
Bangtrakulnonth et al. 2008, Ceyhan et al. 1996, Ashkenazi et al. 1993). The reason for the 
shift in predominant Shigella species in these countries is not understood and although 
economic improvement is clearly an important factor (there is a significant correlation 
between the Gross Domestic Product (GDP) and the frequency of S. sonnei isolation) it is 
not clear how this affects the balance between the species. The predominance of S. sonnei 
over Sflexneri probably reflects the expanding economies in these countries (Ram et al. 
2008). However there has been no study aimed at providing the answer of the change of 
dominant Shigella sero-group in the presence of rising GDP. One possibility is that 
economic improvement leads to better access to health services thus bringing more patients 
with relatively mild diseases caused by S. sonnei to the hospital. 
1.4 Pathogenicity of Shigella: 
The cellular and molecular pathogenicity of Shigella infections has been studied in depth 
in the past decades using S. lexneri infection in animal models or in vitro cell assay 
systems (Sansonetti 1992; Schroeder and Hilbi 2008). Two important mechanisms in the 
pathogenesis of Shigella infection are (i) the production of enterotoxins and (ii) tissue 
invasiveness by the organism. Tissue invasiveness was recognised for a long time and 
attracted more attention because it caused inflammation in the human colon and terminal 
ileum which resulted in typical dysentery picture with bloody diarrhoea and tenesmus. The 
production of enterotoxins was first described thirty years ago (Keusch et al. 1972). 
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1.4.1 Production of enterotoxins: 
Clinicians recognised that many patients with shigellosis manifest only watery diarrhoea, 
and even dysenteric patients passing scanty mucoid-bloody stools usually recount a period 
of watery diarrhoea without blood in the early stage of their illness. This observation plus 
experiments in non-human primate and human volunteer models led to the discovery and 
characterisation of Shigella enterotoxins (Levine 2007). Two enterotoxins (Shigella 
enterotoxin 1 (ShETI) and Shigella enterotoxin 2 (ShET2)) which are secreted by Shigella 
contribute to the pathogenesis of the disease. Deletion of set and sen genes encoding 
Shigella enterotoxin 1 and 2 leads to an attenuated but immunogenic Shigella vaccine 
candidate strain (Kotloff et al. 2004). ShETI is a chromosomally encoded toxin of 55 kDa 
that is essentially expressed by S. flexneri 2a, and ShET2 is a plasmid-encoded enterotoxin 
of 63 kDa which can be secreted by various Shigella species. These enterotoxins are 
thought to be responsible for the early watery diarrhoea) phase at the onset of shigellosis 
(Fasano et al. 1997). Another well described toxin is the Shiga toxin, also known as 
verotoxin, verocytotoxin or Shiga-like toxins, and which are produced by several enteric 
pathogens, most importantly S. dysenteriae (serotype 1 only) and Entero-haemorrhagic 
E. coli (EHEC). 
Shiga toxin is a cytotoxic toxin and is responsible for the development of vascular lesions 
seen in the severe complications of shigellosis such as haemorrhagic colitis and the 
haemolytic-uremic syndrome (HUS) (Cherla et al. 2003). 
1.4.2 Epithelium invasion: 
The most easily visible lesions found in gross pathology of shigellosis are the ulcerations 
in the terminal ileum and colon. This reflects the mucosal invasiveness of the pathogen, 
which is a multi-step process (Figure 1.3). 
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(i) In the initial phase of infection, S.. lexneri does not invade the epithelial barrier from the 
apical side but instead triggers its uptake by the microfold cell (M cells) and is 
transcytosed across the epithelium. 
(ii) After transcytosis, S. flexneri is released into an intraepithelial pocket and is engulfed 
by resident macrophages. Shigella multiplies within infected macrophages then induces 
macrophage apoptosis which releases the organism into the sub-mucosa space. 
Macrophage cell death is accompanied by the release of interleukin-10 (IL-10) and IL- 18. 
Both cytokines are mediators of acute and massive inflammatory response. 
(iii) Once released from the dying macrophage S. flexneri is able to invade other epithelial 
cells from baso-lateral side, and replicates in the cytoplasm. Cytoplasmic S. flexneri then 
spreads to adjacent epithelial cell (via a novel host actin-based propulsion mechanism) 
without exposure to the extra-cellular components of host immune defence. 
(iv) Infected epithelial cell secretes the chemokine 1L-8. IL-8 mediates recruitment of 
polymorphonuclear neutrophil leukocytes (PMN) to the site of infection. The infiltrating 
PMN leukocytes kill S. flezneri but also destroy the integrity of the epithelial lining, thus 
enable more luminal bacteria to reach the sub-mucosa directly (Schroeder and Hilbi 2008). 
The invasiveness of Shigellae occurs at the terminal ileum and colon and clearly explains 
the dysenteric phase of the disease. 
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Figure 1.3 Cellular pathogenesis of Shigella spp.: (i) S. flexneri triggers its uptake by the 
M cell and is transcytosed across the epithelium layer; (ii) After transcytosis, S. flexneri is 
released out off the M cell and is engulfed by resident macrophages; Shigellae multiplies 
within the macrophage then induces macrophage apoptosis releasing the organism into the 
sub-mucosa space plus proinflammatory cytokines; (iii) Free bacteria invade other 
epithelial cell from the baso-lateral side, multiply and spread to adjacent cells; (iv) 
Proinflammatory cytokines activates the innate immune response and attracts PMN to 
cause inflammation and tissue destruction facilitating the invasion of more bacteria. 
Finally, PMNs kill Shigella, thus contributing to the resolution of the infection 
(Reproduced from Schroeder and Hilbi, 2008) 
1.4.3 Molecular basis of Shigella pathogenicity: 
The genetic determinants of virulence in Shigella are located on the "pathogenicity 
islands" (PAI) found in bacterial chromosome and on a large virulence associated plasmid 
of 200kb molecular weight found in all Shigella species. Genes in the large virulence 
plasmid which control the production of proteins secreted by Shigella can be divided into 4 
functional groups. 
Group 1 consists of genes encoded for invasion plasmid antigens IpaA to IpaD that act as 
effectors and translocator proteins directly responsible for inducing cytoskeletal 
rearrangements, membrane ruffling and pathogen uptake which is essential for host cell 
invasion and intracellular survival. 
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Group 2 comprises genes that make up the type III secretion system apparatus (T3SS). 
These consist of the mxi (membrane expression of ipa proteins) and the spa (surface 
presentation of ipa antigens) genes. 
Group 3 contains two transcriptional activators virB and mixE. 
Group 4 includes 4 genes encode chaperones of the T3SS (ipgA, ipgC, ipgE, and spa] 5) 
(Schroeder and Hilbi 2008). 
1.5 Clinical features: 
Man is the only natural host for Shigella spp. although higher non-human primate can 
develop diarrhoeal illness after ingestion of the bacteria. 
1.5.1 Clinical presentations: 
Shigella infection may present a wide range of illness in human from asymptomatic 
infection to frank dysentery syndrome with acute watery diarrhoea) illness in between 
(Stoll et al. 1982). The clinical picture of Shigella infection varies with the bacteria 
inoculation size, host status and Shigella species: low inoculum size can cause a mild 
disease, bigger inoculum size may lead to frank dysentery (DuPont et al. 1989); 
overwhelming dysentery is usually seen in S. dysenteriae type 1 infection while S. sonnei 
infection causes a milder illness. 
In volunteer challenge studies, the classical bacillary dysentery caused by Shigella 
commences with fever, malaise, abdominal cramps and watery diarrhoea for about 18-24 
hours. These symptoms are followed by scanty stools which contain mucus and blood and 
by tenesmus, which is painful straining at defecation (Kotloff et al. 1995a). 
13 
Chapter One: Introduction 
In hospitalised children, few patients presented with the initial stools are bloody (the 
majority of them present initially with watery diarrhoea), while more than 50% of cases 
never develop bloody stools (Ashkenazi 2004). In community surveillance studies the 
proportion of Shigella infection presented with overt dysentery with mucus and blood in 
stool contributes only 11 % to 20% of all Shigella-associated diarrhoea) cases, the majority 
of cases had no fever or blood in stools (Abu-Elyazeed et al. 2004; Kosek et al. 2008; von 
Seidlein et al. 2006). While the presence of mucoid bloody diarrhoea may be indicative of 
shigellosis, the absence of this symptom cannot preclude the diagnosis (Abu-Elyazeed et 
al. 2004). So using the term "bloody diarrhoea" to denote "Shigella infection" or 
"shigellosis" may lead to an under-estimate of the true prevalence of the infection because 
in the majority of cases blood is not visible in stools. 
1.5.2 Complications: 
Severe Shigella infection may lead to a number of systemic complications: 
Severe dehydration and acidosis although rare in shigellosis are a very important 
complication. 
Toxic megacolon (Christianson 1987) and leukemoid reaction (Butler et al. 1984) have 
been reported in Bangladeshi children with high fatality rate but have been rarely reported 
from other areas. 
Haemolytic-uremic syndrome (Bhimma et al. 1997) is a major complication of infections 
due to S. dysenteriae type 1 (and also of Shiga-toxin producing E. co1i) which lead to renal 
failure and death if renal replacement therapy not applied early. 
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Bacteraemia is rare in previously healthy patients but may be seen more frequent in 
malnourished or immunodeficiency children and is accompanied by a high case fatality 
rate (Struelens et al. 1985). 
Seizure may be seen in up to 27% of all children with shigellosis (Hiranrattana et al. 2005; 
Lahat et al. 1984) and mostly have a benign course (Ashkenazi et al. 1987); 
encephalopathy occurs rarely but is associated with increased morbidity and mortality 
(Chisti et al. 2009). 
Some patients infected with S. flexneri and who are genetically predisposed (Human 
Leukocyte Antigen (HLA) B27) can develop Reiter's syndrome (pains in their joints, 
irritation of the eyes, and painful urination) that can lead to a difficult to treat chronic 
arthritis (Calin and Fries 1976). 
Despite formerly thought that Shiga toxin cause all the neurological derangement, a recent 
study showed that Shiga toxin production is not essential for the developing of 
neurological manifestations of shigellosis (Ashkenazi et al. 1990). 
1.5.3 Special cases: 
Neonatal shigellosis is rare possibly because of the presence of maternal derived factors 
which pass through the placenta or are transferred during breastfeeding. Initial clinical 
presentation in neonates may be mild (low-grade fever, mild watery diarrhoea), but 
complications occur more frequent than in older children (septicaemia, toxic megacolon, 
meningitis, colonic perforation) (Haltalin 1967; Viner et al. 2001). 
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Shigellosis inpatients with acquired immunodeficiency syndrome (AIDS) may be 
recurrent and relapsing, and more often is associated with bacteremia requiring prolonged 
antibiotic treatment (Kristjansson et al. 1994). 
1.5.4 Negative impact of Shigella infection on child nutrition: 
Shigellosis exerts a long term impact on the growth of children through its negative effect 
on nutrition leading to malnutrition. Two factors may contribute to this negative effect: 
(i) Shigella dysentery is associated with profound anorexia leading to decreased food 
intake, 
(ii) In Shigella infection, the patients lose considerable amounts of protein in the gut owing 
to epithelial cell death, ulceration, and the transudation of serum into the intestinal lumen 
(Bennish et al. 1993). In Bangladesh, where shigellosis is hyper-endemic, this is an 
important factor contributing to the high prevalence of children malnutrition. 
The mortality rate from Shigella infection, which was as high as 10%-20% in the 1960s, 
has been decreased to 0% to 21 % in most recent hospital-based studies, and to 0% to 2.6% 
in community-based studies (Ram et al. 2008). It seems shigellosis has a more benign 
course in recent years (Sansonetti 2006). The contributing factors for this may be 
improvements in the nutritional status of children, the improvement of the access to health 
services and better case management in health facilities. Risk factors for death included 
very young age, poor nutritional status and central nervous system manifestations such as 
altered consciousness or seizures (Ram et al. 2008). 
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1.6 Diagnosis: 
1.6.1 Clinical diagnosis: 
Typical cases with acute high fever, frequent small-volume bloody diarrhoea with cramp 
and tenesmus are easy to diagnosis but contribute to less than 50% of hospitalised patients. 
The majority of cases presents with watery diarrhoea and are difficult to distinguish with 
diarrhoea caused by viral aetiology (such as rotavirus or norovirus) unless microbiological 
investigations are conducted. 
1.6.2 Bacteriological diagnosis: 
The diagnosis of Shigella infection is based on stool culture on appropriate media. 
Selective media, such as MacConkey, xylose-lysine-deoxycholate (XLD), Hektoen enteric 
(HE), or Salmonella-Shigella agar, are usually used for isolation from clinical specimens. 
Ideally clinical samples should be streaked on plates within two hours of the sample being 
taken. The isolation of Shigellae from clinical stool samples not only confirms the 
diagnosis of Shigellosis but also helps to determine the antibiotic susceptibility of 
Shigellae which is important for the treatment and control of the infection (WHO 2005c). 
However because Shigellae are relatively fragile organisms, the positive culture rate from 
clinical specimens is not high. 
1.6.3 Molecular diagnosis: 
The polymerase-chain reaction (PCR) techniques has been used to detect specific 
pathogenic genes coding for the invasion plasmid antigen H (ipaH) which present in all 
Shigellae and also in enteroinvasive E. co1i (EIEC) (Islam et al. 1998; Sethabutr et al. 
1993). The real time PCR recently detected the presence of ipaH gene sequence in 33% of 
culture-negative specimens (Vu et at. 2004). When the PCR technique was considered as 
gold-standard, the culture technique has 72% sensitivity and 100% specificity (Islam et al. 
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1998). Unfortunately PCR technique requires sophisticated equipment and is expensive 
and not usually available in the settings where Shigella infection is prevalent. Moreover 
PCR techniques could not give information on the sensitivity to antibiotics of the Shigella 
strains to guide treatment. Therefore the techniques may be suitable for incidence studies at 
the field but are not valuable for clinical diagnosis in hospital. 
1.6.4 Rapid test: 
Recently a simple immunochromatographic dipstick based on the detection of S. flexneri 2a 
lipopolysaccharide (LPS) using serotype 2a-specific monoclonal antibodies coupled to 
gold particles has given promising results with the specificity and sensitivity of 99.2% and 
91.5% respectively when testing on clinical specimens (Nato et al. 2007a). 
1.7 Treatment: 
The treatment of shigellosis comprises of (i) providing water and electrolytes rehydration, 
(ii) good nutrition, and (iii) administering appropriate antibiotics. 
1.7.1 Rehydration: 
Rehydration is usually through oral rehydration therapy because in most cases the patients 
have none or mild-to-moderate dehydration (Khan et al. 1999). The use of reduced- 
osmolarity oral rehydration solution (ORS) recommended by WHO is sufficient for the 
majority of cases (WHO 2005c). Intravenous rehydration is indicated in rare cases with 
severe dehydration or profound vomiting. 
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1.7.2 Regular feeding: 
This is an important practice to prevent acute hypoglycaemia and long-term malnutrition. 
High-protein diet can help during convalescence from shigellosis in children (Kabir et al. 
1993). 
1.7.3 Antibiotics: 
Antibiotics are helpful for the treatment of shigellosis. Although diarrhoea caused by 
S. sonnei is generally mild and self-limited in healthy adults in industrialised countries, 
infection with any Shigella species can be lethal to children in developing countries. This 
is particularly true in the very young, malnourished or immuno-compromised patients. 
Without effective antibiotic treatment, mortality due to Shigella infection, especially from 
infection with S. dysenteriae type 1 may exceed 10%, particularly among the young and the 
elderly (Bennish and Wojtyniak 1991). Antibiotics shorten the duration of symptoms, 
prevent severe complications and eradicate Shigellae from the stool more quickly hence 
prevent the spread of the disease in the community (Salam and Bennish 1991). The choice 
of antibiotics to use as first line against Shigella infection should be based on the local 
antibiotic sensitivity patterns and should be updated regularly. The World Health 
Organisation guidelines have recommended ciprofloxacin as the drug of choice for all 
patients with bloody diarrhoea, irrespective of their age. Although quinolones have been 
reported to cause arthropathy in young laboratory animals, the risk of joint damage in 
children appears to be minimal and is clearly outweighed by the value of these drugs for 
treatment of this potentially life-threatening disease. Pivmecillinam (amdinocillin pivoxil), 
ceftriaxone and azithromycin are considered as alternatives for treatment of multi-resistant 
strains of Shigella in all age groups (WHO 2005a). Unfortunately, strains of Shigella 
developed resistance to fluoroquinolones and other antibiotics have been reported (Taneja 
et al. 2005). 
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1.7.4 Other antimicrobial agents: 
Because of increasing concerns about emergence of drug resistance and side-effects, other 
kind of antimicrobial agents have been investigated. Rifaximin, a non-absorbed rifamycin 
derivative, has been shown to be effective in preventing shigellosis in a volunteers 
challenge study (Taylor et al. 2006), but is not approved for the treatment of diarrhoea 
caused by invasive enteric pathogens such as Shigella spp., Campylobacter jejuni, and 
Salmonella spp.. Sodium butyrate, the salt of a short-chain fatty-acid which can increase 
the production of endogenous antimicrobial peptides may help resolve Shigella infection in 
laboratory animals without using antibiotics (Raqib et al. 2006). There are no human 
clinical trials to evaluate this drug in the treatment of Shigella infection. A diet with green 
banana, which is rich in amylase-resistant starch that stimulates colonic production of 
short-chain fatty-acid, has been reported improving the clinical severity of childhood 
shigellosis treated with ciprofloxacin (Rabbani et al. 2009). 
1.8 Antibiotic resistance: 
1.8.1 Occurrence of antibiotic resistance: 
Resistance to antibiotics has been recognized in Shigellae very early in the era of 
antimicrobial therapy. In Japan shortly after sulphonamide, chloramphenicol and 
tetracycline were introduced into clinical practice, strains of Shigella which were resistant 
to these antibiotics developed rapidly from 0.7% in 1956 to 38.7% in 1963 (Hiroshi 1964). 
Japanese scientists carried out experiments to show that resistance to multiple antibiotics 
spreads easily in the Shigellae community and to other Gram negative bacteria by a 
"resistance factor" (R factor) now known as transferable plasmid (Akiba et al. 1960; 
Watanabe 1963). 
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Ampicillin and trimethoprim-sulfamethoxazole (co-trimoxazole) were then used and 
continue to be effective in many industrialized countries. Unfortunately, resistance to these 
low-cost oral antibiotics developed quickly in both tropical and industrialized countries 
(Salam and Bennish 1991; Sivapalasingam et al. 2006). 
Nalidixic acid, a drug of the first generation of quinolone family, was then introduced for 
the treatment of shigellosis. At first, the clinical response to Nalidixic acid treatment was 
impressive, but resistance developed very quickly. The story of Central Africa best 
illustrates the typical scenario of antibiotic resistance. An epidemic of shigellosis started in 
south-eastern Zaire in November 1979, and quickly spread to neighbouring areas of 
Rwanda, Burundi, and the United Republic of Tanzania. The initial S. dysenteriae type 1 
isolates were resistant to ampicillin, chloramphenicol and tetracycline. 
In July 1981 co-trimoxazole replaced tetracycline as the first-line treatment, and by 
September of that year trimethoprim resistant strains were isolated. In November 1981, 
Nalidixic acid was introduced as first-line therapy for Shigellosis, which reduced the case 
fatality rate. Predictably, by April of 1982, the first S. dysenteriae type 1 strains resistant to 
Nalidixic acid were reported (Shears 1996). 
Fluoroquinolones, the second generation quinolones including ciprofloxacin, norfloxacin, 
ofloxacin, have wider antibacterial spectrum and better intracellular distribution, and 
proved highly effective in vitro against Shigella. Controlled clinical trials have supported 
the clinical efficacy of these fluoroquinolones for the treatment of drug-resistant shigellosis 
(Gotuzzo et al. 1989; Vinh et al. 2000; ZimBaSA_Dysentery_Study_Group 2002). 
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Since 2005 the World Health Organization recommended ciprofloxacin as the drug of 
choice for the treatment of shigellosis in both adult and children (Anonymous 2005). 
Unfortunately, ciprofloxacin-resistant S. dysenteriae type 1 strains were detected at the 
start of the 215` Century (Naheed et al. 2004; Taneja et al. 2005). 
Ceftriaxone, the injectable third generation cephalosporin antibiotics, has been used to treat 
severe shigellosis with good results (Eidlitz-Marcus et al. 1993; Varsano et al. 1991). 
Cefixime, the oral third generation cephalosporin drug however failed in the treatment for 
shigellosis in adults when used in standard dosage (400mg/dayX 5 days) (Salam et al. 
1995), but still had some efficacy in children (Martin et al. 2000). Strains of Shigella which 
are resistant to third generation cephalosporin have been recognized recently (Fortineau et 
al. 2001; Radice et al. 2001) and have spread widely (Vinh et al. 2009a). 
Azithromycin is a second generation macrolide. It inhibits growth of Shigella in vitro and 
has high intracellular concentration (40 times the extracellular concentration). In a malaria 
control campaign, azithromycin prophylaxis prevented epidemic dysentery caused by 
S. dysenteriae (Shanks et al. 1996). Later on Azithromycin proved effective in the treatment 
of moderate to severe shigellosis caused by multidrug-resistant strains (W. A. Khan et al. 
1997). Azithromycin resistant S. sonnei has been identified recently (Boumghar-Bourtchai 
et al. 2008). 
1.8.2 Mechanisms of resistance: 
Similar to other Gram negative bacteria, the mechanisms of antibiotic resistance of 
Shigella include: alteration/modification of the target site; modification/degradation of the 
antibiotic molecule; reduced drug uptake, and the energy-dependent efflux leading to 
decreased intracellular antibiotic concentration. Resistance to commonly used antibiotics 
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(sulphonamide, trimethoprim, beta-lactams, tetracycline, and streptomycin) can be 
transferred from Shigella spp. to E. coli and vice versa by transferable plasmids (Tanaka et 
al. 1983). This may help explain the rapid emergence of drug resistant Shigella strains 
resulting in dysentery outbreaks (Shears 1996). 
Trimethoprim-Sulfamethoxazole resistance in Shigellae was first detected in 1980 
(Finlayson 1980). Trimethoprim inhibits bacterial dihydro-folate reductase (DHFR) 
enzyme, sulfamethoxazole blocks dihydroopterate synthase (DHPS) enzyme. Synergy 
between TMP and SMZ is based on their blocking sequential steps in the pathway of folic 
acid which is essential for nucleic acid synthesis. The most common mechanism of 
resistance to TMP is acquisition of an additional variant DHFR enzyme which has reduced 
affinity to TMP. The most common variant is DHFR I. Similar to TMP resistance, the most 
common mechanism for SMZ resistance in Gram negative bacteria including Shigella is 
the acquisition of a plasmid encoding altered DHPS with reduced affinity for SMZ. 
Tetracycline resistance was first recognized in S. dysenteriae in 1953 and demonstrated to 
be plasmid-transferable (Roberts 1996). The resistance gene tet is carried on a transposon 
or on a plasmid. Streptomycin and aminoglycoside resistance are encoded by aadAl a and 
aadA2 genes usually located in a Class 1 integron (Navia et al. 2004). 
Nalidixic acid resistance is usually mediated by a mutation at position 83 and 87 in gyrA or 
position 80 in parC genes (Chu et al. 1998; Pu et al. 2009). There have been reports of 
fluoroquinolone resistance mediated by double mutations (Ser83-)Leu, Asp87-*Asn or 
Gly) in the gyrA gene and a single mutation (Ser804I1e) in parC gene (Talukder et al. 
2006). 
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Ampicillin is the most commonly used antibiotic of the beta-lactam class for the treatment 
of Shigella infection. Beta-lactams target penicillin-binding proteins (PBPs), which carry 
out functions essential for the bacterial cell-wall. The binding of beta-lactams to PSBs in 
susceptible species results in bactericidal activity. The resistance to beta-lactams may arise 
in Shigella as a result of mutations which reduce affinity of PBPs to antibiotics. But the 
most important mechanism of resistance to this class of antibiotics is the production of 
beta-lactamases. Beta-lactamases are a diverse group of enzymes which hydrolyzed the 
beta-lactam ring, inactivating the drug. Classification of beta-lactamases has been based on 
the functional characteristics (group 1,2,3,4) and molecular structure (class A, B, C, D) 
of the enzymes. The majority of beta-lactamases belong to the TEM (Temoniera), SHV 
(Sulphydryl variable), OXA (oxacillinase), and extended-spectrum beta-lactamase 
(ESBLs). The genes encoding these enzymes may be located on the chromosomes, on 
plasmids, or on transposons. 
Resistance to third generation cephalosporin is primarily through the production of ESBLs. 
Most ESBLs produced by Shigella belong to the CTX-M group, very few are TEM and 
extremely rare are those from the SHV group. 
Macrolide resistance is mediated by a plasmid-born mph(A) gene encoding a macrolide 2'- 
phosphotransferase that inactivates macrolides (Boumghar-Bourtchai et al. 2008; Phuc 
Nguyen et al. 2009). 
1.8.3 Randomised controlled trials in the treatment of drug-resistant shigellosis: 
Antibiotic resistance is a well-known phenomenon in Shigella spp., new and effective 
antibiotics are needed to replace old ones in the treatment of shigellosis caused by resistant 
strains. A good antimicrobial drug should be effective microbiologically to local strains 
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(low MIC, good intracellular penetration), easy to use (administered orally is preferable to 
intravenous administration), less side-effects particularly in children, and be available at an 
affordable price. Clinical trials have been carried out in the hope of finding such 
appropriate antibiotics. 
The International Centre for Diarrhoea) Diseases Research, Bangladesh has been one of the 
most innovative institutions in the treatment of diarrhoea and have carried out a large series 
of randomised controlled trials looking for effective antimicrobial agents for the treatment 
of shigellosis (Alam et al. 1994; Bennish et al. 1990; W. A. Khan et al. 1997; Salam and 
Bennish 1988; Salam et al. 1995). Studies from other places in the world have also 
contributed to the guidance on effective antibiotics for the treatment of shigellosis 
(Basualdo and Arbo 2003; Martin et al. 2000; Vinh et al. 2000; 
ZimBaSA Dysentery_Study_Group 2002). 
A systemic review of randomised controlled trials comparing antibiotics of different class 
for the therapy for Shigella dysentery has been recently published (Christopher et al. 
2009). The results of this systematic review provide evidence that the most commonly used 
antibiotics are potentially effective against Shigella dysentery, provided the local species 
and strains of Shigella are susceptible. Regular, periodic antibiotic-susceptibility testing of 
isolates is essential to guide local empiric therapy for Shigella dysentery. 
Another paper reviewed all literature reporting the effect of ciprofloxacin, ceftriaxone and 
pivmecillinam for the treatment of dysentery in children in the developing countries has 
also been recently released. The authors concluded "The antibiotics recommended by the 
WHO-ciprofloxacin, ceftriaxone and pivmecillinam-are effective in reducing the 
clinical and bacteriological signs and symptoms of dysentery and thus can be expected to 
decrease diarrhoea mortality attributable to dysentery" (Traa et al. 2010). 
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1.9 Prevention: 
The source of Shigella is primarily infected humans and the transmission faecal-oral route. 
Hence prevention of Shigella infection should firstly comprise better individual hygiene 
and improvement in community sanitation. Frequent hand washing with soap before food 
preparation, before meals, after defecation and changing baby diapers, will reduce the 
spread of the disease, particularly in outbreaks (Pal 2004). In some regions, the control of 
house-flies may be helpful for the prevention of shigellosis. 
Safe water supply and storage as well as proper disposal of human excreta are of utmost 
important in the prevention of shigellosis and other diarrhoeal diseases. While improving 
environment sanitation and personal hygiene cannot be achieved in a short period of time, 
an effective and cheap vaccine is obviously a high priority. 
1.9.1 Vaccine: 
A vaccine for the prevention of shigellosis was set as a high priority by the World Health 
Organisation almost two decades ago (Anonymous 1987). 
1.9.1.1 Protective immune response: 
Shigella infection confers protective immunity, although its mechanisms are not fully 
elucidated. Epidemiologically, shigellosis peaks during the first five years of life and 
subsequently declines suggesting that immunity occurs following repeated exposures to 
Shigella during childhood. The natural immunity to Shigella infection is species and 
serotype-specific. A study in Chilean children showed that the primary Shigella infection 
conferred 72% protective efficacy against re-infection with a homologous serotype 
(Ferreccio et al. 1991). Serum and stool levels of antibodies to Shigella O-antigen LPS and 
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Ipa proteins have been detected following natural infection and infection in volunteers 
(Cam et al. 1993). 
Considering that the protective immunity against Shigella infection is species and 
serotype-specific, the protective capacity of any Shigella vaccine candidate will depend 
greatly on the representation of species and serotypes incorporated in the vaccine and the 
epidemiological importance of these respective serotypes in the area. Because the 
prevalence of Shigella species and serotypes in an area may change by time, it is prudent to 
monitor the disease burden and the prevalence of representative of Shigella species and 
serotypes in any area where such vaccine candidates are to be studied. 
The highest incidence, morbidity, and mortality of shigellosis are in children less than 5 
years old. There a good vaccine must elicit sufficient protective immunity in this age 
group. 
1.9.1.2 Current approaches to Shigella vaccines: 
In addition to the preparation of sub-cellular vaccines (such as ribosomal-based vaccine 
composed of O-antigen and ribosome of S. flexneri 2a which has been shown to be 
immunogenic and provide efficacy in mice (Shim et al. 2007), however there still needs to 
demonstration of the protective capacity in humans), two major approaches have been 
investigated recently with encouraging results: live, attenuated vaccine and inactivated 
vaccine. 
- Live, attenuated Shigella vaccine: An oral live-attenuated vaccine which mimics the 
natural infection without causing symptoms should be an ideal candidate given that it 
elicits good immunity and potentially has fewer associated adverse events. Three vaccine 
candidates using this approach have been tested recently in various phase of clinical trials. 
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SC602 is an S.. lexneri 2a vaccine constructed at the Institute Pasteur Paris, by deleting the 
icsA and iuc genes. SC602 is fully invasive for tissue culture cell, but intercellular spread is 
negated. Studies in North American volunteers have demonstrated that SC602 can evoke 
protection against the most severe symptoms of shigellosis in a stringent human challenge 
model of disease (Katz et al. 2004). But clinical studies in children in Bangladesh showed 
that the candidate vaccine is apparently overly attenuated for the target population in an 
endemic region. 
SC599 S. dysenteriae type 1 vaccine strain was constructed by creating deletions in several 
genes including icsA, ent, fep and stxA-negative: HgR. Phase I and II clinical trials in St. 
George's Vaccine Institute in London and Cochin-Vaccinology Centre (France) showed 
that it was highly attenuated, well tolerated and capable of inducing mucosal IgA ASC 
response and significant serum antibody response (Launay et al. 2009). 
WRSS1 is an S. sonnei vaccine strain in which the icsA gene has been deleted. The vaccine 
candidate elicited a dose-dependent anti-LPS IgA response (Orr et al. 2005). Second 
generation of the live vaccine strain has been constructed recently by further deleting the 
genes encoded for ShET2-1 enterotoxin which showed lower level of reactogenicity 
without hampering the robust immune responses achieved with previous live vaccines 
(Barnoy et al. 2010; Ranallo et al. 2007). 
CVD series of Shigella vaccines: live, attenuated vaccine candidates have been constructed 
at University of Maryland Center for Vaccine Development (CVD). CVD 1023, an 
S. flexneri 2a vaccine (with deletion of aroA and icsA) gave unacceptable reactogenicity, 
CVD 1207 (with deletions in guaBA, set, sen and icsA) gave immunogenic response but 
could have been hyperattenuated. CVD 1208 (deletion in guaBA and sen and set) was 
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considered a highly attractive candidate that reflects the desired balance clinical 
acceptability and robust immunogenicity (Kotloff et al. 2007). 
Multivalent Shigella vaccines: A global Shigella vaccine must protect against 16 serotypes 
and sub-serotypes, namely S. dysenteriae type 1, S. sonnei and all 14 classical S. flexneri 
types and sub-serotypes (Levine et al. 2007). Such a vaccine would be impractical and 
expensive. An alternative approach proposed by researchers at CVD is to include 
S. dysenteriae type 1, S. sonnei and S. flexneri 2a, S. flexneri 3a and S. flexneri 6 in a 
multivalent vaccine, because these 3 S. flexneri serotypes have O-antigen group 
determinants that are shared by the remaining 11 Sflexneri serotypes and sub-serotypes 
(Noriega et al. 1999). 
- Shigella conjugate vaccine: In subjects immune to Shigella a small amounts of serum IgG 
transudate onto the gut surface where they can neutralized or inactivate inocula of wild- 
type Shigella organisms (Robbins et al. 1992). Based on this concept researchers created 
parenteral conjugate vaccines that consist of 0-polysaccharides derived from the LPS of 
relevant Shigella serotypes covalently linked to a carrier protein (Pseudomonas aeruginosa 
exotoxin A (PsA) or CRM9-mutant diphtheria toxin). In a randomised, controlled, double- 
blind Phase III efficacy trial involving several hundred Israeli soldiers, a single dose of the 
S. sonnei conjugate vaccine conferred 74% protection against S. sonnei diarrhoea during 
outbreaks on army bases (Cohen et al. 1997). The efficacy of the S. sonnei-CRM9 and 
S. flexneri 2a-rEPA vaccine in 1-4-year-old children was related to the level of conjugate- 
induced IgG anti-O-antigen antibody (Passwell et al. 2003). 
Alternative strategies with inactivated vaccines: A new generation of Shigella conjugate 
vaccine, synthetic carbohydrate-protein conjugate vaccine, based on synthetic 
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oligosaccharides conjugated with proteins, offers promise for enhanced immunogenicity 
and diminished production costs (Phalipon et al. 2009). Formalin-inactivated whole-cell 
Shigella spp. retains the ability to induce protective immune response in mice and therefore 
may be an effective vaccine candidate approach (Osorio et al. 2007). 
Despite many attractive candidate vaccines having entered clinical trials, none of Shigella 
vaccines is yet available for use. There is clearly a long way to go and much work to be 
done before a Shigella vaccine will help protect the vast majority of young children in 
developing countries as well as travelers from industrialized countries from shigellosis. 
1.10 Studies on Shigella infection in Viet Nam: 
As an important cause of diarrhoeal diseases in Viet Nam, Shigella infection has been 
studied as early as the 1950s (Le Gac et al. 1954), and continued to the 1960s but mainly in 
patients belong to foreign military forces working in Viet Nam (Grant et al. 1969; 
Vaichulis et al. 1967). From the 1990s, more and more studies were carried out in Viet 
Nam dealing with epidemiology and immune responses to Shigella infection (Cam et al. 
1992; Cam et al. 1993; Li et al. 1993; Lindberg et al. 1991). 
In Viet Nam shigellosis (as well as cholera and typhoid fever) are reportable diseases by 
the national health system. The median reported incidence rate for shigellosis for the whole 
country in the period 1991-2001 was 41/100,000/year (Kelly-Hope et al. 2007). Because 
microbiological facility is limited in most provinces, the report of shigellosis cases was 
usually based on treated episodes of acute dysentery; so that the number will undoubtedly 
be an underestimate. 
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From the turn of the 21st century more studies on the incidence rate of Shigella infection 
were carried out at the community and at the hospital level. At the community level, 
Campylobacter, enterotoxigenic E. coli and Shigella were most commonly isolated from 
diarrhoea stools of children living along the Red River Delta in northern Viet Nam 
(Isenbarger et al. 2001). Recently, the data of a prospective population-based study in six 
Asian countries showed that Shigella incidence rate was 4.9/1000/year in Viet Nam, higher 
than that of Thailand but lower than those of Indonesia, Pakistan, China and Bangladesh 
(von Seidlein et al. 2006). A study in children hospitalised because of acute diarrhoea in 
Ha Noi revealed that Shigella was the most important bacteria (along with rotavirus, the 
most important virus) associated with acute diarrhoea (Hien et al. 2008; Isenbarger et al. 
2001; von Seidlein et al. 2006). Studies investigating the willingness of people to purchase 
or use a Shigella vaccine were also published (DeRoeck et al. 2005; Kaljee et al. 2004). 
The epidemiology of Shigella infection in southern Viet Nam has been changing 
dramatically: the dominant Shigella species circulating in southern Viet Nam changed 
from S. flexneri in the 1990s to S. sonnei at the first decade of the 21st century (Vinh et al. 
2009a; Vinh et al. 2009b). 
The occurrence of multiple drug resistant Shigella strains were increasingly recognized: 
62% of 63 Shigella strains in Ho Chi Minh City were resistant to multiple antibiotics (Vinh 
et al. 2000); antibiotics susceptibility of Shigella strains and other enteric pathogens in Viet 
Nam was comparable with those in Thailand (Isenbarger et al. 2002). The proportion of 
nalidixic acid resistant Shigella strains was 2% in mid 1990s (Vinh et al. 2000) has 
increased to 68% in 2008 (Vinh et al. 2009b). Recently, the rapid occurrence of 
ceftriaxone-resistant Shigella strains was reported for the first time in Viet Nam (Vinh et 
al. 2009a). The molecular nature of the third-generation cephalosporine resistant genes 
were characterised and the transferrable plasmids which carried these genes were also 
described (Nhu et al. 2010). 
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1.11 Conclusion: 
It is more than 100 years from the days Dr. Shiga and the first identification of the microbe 
that causes severe dysentery. However in 2010 shigellosis remains a very real public 
health issue globally. The true burden of disease is difficult to assess because the fragility 
of the causative organism and a lack of microbiological facilities in many parts of the 
world. An effective vaccine is as elusive as ever for the prevention of the disease and there 
is the continued emergence and spread of drug resistance. 
More work needs to be done to better document the importance of Shigella, the wide range 
of clinical pictures of the disease, the changing distribution of Shigella species and the 
extent and importance of antibiotic resistance. My thesis focuses on these issues in a 
country still troubled by shigellosis despite its impressive developmental and economic 
gains. 
1.12 Focus, aims and structure of the thesis: 
This thesis focuses upon the clinical features, epidemiology and treatment of Shigella 
infection in Vietnamese children and aims to address four questions: 
- What is the magnitude of Shigella infections as a causative agent of childhood acute 
diarrhoea in southern Viet Nam? Is clinical picture specific enough to differentiate acute 
diarrhoea caused by Shigella from that caused by rotavirus? 
- Are there changes in epidemiology, antibiotic susceptibility and clinical aspects of 
childhood shigellosis in southern Viet Nam over the last 15 years? 
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- What is the molecular characteristic of ESBL genes in Shigella population in Viet Nam? 
What plasmids are responsible for the transmission of ESBL genes? 
- Is gatifloxacin as effective as ciprofloxacin in the treatment of Shigella infection in 
children? 
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Chapter Two 
Materials and Methods 
2.1 Introduction: 
This chapter describes the setting of the work undertaken, the region, the hospitals and 
the study wards. Clinical and laboratory methods are also described, although further 
relevant details are provided in subsequent chapters. Statistical tests and statistic 
software used for data collection and analysis are included in this chapter. 
The studies included in this thesis were carried out at The Hospital for Tropical 
Diseases (HTD) in Ho Chi Minh City, Dong Thap Provincial Hospital (DTP) in Dong 
Thap Province in the Mekong Delta, and the Oxford University Clinical Research Unit 
(OUCRU), Ho Chi Minh City, Viet Nam. 
2.1.1 Geography of Viet Nam: 
Viet Nam, officially the Socialist Republic of Viet Nam (SRV), is an S-shaped country 
located in Southeast Asia. It is bordered by China to the north, Laos to the northwest, 
Cambodia to the southwest, and the Tonkin Gulf and the South China Sea, referred to as 
East Sea, to the east and the Gulf of Thailand to the south. 
The total area of Viet Nam is 331,210 sq km of which land 310,070 sq km and water 
21,140 sq km. The climate in Viet Nam is tropical in the south and temperate in the 
north. The average annual temperature is generally higher in the plains than in the 
mountains and plateau, and higher in the south than in the north. Temperature in the 
southern plains (Ho Chi Minh City and the Mekong Delta) varies less, and is between 
21 and 38°C over the course of a year. The temperature variations in the mountains and 
34 
Chapter Two: Material and Methods 
plateaus and in the north are more dramatic, and temperature may vary from 5°C in 
December and January to 37 °C in July and August. The annual average amount of 
rainfall is 1960 mm. Bac Quang in the north has the highest rainfall with an annual 
average of 4760 mm. The lowest average rainfall is Phan Rang in Central Viet Nam 
with only 650 mm per year. 
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Figure 2.1 Map of Viet Nam (right upper black and white map) and study sites in 
southern Viet Nam (left colour map): (1) Ho Chi Minh City and (2) Dong Thap 
Province with adjacent provinces in the Mekong Delta. 
2.1.2 Health Care in Viet Nam: 
Viet Nam has a population of over 86 million making it the 13th most populous country 
in the world. Children aged 0-14 years comprise 26.1 % of the population. The 
population growth rate was 1.1 % in 2009. The birth rate was 17.73 births/1000 
population (2009) and the death rate 5.98 deaths/1,000 population (2009). 
(General 
_Statistics_Office 
2010). Literacy rates are estimated to be 90.3% (2002) 
(www. cia. gov/library/publications/the-world-factbook/geos/vm. html, accessed 20-4- 
2010). 
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The Gross Domestic Product per capita was US$1064 (2009), with an annual growth 
rate or 6.31% (2008) (General-Statistics Office 2010) and per capita purchasing power 
parity of approximately $3,300 (2006). 
The Viet Nam health system has been established at four levels across the country: 
Commune, District, Provincial and National levels. The overall health system 
performance in Viet Nam was ranked 160 over 191 by the World Health Organization 
(WHO 2000, Annex Table 1). Infant mortality rate (IMR) was 22.26 deaths/1,000 live 
births, life expectancy at birth total population: 77.71 years (2009). Although Viet Nam 
has made rapid progress in improving its water supply situation over the past decades, 
many parts of the country, especially those areas heavily populated with ethnic minority 
groups, often rural and remote and with the poorest communities have been left behind. 
Progress towards providing access to sanitation and hygiene has been especially slow. A 
recent survey on sanitation revealed that 52% of rural populations have access to some 
sort of sanitation facilities; however, only 18 per cent of them have access to latrines 
that meet acceptable hygienic standards. The same survey indicates that only 12% of 
schools have hygienic sanitation facilities (http: //www. unicef. org/Viet Nam/wes. html. 
Accessed 20 April 2010). 
Across the country there are a total of 974 hospitals, 781 regional polyclinics with 
170,500 beds and approximately 6.7 doctors per 10,000 populations 
(General_Statistics_Ofice 2010). The health expenditure per capita was US$58 per 
year in the year 2007 by World Bank estimation (Source: World Bank http: // 
data. worldbank. org/indicator/SH. XPD. PCAP, accessed 10 July 2010) and according to 
the World Health Organisation the total expenditure on health at purchasing power 
parity per capita of Viet Nam in 2006 was US$151 (WHO 2009). 
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2.1.3 The Hospital for Tropical Diseases, Ho Chi Minh City: 
Ho Chi Minh City is the largest city in Viet Nam (2095.5 sq km) with an estimated 
population of 7,165,200. The population density is 3419/ sq km 
(Gene ral_Statistics_Office 2010). The Hospital for Tropical Diseases (HTD) in Ho Chi 
Minh City is a tertiary referral centre for patients with infectious diseases and serves the 
whole of southern Viet Nam (population approximately 42 million). It also acts as a 
primary and secondary care health facility for patients living around the hospital. The 
hospital has 550 beds, with 200 beds for paediatric patients. The HTD has laboratories 
for haematology, biochemistry, microbiology and parasitology. 
Paediatrics Ward B located at the 4`h floor of the HTD has 44 beds dedicated to the 
treatment of children with enteric infections (diarrhoeal diseases and typhoid fever) 
from Ho Chi Minh City and adjacent areas including the provinces of the Mekong 
Delta, Long An, Tien Giang, Vinh Long, Ben Tre and Binh Duong. 
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Figure 2.2 The Hospital for Tropical Diseases in Ho Chi Minh City, Viet Nam. 
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2.1.4 Dong Thap Provincial Hospital: 
Dong Thap is a province in the Mekong Delta of southern Viet Nam with a population 
of 1,667,700 living in an area of 3375 sq km. The population density is 494/sq km. 
Dong Thap province has many rivers and canals and is predominantly a rural rice 
farming region. Between June 2006 and March 2009 the randomised clinical trial (EG 
study - see Chapter 6) was conducted at the Infectious Diseases Ward, Dong Thap 
Provincial Hospital (DTH). DTH is the general hospital of Dong Thap Province with 
740 patient beds 120 km south of Ho Chi Minh City. The Infectious Diseases Ward has 
60 beds for adults and children. 
vlinýs. rvrýýn nýv 
.......... a....,.... . ti. ....,:. ..:..,.,......... .,....... .... ý.. ..... ..,... """ . .. qý... ..... .......... i...... - ------- 
;;; i; ii ii iipi-. ve if, v- ýy 
-ý! 
fc ..... ý 
Figure 2.3 Dong Thap General Hospital in Cao Lanh City at the Mekong Delta, 
Southern Viet Nam. (Photo by Mai Ngoc Lanh) 
2.1.5 Oxford University Clinical Research Unit (OUCRU): 
The Oxford University Clinical Research Unit opened in 1991, funded by the Wellcome 
Trust of Great Britain. The unit, located within the HTD, serves as a collaborative 
centre between the HTD in Ho Chi Minh City, the Department of Health, Ho Chi Minh 
City and Oxford University. The Unit started as an 8- bed ward for the treatment and 
38 
Chapter Two: Material and Methods 
research on severe and complicated malaria. Over two decades the Unit has expanded 
with a modem 4-storey laboratory with all facilities including classical medical 
microbiology but also with sophisticated molecular techniques for the diagnosis and 
investigation of most severe infections including influenza, malaria, dengue, 
tuberculosis, typhoid fever and other enteric infections, central nervous system infection 
and tetanus. The OUCRU has developed strong links not only with HTD, but also other 
hospitals, institutes and universities in Ho Chi Minh City, Hanoi, Hue, the Mekong 
Delta and other centres in Asia (Nepal, Indonesia and China). 
Figure 2.4 The Oxford University Clinical Research Unit, Ho Chi Minh City, Viet 
Nam. 
In the following parts of this chapter (2.2 and 2.3) 1 describe the general clinical and 
microbiology methodology used subsequently in the whole thesis. Further relevant 
details are provided in subsequent chapters. 
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2.2 Microbiological methods: 
From all studies, stool samples were collected from patients and cultured directly within 
2 hours on the day of sampling. All specimens were processed in the microbiology 
laboratory of the HTD. 
2.2.1 Stool culture: 
2.2.1.1 Bacteria identification: 
Samples were cultured directly, and after overnight enrichment in selenite F broth 
(Oxoid, Basingstoke, UK) onto MacConkey and XLD agar (Oxoid) at 37°C. Colonies 
suggestive of Salmonella or Shigella (non-lactose fermenting) were sub-cultured on to 
nutrient agar and were identified using a `short set' of sugar fermentation reactions 
(Kliger iron agar, urea agar, citrate agar, SIM motility-indole media (Oxoid)). After 
incubation for 18 - 24 h at 37 °C, the test media were read for characteristic Shigella 
reactions. Serology and API 20E test strips of biochemical reactions (BioMerieux, Paris, 
France) were used to confirm the identity of Shigella spp. (Figure 2.5). 
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Figure 2.5 Example of API 20E test (bioMerieux, Paris, France) for identification of 
enteropathogens. Upper half: biochemical reaction, lower half: interpretation of reaction 
and result of online identification at https. //apiweb. biomerieux. com/. 
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Serologic identification was performed by slide agglutination with polyvalent somatic 
(0) antigen grouping sera, followed by testing with available monovalent antisera for 
specific serotype identification as per the manufacturer's recommendations (Denka 
Seiken, Japan). API 20E test was performed as directed by the manufacturer 
(BioMerieux, Paris, France). 
2.2.1.2 Antibiotic susceptibility testing: 
Antimicrobial susceptibility testing of all Shigella isolates against Ampicillin (AMP), 
Chloramphenicol (CHL), Trimethoprim - Sulfamethoxazole (SXT), Tetracycline 
(TET), Nalidixic Acid (NAL), Ofloxacin (OFX; ), Ciprofloxacin (CIP), Gatifloxacin 
(GAT) and Ceftriaxone (CRO) was performed by Kirby-Bauer's disk diffusion test 
following standardized Clinical and Laboratory Standards Institute methods (Figure 2.6) 
(CLSI, 2007). The minimum inhibitory concentrations (MICs) were additionally 
calculated for all isolates by E-test, according to manufacturer's recommendations (AB 
Biodisk, Sweden) (Figure 2.7). 
Figure 2.6 Example of Kirby-Bauer antibiotics susceptibility test. This strain is 
susceptible to ciprofloxacin (CIP, lower right) and ofloxacin (OFX, upper left) but 
resistant to nalidixic acid (NAL, lower left) and ceftriaxone (CRO, upper right). 
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Figure 2.7 Example of E-test to measure the Minimum Inhibitory Concentration (MIC) 
of bacteria with antibiotics (NAL: nalidixic acid, OFX: ofloxacin). 
2.2.1.3 Extended-spectrum-beta-lactamase (ESBL) investigation: 
Those strains that were identified as resistant to ceftriaxone using the disk diffusion 
susceptibility test were further subjected to the "combination disc method" or modified 
double disc synergy test (DDST) to confirm ESBL production. The combination disc 
method utilizes discs containing only cefotaxime (CTX) (30 µg) and ceftazidime (CAZ) 
(30 µg) and both antimicrobials combined with clavulanic acid (CLA) (10 µg). ESBL 
producing strains were identified as those with a greater than 5 mm increase in zone of 
inhibition with the single antimicrobial compared to the combined antimicrobial, i. e. 
demonstrating ESBL inhibition (Figure 2.8). 
Figure 2.8 Combination disc test for confirming the presence of ESBL. The increase 
of >5mm of inhibition zone diameter of CTX-CLA (upper left) compare with CTX 
alone (lower) confirms the presence of ESBL produced by this strain. 
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In the modified double disc synergy test, a disc containing amoxycillin plus clavulanic 
acid was placed at the centre of the plate surrounded by discs of CTX, CTX-CLA, CAZ, 
CAZ-CLA, FEP at regular distances (Figure 2.9). 
All antimicrobial testing was performed on Mueller-Hinton agar and interpreted 
according to the Clinical and Laboratory Standards Institute Guidelines (CLSI, 2007). 
Quality control of disk diffusion testing is performed weekly with ATCC 700603 
Klebsiella pneumoniae and E. coli ATCC 25922 following CLSI guidelines (CLSI, 
2007). 
Figure 2.9 Modified double disc synergy test (DDST) to confirm the presence of 
ESBL. Note the keyhole formations between the pairs CAZ (upper most) and AMC 
(centre), FEP (left) and AMC, CTX (lower right) and AMC are typical of ESBL 
producing strains. (CAZ: Ceftazidime; CTX: Ceftriaxone; FEP: Cefepime; CLA: 
Clavulanic acid; AMC: Amoxycillin plus Clavulanic acid). In this modified DDST, the 
placement of CTX-CLA and CZA-CLA disc allows comparing their inhibition zone 
diameters with those of CTX and CZA alone as practiced in combination disc test. 
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2.2.2 Stool microscopy: 
Stool was examined under microscope (HPF (x400)) for white blood cell, red blood cell 
and parasite. White blood cell and red blood cell count were scored on scale from zero 
to 4, scale 0 cells = 0/10 HPF, scale 1=I to 10 cells/HPF, scale 2= 11 to 20 cells/HPF, 
scale 3= >20 cells/HPF. 
2.3 Clinical methods: 
All children admitted to the study were examined by research doctors, a detailed history 
of illness and physical examination was recorded at enrolment. Body temperature, 
number and characteristics of stools passed were recorded every 6 hours until discharge. 
The detailed methodology is described in chapter 6. 
2.4 Molecular methods: 
2.4.1 Bacterial Conjugation Experiment: 
Bacterial conjugation experiments were performed at a 1: 1 ratio in liquid cultures. The 
detailed procedure is described in chapter 5, 
2.4.1.1 Transfer of ceftriaxone-resistant genes from wild-type Shigella strains to 
ceftriaxone-sensitive laboratory E. co1i strain: 
The donor strains were Shigella clinical isolates carrying ceftriaxone-resistant genes and 
the recipient was E. coli J53 (sodium azide resistant, ceftriaxone susceptible) (Figure 
2.10). 
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Conjugation Experiment (Broth mating) 
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Figure 2.10 Schema of conjugation experiment to confirm the transfer of ESBL genes 
from the donor wild-type Shigella to laboratory E. coli J53 AzR. 
2.4.1.2 Transfer of ceftriaxone-resistant genes from ceftriaxone-resistant 
transconjugant back to wild-type ceftri axon e-s u scepti ble S. sonnei: 
The donor strain in this experiment was a transconjugant resulting from the conjugation 
of ceftriaxone-resistant strain EG0187 with E. coli J53 (the transconjugant was named 
EGI87c), and the recipient was wild-type S. sonnei EG 0211, which was a ceftriaxone- 
susceptible nalidixic acid-resistant S. sonnei. Both EG0187 and EG0211 strains were 
isolated at Dong Thap Provincial Hospital in 2008. The final transconjugant selection 
was carried out in selective LB media containing nalidixic acid 30 mg/L and ceftriaxone 
6 mg/L. 
Potential transconjugants were verified by biochemical tests using API 20E set, 
antibiotic susceptibility test and ESBL confirmation test (Figure 2.11). 
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Conjugation Experiment (Broth mating) 
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Figure 2.11 Schema of conjugation experiment to confirm the transfer of ESBL genes 
from the donor transconjugant EGI87c (ceftriaxone-resistant) to the wildtype S. sonnei 
EG211 (ceftriaxone-susceptible, nalidixic acid resistant). The resultant transconjugant 
EG211 187c was resistant to both nalidixic acid and ceftriaxone. 
2.4.2 Plasmid extraction and visualization: 
Plasmid DNA was isolated from ESBL negative Shigella isolates, ESBL positive 
Shigella isolates, their transconjugants, and the laboratory recipient strain E. coli J53 
AzR using a modified version of the methodology previously described by Kado and 
Liu (Kado and Liu 1981). E. coli 39R861 containing plasmids of 7,36,63 and 147kbp 
were used for sizing plasmid extractions on agarose gels (Figure 2.12). 
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Plasmid Extraction (Kado & Liu) 
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Figure 2.12 Steps in plasmid extractions (Modified Kado& Liu method) 
2.4.3 ESBL gene PCR amplification and characterization is described in detail at 
chapter 5. 
2.5. Virology methods: 
2.5.1 Electron microscopy: 
Faecal suspensions (1 O%-20%, v/v) were prepared in phosphate-buffered saline (pH 
7.2). Copper, electron-microscopy grids (3mmin diameter; 400 mesh) that had been 
precoated in polyvinyl formal resin (Formvar®) were dipped into the suspension and 
air-dried. The grids were then negatively stained with 2% (v/v) phosphotungstic acid 
and then viewed on a Philip's 301 electron microscope at an initial screen magnification 
of x45,000. 
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2.5.2 Extraction of rotavirus dsRNA: 
The faecal suspensions were centrifuged in a bench-top microcentrifuge (13,000xg for 
I0min). The double-stranded RNA (dsRNA) of any rotavirus present was then extracted 
from the supernatant solutions, using a guanidine-isothiocyanate-silica glass-powder 
method (Boom et al., 1990; Gentsch et al., 1992). The dsRNA was analysed by PAGE 
and also used for G-and P-typing, by reverse-transcriptase PCR. 
2.5.3 P- and G-genotyping: 
A semi-nested, multiplex, reverse-transcriptase PCR (RT-PCR) was used to identify the 
P- and G-genotypes represented in each dsRNA sample. The primers used enable the 
detection not only of P[4], P[6], P[8], P[9], P[10], G1, G2, G3, G4, G8 and G9, but also 
of a novel variant of G1 (G1*) that has been detected in Malawi and a novel variant of 
P[8] - P[8*] - that has been detected in Malawi and the U. K. Amplicons were 
subjected to electrophoresis in 2% (w/v) agarose, stained with ethidium bromide and 
then visualized by ultra-violet trans-illumination. Genotypes were assigned by 
comparison of the banding patterns with those produced with reference samples of 
known genotype. 
2.5.4 Sequencing: 
The variant G1 * and P[8*] amplicons were cut from the agarose gels, eluted and 
purified using a commercial gel purification kit (Qiagen, Crawley, U. K. ), cloned into 
pGEM-T (Promega, Madison, WI) and then transformed into Escherichia coli TG2. 
Plasmid DNA containing the insert was isolated from the E. coli, using another 
commercial kit (Qiagen), and then sequenced, using M12 primers, by Lark Technologies 
(SaVron Walden, U. K. ). The sequences were compared using the clustal x software 
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package (Institut de Ge'ne'tique et de Biologie Mole'culaire et Cellulaire, Strasbourg; 
Thompson et al., 1994) and weighted residue tables. 
2.6. Statistical methods: 
2.6.1 Sample size calculation: 
We calculated the sample size of the EG study as follows: based on the result of 
previous study, the cure rate of the current treatment (ciprofloxacin) was 65% 
(ZimBaSA_Dysentery_Study_Group 2002), and the expected cure rate of the 
gatifloxacin was 90%. For 80% power and 5% significance each group needed 50 
culture-confirmed cases. Because the stool culture positivity rate was anticipated to be 
approximately 25%, and the dropped out rate 5%, we enrolled estimated that we needed 
to enrol 250 cases in each treatment arm. 
2.6.2 Statistical analysis: 
Data were double entered into Microsoft Excel 2003, Microsoft Access 2003 (Microsoft 
Corporation, Redmond, 2003) or Epidata version 3.1 (www. epidata. dk) for storage and 
manipulation. The Mann-Whitney U, Wilcoxon rank sum, and Kruskal-Wallis test were 
used for non-normally distributed data. Chit test with Yates' correction was used for 
categorical variables or Fisher's exact test if the number in any cell was less than 5. The 
survival analysis with log rank test was used to compare the fever clearance time, 
diarrhoea clearance time and bacteriological clearance time. 
2.6.3 Statistical software: 
Softwares used for data analysis: 
Epilnfo version 6.04d, CDC, Georgia, 2001, 
Epidata version 3.1 (www. epidata. dk) 
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Maplnfo Professional software (PitneyBowes, Maplnfo Corporation, USA) 
SPSS for Windows version 15, SPSS Inc., Chicago, 2006, 
and R (http: //www. r-project. org/). 
2.7. Ethical approvals: 
All studies were approved ethical assessment by the Scientific and Ethical Committees 
of 
- The Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam 
-Dong Thap Provincial Hospital, Viet Nam 
-Oxford Tropical Research Ethics Committee, UK (ref OXTREC 010-06). 
The clinical trial was registered at International Standard Randomized Controlled Trials 
Registry (ISRCTN55945 881). 
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Chapter Three 
Acute Childhood Diarrhoea: Shigella versus Rotavirus 
3.1 Introduction: 
Acute diarrhoea is a familiar clinical presentation to paediatricians around the world. In 
the United States alone, an estimated 211-375 million episodes of diarrhoeal illness 
occur each year, resulting in 73 million physician consultations, 1.8 million 
hospitalizations, and 3100 deaths (Guerrant 2001). For children under 5 years of age 
living in developing countries, there are a median of 3.2 episodes of diarrhoea per child- 
year. Estimates of mortality in developing countries based on studies published between 
1992 and 2000 showed a median mortality rate of 4.9 children per 1000 per year in the 
first 5 years of their lives (Kosek et al. 2003). An update of the World Health 
Organisation Global Burden of Diseases estimates in 2007 showed that mortality from 
diarrhoea has declined over the past two decades from an estimated 5 million deaths 
among children under-five to 1.5 million deaths in 2004, which parallels downward 
trends in overall under-five mortality during this period. Despite these declines, 
diarrhoea remained the second most common cause of death among children under-five, 
following closely behind pneumonia, the leading killer of young children. Together, 
pneumonia and diarrhoea account for an estimated 40 per cent of all child deaths around 
the world each year. Nearly one in five child deaths is due to diarrhoea, a loss of about 
1.5 million lives each year. The toll is greater than that caused by AIDS, malaria and 
measles combined (UNICEF/WHO 2009). 
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Acute diarrhoea may be fatal because of serious complications developing particularly 
in young children including severe dehydration and acidosis (Farthing 2007). In 
children in whom the illness lasts two weeks or more (i. e. persistent diarrhoea), nutrition 
status may deteriorate leading to malnutrition and hence further predispose them to 
pneumonia and other infections. 
More than twenty viral, bacterial, and parasitic enteropathogens are currently associated 
with acute diarrhoea (O'Ryan et al. 2005). The aetiology of infectious diarrhoea) illness 
varies in time and places of studies, but generally viruses are the main agents, bacteria 
rank second and parasites contribute a relatively small part of the overall burden of 
disease. 
In Viet Nam, there have been relatively few studies on the aetiology of acute diarrhoeal 
diseases and most have been conducted in Ha Noi. These have shown that rotavirus was 
the main agent, and Shigella was the most important bacteria associated with acute 
diarrhoeal diseases in children under-5 years old admitted to hospitals (Bodhidatta et al. 
2007; Hien et al. 2008; Vu et al. 2006). 
Knowledge of the agents causing acute diarrhoea in a region is important in informing 
the public health authorities and guiding the choice of appropriate prevention measures. 
Because a microbiological diagnosis of acute diarrhoea is not feasible in all cases, 
clinicians working at the bed-side also need information about aetiology of acute 
diarrhoea to guide clinical management. Until now comprehensive data on the aetiology 
of childhood diarrhoeal diseases in Ho Chi Minh City and surrounding provinces at the 
southern part of Viet Nam was lacking. 
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In this chapter I describe the aetiology of acute diarrhoea in children admitted to The 
Hospital for Tropical Diseases at Ho Chi Minh City and compare the clinical and 
epidemiological features of the two most important enteropathogens in the region: 
rotavirus and Shigellae. The aim of this study is to develop an algorithm to distinguish 
acute invasive diarrhoeal diseases (the prototype is shigellosis) from acute non-invasive 
diarrhoea) diseases (the prototype is rotavirus diarrhoea). 
3.2 Materials and methods: 
Children under 6 year-old of either sex admitted to Paediatric Ward B (See section 
2.1.3), The Hospital for Tropical Diseases in Ho Chi Minh City, Viet Nam with a 
primary history of diarrhoea for less than 7 days were entered into the study provided 
their parents or care-givers gave informed consent. One admission stool sample from 
each patient was collected for investigation. Because of laboratory facility limited, only 
the first 5 patients admitted each day were considered eligible for the study. 
Microbiological, virological and clinical methods were described in section 2.2,2.3 and 
2.5 in chapter two. Briefly, stool samples examined by microscopy for white cells, red 
cells and parasites (E. histolytica, Ascaris); a smear was made using the modified Ziehl- 
Nielson stain for detecting Cryptosporidium and Cyclospsora. Standard culture methods 
were used for Shigella spp., Salmonella spp., Campylobacter spp., Vibrio spp., 
Aeromonas spp., Clostridium dificile and Yersinia spp. C. dificile toxin was detected by 
antigen detection kits. Virus was detected by negative-stain electro-microscopy and 
genotyping (Landaeta et al. 2003). For E. coli identification, 5 E. coli-like colonies on 
McConkey agar from each sample was saved at -20°C for later molecular diagnosis of 
diarrhoeagenic E. coli [ETEC, EPEC, EIEC, EHEC, EAEC] by multiplex PCR. 
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Patients were treated according to the Hospital for Tropical Diseases guidelines which 
were adopted from the World Health Organisation and American Academy of Pediatrics 
Guidelines (Anonymous 1996). Fluid rehydration (oral or parenteral) and antibiotics 
were used under the physician's decision not waiting for the stool culture results. 
Details on demography, epidemiology and basic laboratory results, antibiotics used, 
clinical response and outcome were recorded in a standard clinical record form. 
The study was reviewed and approved by The Scientific and Ethical Committee of The 
Hospital for Tropical Diseases in Ho Chi Minh City, Viet Nam. 
3.3 Results 
In the initial twelve month phase of the study there were 556 patients from which 
comprehensive investigation of enteropathogens (virus, bacteria and parasites) were 
done. In the second twelve month phase of the study 866 samples were cultured only for 
Shigella spp. (Figure 3.1). 
Screening for virus, bacteria and parasites Screening for Shigella only 
556 patlents 
3-2000 
"-----". 
aotavieus 3-20016-2001 
Genocynrq 
sbwv 
M patNents 
12-2002 
Figure 3.1 Diagram of participant recruitment for diarrhoeal aetiology investigation. 
3.3.1 Aetiology of acute diarrhoea: 
The microbiological result of Phase I study is presented in Table 3.2. At least one 
enteropathogen was found in faecal samples of 346 children (62% of total samples). 
Rotavirus was found in 259 patients (46%) and was the most common agent detected 
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including 25 mixed infection with other pathogens. Shigella was found in 52 cases (9% 
of total) in which S. flexneri 30, S. sonnei 20, S. dysenteriae 1 (not type 1) and S. boydii 1. 
There were 33 mixed infections in which 2 pathogens were found (6% of total) (Among 
which rotavirus + Shigella in 8 cases and rotavirus + Campylobacter in 6 cases) (Table 
3.1). The molecular diagnosis of E. coli was not successful because the saved samples 
were damaged during storage. 
Table 3.1 Enteropathogens found in 556 children with 
acute diarrhoea, including cases with mix infections 
Pathogen No. of cases (%) 
Rotavirus 259 46 
Adenovirus 16 2.8 
Calicivirus 61 
Astrovirus 51 
Shigella: S. flexneri 30 
S. sonnei 20 9 
S. dysenteriae 1 
S. boydii 1 
Campylobacter spp. 20 3.6 
Salmonella spp. 12 2.1 
C difficile 3 0.5 
Ascaris lumbricoides 3 0.5 
Cryptosporidium 3 0.5 
E. histolytica 1 
None 210 38 
* Rotavirus-Shigella 8, rotavirus-Campy/obacter 6, rotavirus- 
Salmonella 2, Adenovirus-Shigella 2 
In Phase II of the study there were 866 samples cultured and 61 strains of Shigella was 
isolated (33 S. sonnei, 22 Sflexneri, 6 Shigella spp. ). Total Shigella strains isolated in 
two periods was 113. 
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3.3.2 Epidemiological features of rotavirus and Shigella infection: 
In order to help clincians to distinguish Shigella infection from rotavirus infection in 
children I compared the clinical and epidemiological features of rotavirus and Shigella 
infection after excluding cases with mixed infection. 234 children with confirmed 
rotavirus infection and 99 Shigellosis cases were available for comparison. 
Seasonal variation of rota virus and Shigella infection: 
There was no peak incidence during the year for either rotavirus or Shigella diarrhoea 
cases in the first period of study (Figure 3.2). 
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Figure 3.2 Monthly distribution of childhood diarrhoea) cases caused by rotavirus (234 
cases) and Shigella (99 cases) from March 2000 (3_00) to February 2001 (2_01). 
Age distribution of rota virus and Shigella infection: 
The distribution of age group in rotavirus and Shigella infection (Figure 3.3) showed 
that diarrhoea caused by rotavirus peaked in children between 7 to 12 months old. 
Ninety percent of rotavirus-associated diarrhoea cases were in children < 24 months old, 
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including 8% in children 3 to 6 months old. Shige//a spp. affected children in an older 
age group 13-24 months group, and was rarely seen in children less than 6 months old. 
The median age of children infected by rotavirus was II months (IQ range 8-17 
months) while the median age of shigellosis patients was 23 months (IQ range 15-30 
months). The difference was statistically significant (p=0.001, Mann-Whitney U test) 
and clinically relevant. Children younger 6 months may be infected by rotavirus but 
rarely by Shige! /a, suggesting that maternally derived immunity offered some protection 
against shigellosis but not against rotavirus in this period of the children life; in children 
older than 24 months the chance of getting shigellosis is higher than for rotavirus. 
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Figure 3.3 Age distribution in rotavirus and Shigella infection (p=0.001, Mann- 
Whitney U test). 
Gender in acute diarrhoea caused by rota virus and Shigella: 
More boys suffered from rota-virus than girls with the ratio of boy : girl was 1.5. In 
contrary the boy : girl ratio of shigellosis cases was 1. 
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Gender Distribution in Acute Diarrhoea Caused 
by Rotavirus or Shigella 
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Figure 3.4 Gender in acute diarrhoea caused by rotavirus or Shigella. 
Geographic distribution of rotavirus and Shigella diarrhoea: 
The majority of cases were from Ho Chi Minh City with 303 cases. Long An, the 
province next to Ho Chi Minh City to the west contributed 25 cases (Table 3.2). 
Table 3.2 Location distribution of cases of acute 
diarrhoea caused by rotavirus or Shigella 
Province 
Rotavirus Shigella 
(No. cases) (No. cases) 
Ho Chi Minh City 215 88 
Long An 16 9 
Tien Giang 21 
Lam Dong I0 
Ben Tre 01 
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Within Ho Chi Minh City cases of acute diarrhoea were distributed in all 14 districts. 
The highest number of cases came from District 8 (101 cases) the closest district to 
HTD. District 6, Binh Chanh and 5 are second, third and forth place (Table 3.3). 
Table 3.3 District distribution of acute diarrhoea 
cases in Ho Chi Minh City (303 cases) 
District Rotavirus 
Shigellosis 
(No. of cases) (No. of cases) 
8 65 36 
6 46 11 
5 23 9 
Binh Chanh 15 12 
11 14 3 
10 12 2 
Tan Binh 10 5 
784 
162 
Nha Be 43 
441 
Go Vap 30 
330 
910 
Thu Duc 10 
3.3.3 Genotypes of rotavirus in Ho Chi Minh City. I 
Stool samples which were positive for rotavirus by negative-stain electron microscopy 
were subjected to reverse transcriptase polymerase chain reaction (RT-PCR) to identify 
the P- and G-genotypes. The primers used enable the detection of not only the P[4], 
P[6], P[8], P[9], P[10], G1, G2, G3, G4, G8 and G9, but also the variant of GI (G1*) 
and of P8 (P8*). The results of the analysis of 49 isolates were presented on Table 3.4 
(Landaeta et al. 2003). G1 [P8] and it's variants Gl* P[8], G1* P[8*], G1/G1* P[8]/P[4] 
This part of the thesis had been published in details else where: M. E. 
Landaeta et al., 'Characterization 
of Rotaviruses Causing Diarrhoea in Vietnamese Children', 
Ann Trop Med Parasitol, 97/1 (Jan 2003), 53- 
9. 
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was the predominant genotype (20 isolates). Of note was the second place G2 [P4] 
which has been isolated in 16 patients. 
Table 3.4 Genotypes of rotavirus isolated in Ho 
Chi Minh City, 9-12/2000. 
G1 P[8] 2 
G1* P[8] 5 
G1* P[8*] 12 
G1/Gl* P[8]/P[4] 1 
G1* P[4] 4 
G I* P[4]/P[6] 1 
G2 P[4] 16 
G2/G1 P[4]/P[8] 1 
G2 [P6] 1 
G2 P[8*] 1 
G2 P[NT] 1 
G4 P[6]/P[4] 1 
G4 P[8*] 2 
* mutation variation of G or P genes; 
NT: not typed 
3.3.4 Clinical features of acute diarrhoea caused by rotavirus and Shigella. 
The symptoms and laboratory characteristics of 333 children with acute diarrhoea is 
shown in Table 3.5. Patients with diarrhoea caused by rotavirus were more likely to 
present with the triad "fever-vomiting-watery diarrhoea"; whereas children with 
shigellosis more typically presented with "fever-mucoid diarrhoea-abdominal pain" 
while about half of them also suffered from vomiting and passed watery diarrhoea. 
Shigellosis cases also had higher blood white cell count than patients with rotavirus 
diarrhoea (pß. 001), and higher chance of having WBC (94% versus 32%, p= 0.0001) 
and RBC (70% versus 10%, p=0.000 1) in their stools (Table 3.5). 
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Table 3.5 Clinical symptoms and laboratory findings in children with acute 
diarrhoea caused by rotavirus or Shigella (n=333) 
Symptoms 
Fever 
Vomiting 
Watery diarrhoea 
Mucoid diarrhoea 
Abdominal pain 
Convulsion 
Dehydration 
Temperature (°C) 
Blood WBC /µL 
Presence of Faecal WBC 
Presence of Faecal RBC 
Rotavirus Shigella 
(n=234) (n=99) 
P value 
87% 94% 0.1* 
89% 56% 0.001* 
93% 46% 0.001* 
7% 54% 0.001 * 
11% 38% 0.001* 
1% 7% 0.01* 
1% 6% 
. 
5* 
38.0 (37-38.5) 38.0 (37.5-39.5) 0.05** 
7400(5800- 10150(7700- 
9300) 13100) 0.001** 
32% 94% <0.001* 
10% 70% <0.001* 
RBC: red blood cell; WBC: white blood cell 
* Fisher exact test 
** Mann-Whitney U test, values are medians (IQ range) 
Of note 14/99 (14%) shigellosis cases recovered well despite not having been treated 
with antibiotics, and 85/234 (36%) cases of rotavirus diarrhoea has been treated with 
antibiotics (Table 3.6). Five antibiotics were used in these cases: Ofloxacin (41), 
Norfloxacin (34), Spiramycin (6), Cefaclor (3) and Ceftriaxone (1). 
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Table 3.6 Clinical outcomes and antibiotic use in acute childhood diarrhoea cases 
caused by rotavirus or Shigella (n=333) 
Rotavirus Shigella P value 
Illness before admission (days)" 3 ±1.8 2.2 ±1.2 0.001* 
Fever Clearance Time (days)# 2.1 ±1.6 1.7 ±1.0 0.3* 
Diarrhoea Clearance Time (days)" 3.1 ±1.8 2.5 ±1.5 0.1* 
Hospital stay (days) # 4.7 ±2.1 4.0 ±2 0.001 * 
Treated with Antibiotics 36% 86% p=0.001 ** 
* (Mann-Whitney U test) 
** Chi2 test 
*Values are means ±SD 
3.4 Discussion: 
3.4.1 Aetiology of acute diarrhoea: 
Confirming the causative agent in acute diarrhoea is important not only to inform public 
health authorities but also in guiding appropriate intervention measures for prevention 
and treatment. The aetiology of acute diarrhoea varies by location, timing of 
investigation and the setting in which the study was carried out (hospital-based or 
community-based). In this hospital-based study in Ho Chi Minh City in the southern 
part of Viet Nam, at least one enteropathogen was detected in 346 out of 556 (62%) 
children hospitalised for acute diarrhoea. Rotavirus is the most common agent causing 
acute diarrhoea in children with 259/556 (46%); Shigella spp. ranks second with 52/556 
(9%) of all cases. These two were the most important enteropathogens associated with 
acute diarrhoea in children in Ho Chi Minh City and surrounding provinces. This 
finding is concordant with data from northern Viet Nam where an study in Ha Noi 
revealed rotavirus 33/104 (31 %) and Shigella 21/249 (8.4%) to be the most important 
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enteropathogens associated with acute diarrhoea in children under 5 years of age 
admitted to hospitals (Bodhidatta et at. 2007; Hien et al. 2008). 
Other viruses were also present in childhood diarrhoea cases in our study: adenovirus 
16/556 (2.8%) and astrovirus 5/556 (1%). Calicivirus (including norovirus and 
sapovirus) were detected in our study in Ho Chi Minh City at low percentage 1% (6/556 
samples). However the prevalence of norovirus has been noted to have increased in to 
5.5% (56/1010 samples) in a study from October 2002 to September 2003 at Children 
Hospital Number 1 Ho Chi Minh City (Nguyen et al. 2007), and recently (year 2009) to 
27.8% of 187 stool samples from paediatric acute diarrhoea patients in 3 hospitals at Ho 
Chi Minh city (Steve Baker, personal communication). Campylobacter spp. was 
detected in 20/556 (3.6%) and Salmonella spp. in 12/556 (2.1 %) of all cases in our 
study, and were the second and third most important bacteria associated with acute 
diarrhoea in children. This ranking is different from that reported in Ha Noi where 
Salmonella was the second more important bacteria with 19/291 cases (7%) and 
Campylobacter third with 11/291 (4%). A community-based study carried out in a rural 
area along the Red River approximately 50 kilometres northwest of Ha Noi isolated 
Campylobacier from 150/2160 (6.8%) of children presenting with acute diarrhoea but 
also from 8/203 (3.9%) of healthy control children (Isenbarger et al. 2001). The 
presence of Campylobacter as an important bacteria associated with acute childhood 
diarrhoea may reflect a change of life style in Viet Nam where poultry, increasingly 
raised by intensive farming methods, processed and sold through supermarkets is being 
consumed. Cryptosporidium was also found in a small number 3/559 (0.5%) of our 
children with diarrhoea. Enterotoxigenic Bacterioides fragilis, an emerging agent 
causing acute diarrhoea which has been described recently from Ha Noi was not 
detected in our study (Vu et al. 2006). 
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Unfortunately for unexpected prolong power cut to the freezer, the E. coli identification 
was unable to perform. Hien and colleagues in their study on aetiology of diarrhoeal 
diseases in children at Saint Paul Hospital, Ha Noi, detected diarrhoeagenic E. coli in 
64/249 (25.7%) of diarrhoea children and in 13/126 (10.5%) of healthy children control 
group (Hien et al. 2008). The pathogenicity index2 of diarrhoeagenic E. coli as a whole 
in Ha Noi is 2.5 (25.7% / 10.5%) suggesting their role in acute diarrhoea; but separately 
EPEC, E/EEC and EAggEC were isolated at a high frequency from both cases and 
controls (Hien et al. 2008). Using multiplex PCR technique to detect diarrhoeagenic 
E. coli in stool samples, Vu et al in Ha Noi also reported the prevalence of isolation of 
diarrhoeagenic E. coli strains from under-5 years old children with diarrhoea was 
slightly higher than that from the age-match healthy controls: 132/587 (22.5 %) in cases 
versus 30/249 (12 %) in controls (T. V. Nguyen et al. 2005). Further in-depth studies of 
E. coli are needed before firm conclusions can be reached about the role of these 
potential enteropathogens in Vietnamese children (Hien et al. 2008; Vu et al. 2006). 
In northern Ghana, the most common pathogens in paediatric patients were rotavirus 
(55%), adenovirus (28%) and norovirus (10%); intestinal parasites (5%) and bacteria 
(5%) were rare. Rotavirus was the only pathogen found significantly more frequently in 
patients than in controls (odds ratio 7.7; 95% Cl, 4.2-14.2) (Reither et al. 2007). In The 
United States, enteric bacteria contributed only -5 % while virus contributed 21 % as 
the cause of acute diarrhoea in children evaluated in outpatient settings (Denno et al. 
2005). In a study involved patients who presented with diarrhoea to a children's hospital 
emergency department at Washington, United States, bacteria were isolated in 119/1626 
(7.3%) and virus in 138/417 (33%) of cases (Klein et al. 2006). Rotavirus is the most 
2 Pathogenicity Index (PI): the percentage of diarrhea patients shedding a particular 
pathogen or shedding E. coli carrying a target gene, divided by the respective 
percentage of control patients with positive test results for that same pathogen or factor. 
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important virus detected in diarrhoeic children in the United States, just the same with 
that in Viet Nam in this study and other studies (Bodhidatta et al. 2007; Vu et al. 2006). 
In contrast, while Shigella is the most important bacteria associated with childhood 
acute diarrhoea in Viet Nam (Hien et at. 2008), in the United States it is Campylobacter 
(Denno et at. 2005). 
In our study there were 22 cases (4%) in which two enteropathogens were detected in 
faecal samples and one case with 3 pathogens (rotavirus plus astrovirus and 
Campylobacter spp. ). The presence of poly-microbial infection has been reported in 
56/1010 stool samples (5.5%) in another study at Ho Chi Minh City (Nguyen et al. 
2007). Mixed infection was also found 2.4% in Pakistan (Khan et al. 1988), 5% in a 
study in Spain (Roman et al. 2003) and 6% in Greece (Kafetzis et al. 2001). Mixed 
infection did not cause a more severe clinical picture, particularly the severity of 
dehydration (Nguyen et al. 2007). 
3.4.2 Genotypes of rotavirus in Ho Chi Minh City: 
The predominant genotype was Gi [P8] and variants of this genotype (in 20 cases). 
Interestingly the G2 genotype [P4] was found in 16 patients (Table 3.4). In a study 
undertaken at the same time at Children Hospital No. I at Ho Chi Minh City G1 [P8] 
was the most prevalent with 517/889 (58.2%) of all isolates (Doan et al. 2003). Another 
study in 2002-2003 also in Children Hospital No. 1 at Ho Chi Minh City revealed for the 
first time the emergence of genotype G9 as the third most common rotavirus G-type in 
67/681 samples (13.7%) (Nguyen et al. 2007). 
The diversity of rotavirus G and P-genotypes should be taken account when considering 
vaccine implementation for the prevention of rotavirus diarrhoea) diseases in Viet Nam. 
A good rotavirus vaccine should provide protection against the majority of viral 
65 
Chapter Three: Shigella versus Rotavirus 
genotypes circulating in the region. In the case of Viet Nam, where rotavirus presented 
with many important genotypes, a monovalent vaccine may not offer sufficient 
protection against the circulating strains of rotavirus. In March 2006, Brasil innitiated 
universal immunisation of infants with 2 doses of a monovalent G1 [P8] rotavirus 
vaccine. Two years after that, the hospitalisation of acute rotavirus diarrhoea cases 
decreased 59%, the number of all-cause acute gastroenteritis hospitalisation reduced 
29% among under-five children (Safadi et al. 2010). Among 133 faecal samples 
collected from February 2005 to December 2007 the genotype G2[P4] was found in 
1.4% in 2005, in 44% in 2006, and in 96% in 2007 (Carvalho-Costa et al. 2009). In a 
study allocating 926 children with acute diarrhoea in Recife City, Brasil, 119 cases were 
found rotavirus positive in faecal samples. Among 80 severe rotavirus positive cases 
(defined as cases requiring intravenous fluid rehydration at the Emergency Department 
or hospitalisation), 70 cases were of G2 [P4] genotype (Correia et al. 2010). The shift of 
dominant rotavirus genotype from GI [P8] to G2 [P4] may reflect the cyclic genotype 
fluctuation in Brasil or may be a consequence of low protection of the monovalent 
vaccine against G2 [P4] genotype infection. 
3.4.3 The difference in clinical and epidemiological features of acute diarrhoea 
caused by rotavirus and Shigella: 
An important question for the clinician confronted with a sick child with acute diarrhoea 
is whether an antibiotic is indicated. To answer this question, the clinician has to make a 
presumptive diagnosis: if it is thought to be viral then no antibiotic is required, if 
thought to be caused by cholera or other invasive bacteria, such as shigellosis, antibiotic 
should be administered (WHO 2005a). This study revealed a number of important 
differences in the clinical presentation of diarrhoea caused by rotavirus and by Shigella. 
The typical case of diarrhoea caused by rotavirus is a boy 7-12 months old, admitted to 
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hospital with the triad of fever-vomiting-watery diarrhoea, blood white cell count within 
normal limit and without white cells in the stool. A typical shigellosis cases presented 
with fever-mucoid diarrhoea-abdominal pain with leukocytosis and the presence of 
white blood cell in stool. However the reality is that in practice, there is significant 
overlap in the clinical and laboratory symptoms and signs of these two diseases. Data 
from this study showed that 46% of 99 children with shigellosis passed only watery 
stool, not mucoid stools. This is similar to Hien et al's finding in Ha Noi where 48% 
(10/22 cases) of shigellosis in their study passed only watery diarrhoea (Hien et al. 
2008). von Seidlein found that less than one-third of culture-proven shigellosis episodes 
presented with dysentery (von Seidlein et al. 2006). The proportion of Shigella infection 
episodes presented as non-dysenteric diarrhoea is as high as 80% (50/63 cases in Peru) 
to 89% (106/119 cases in Egypt) in community-based studies (Abu-Elyazeed et al. 
2004; Kosek et al. 2008). In our study, 32% of 234 rotavirus infection cases had white 
blood cell in their stool and 10% of all rotavirus diarrhoea cases even had red blood cell 
in stools. These findings underscore the difficulty in making a differential diagnosis of 
cases presented with acute diarrhoea in children. Shigella, in addition to their 
invasiveness, also produced enterotoxins ShET1 and ShET2 through the control of the 
set and sen genes. These toxins may explain the watery diarrhoea phase seen early in the 
course of the illness (Niyogi 2005). In many patients the dysenteric phase of bloody 
diarrhoea may never be a feature of the illness. Because of this, the clinical case 
definition that includes only patients with a history of dysentery, frequently used in 
government data collections may miss more than two-thirds of shigellosis cases (von 
Seidlein et al. 2006). The diagnosis of shigellosis should not be excluded in those 
patients with watery diarrhoea as the sole presentation (Wu et al. 2009). A call has been 
launched for revision of clinical guidelines for the diagnosis and treatment of diarrhoeal 
illness in limitted source health settings such as rural areas where primary care 
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physicians are unlikely capable of performing bacterial culture (Abu-Elyazeed et al. 
2004). Rapid tests, such as immuno-chromatographic dipstick which have been 
available for rotavirus (Weitzel et al. 2007) and on-developing for Shigella diagnosis 
(Nato et al. 2007b), may be of great value to help clinician having the correct diagnosis 
sooner. Early diagnosis of rotavirus prevents unnecessary use of antibiotics (which were 
used in 38% of our cohort) thus minimizes the chance of emerging resistance to 
antibiotics in gut flora. Early diagnosis of Shigella infection may helps clinicians giving 
antimicrobials earlier to prevent the spread of the bacteria to house-hold members or to 
the community. 
From the data of my study, I suggest a simple algorithm to help clinicians making a 
differential diagnosis between acute invasive diarrhoea (the prototype is shigellosis in 
which antibiotics are indicated) with non-invasive acute diarrhoea (the prototype is 
rotavirus infection in which antibiotics are usually not indicated) (Figure 3.5). The 
algorithm was developed using simple clinical data (bloody/non-bloody diarrhoea, 
with/without abdominal pain ± tenesmus, Blood WBC high/not high, presence/absence 
WBC in stool). The value of the algorithm needs to be validated in a larger diarrhoea 
population in the future. 
3.4.4 Limitations of the study: 
The present study had several limitations which need to be taken into account when 
interpreting the data. Firstly, the lack of a control group may lead to overestimate the 
role of a potential pathogen such as Enterovirus or Salmonella spp.. Secondly, the E. coli 
identification by PCR techniques has not been carried out because of reasons beyond 
our control. Without data on the E. coli isolation rate, the importance of this genus as a 
cause of acute diarrhoea in children cannot be evaluated. Studies in Viet Nam as well as 
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Tunisia reported a high rate of isolation of diarrhoeagenic E. coli in both cases and 
control population (Al-Gallas et al. 2007; Hien et al. 2008; T. V. Nguyen et al. 2005). 
Because of these limitations more studies are needed to clarify the magnitude ofE. coli 
in causing childhood diarrhoea in the setting of tropical region such as Viet Nam. The 
technique used for virus detection (negative-stain electro-microscopy) in this study is 
time consuming and labour-intensive and has been replaced recently either by rapid 
immunochromographic tests or enzyme-link immunosorbant assay (Atchison et al. 
2009) or real-time reverse transcription (RT)-PCR assays with specific primers (Svraka 
et al. 2009). 
3.5 Conclusion: 
Despite the limitations mentioned above, this study was the first comprehensive 
investigation of the aetiology of acute childhood diarrhoea in in-patients at Ho Chi 
Minh City, which showed that rotavirus and Shigella spp. to be the most importance 
virus and bacteria associated with acute diarrhoea. 
The study has also revealed the diversity of the rotavirus genotypes circulating in the 
region, in which variants of G1 [P8] and G2 [P4] contributed more than 69% (34/49 
isolates). This should be considered by the health policy decision-makers in designing 
the appropriate rotavirus vaccine for children in the region. Norovirus and 
Campylobacter spp are emerging causes of acute diarrhoea in this region. Regular 
surveillance studies are needed to document the aetiology of acute diarrhoea from which 
appropriate public health and clinical interventions can be applied. 
The overlap in the clinical presentations and results of basic laboratory test of acute 
diarrhoea caused by rotavirus and Shigella spp. also presents a challenge for the 
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clinician. A practical algorithm based on simple clinical data and easy-to-use rapid tests 
to diagnose these two important causative agents would be useful in helping the 
clinician making a diagnosis and plan treatment. 
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Acute diarrhoea: 
3 or more unformed stools 
in the last 24 hours 
Viral infection: eg. rotavirus 
OR non-invasive bacterial 
infection 
Figure 3.5 Algorithm for differential diagnosis of acute invasive diarrhoea (e. g. 
shigellosis) with acute non-invasive diarrhoea caused by viral infection (e. g. rotavirus) 
or enterotoxin-producing bacteria (e. g. cholera). 
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Chapter Four 
Changing Epidemiology, Antimicrobial Susceptibility 
and Clinical Features of Shigella Infection in Southern 
Viet Nam 
4.1 Introduction: 
Shigellosis is a major global public health problem. Each year approximately 1.1 
million people are estimated to die following infection and there are an estimated 165 
million episodes of Shigella infection (Kotloff et al. 1999). Shigella infection occurs 
mainly in developing countries where people live in overcrowded conditions often with 
personal hygiene, sanitation and safe water supply often not optimal. The incidence of 
Shigella infection varied from 0.6 episodes/1000 person-years in Thailand to 107/1000 
person-years in Egypt (Ram et al. 2008). Although on a different scale shigellosis 
remains an important public health issue in developed countries. A report from the 
National Center for Infectious Diseases in the United States of America found the 
incidence of shigellosis to be 5.6 cases per 100,000 persons in the 1989-2002 (Gupta et 
al. 2004). 
Four species (i. e. sero-groups) of the genus Shigella can cause diarrhoeal diseases in 
human: Shigella dysenteriae (sero-group A), Sfexneri (sero-group B), S boydii (sero- 
group C) and S. sonnei (sero-group D). All the members of the genus Shigella are human 
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restricted pathogens (and higher primates) and exert their effects on the gastrointestinal 
mucosa via the production of a number of virulence factors and enterotoxins (Niebuhr 
and Sansonetti 2000; Philpott et al. 2000). S. dysenteriae (15 serotypes) is the most 
dangerous Shigella species in which serotype 1 has been associated with epidemics of 
severe dysentery that have killed thousands of people in Central America, India sub- 
continent and Africa (Levine et al. 2007). S. flexneri (6 serotypes) is the predominant 
endemic sero-group in developing countries while S. sonnei is the most commonly 
isolated species in developed countries, over 70% of the total worldwide cases, are 
reported from the Unites States of America and Israel suggesting a reporting bias and 
the probability of massive under-reporting (Gupta et al. 2004; Mates et al. 2000). 
S. boydii contributes a very small part of Shigellosis, mainly in India where it first 
isolated. 
In a recent community-based surveillance, von Seidlein et al. found variation in the 
dominant Shigella species across Asia (S. sonnei predominated in Thailand, S. flexneri 
was dominant in other Asian countries including China, Viet Nam, Bangladesh, 
Pakistan and Indonesia), with fluctuations in S. flexneri serotypes in the same location 
over the duration of the study (von Seidlein et al. 2006). The authors concluded that 
"Shigella appears to be more ubiquitous in Asian impoverished populations than 
previously thought and antibiotic-resistant strains of different species and serotypes 
have emerged" (von Seidlein et al. 2006). Such findings have important implications for 
treatment and prevention strategies of shigellosis. Increasing antimicrobial resistance is 
a constant threat and suggests that current treatment regimes may be compromised. 
It is known that the circulating species and serotypes may be considered as a marker for 
the socio-economic conditions in an individual setting (Chompook et al. 2005). It is 
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clear that Viet Nam, in particular Ho Chi Minh City has undergone rapid economic 
development since the early 1990's. The improvement of living condition of people in 
the region may influence to the epidemiology and clinical feature of Shigella infection. 
In this chapter I have retrospectively compared the microbiological, epidemiological 
and clinical data from a series of studies on childhood shigellosis conducted in southern 
Viet Nam between 1995 and 2009 to gain a broader understanding of the changing 
epidemiology and antibiotic resistance pattern of Shigella infection in this region. 
4.2 Materials and methods: 
All the studies were carried out at the Paediatric Ward B of the Hospital for Tropical 
Diseases in Ho Chi Minh City (HTD). In addition, from June 2006 to December 2008 
part of the clinical trial (EG study) was also carried out at The Infectious Diseases 
Ward, Dong Thap Provincial Hospital (DTP). Both locations are in urban settings, 
however due to the referral patterns, both hospitals have a wide catchment area and 
accept patients from their locality and also from other rural provinces in the vicinity 
(Figure 2.1, chapter two). 
Data from paediatric in-patients enrolled in this thesis come from 3 studies covering 3 
periods. 
(i) The first period (referred to as Period A) was data taken from a study performed at 
the Paediatric Ward B between January 1995 and August 1996. This was a randomized 
controlled trial comparing ofloxacin (15mg/kg divided in 2 doses in a single day) with 
nalidixic acid (55mg/kg/day divided in 4 doses for 5 days) in the treatment of childhood 
bacillary dysentery and has been published elsewhere (Vinh et al. 2000). Additional 
strains for microbiological assessment only (nine in total) were collected for comparison 
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within the same period of the study duration from Dong Thap Provincial Hospital. 
Overall 80 strains were isolated from enrolled children over this period; clinical data 
was available for analysis on 63 patients with culture confirmed shigellosis. 
(ii) The second period (referred to as Period B) used data available from a study 
conducted at the HTD, between March 2000 and December 2002. This period was a 
clinical and microbiological investigation of the aetiology of diarrhoea in the paediatric 
population admitted to the HTD in Ho Chi Minh City. Whilst the treatment criteria for 
this descriptive study were not controlled (> 90% of patients received treatment with 
fluoroquinolones (either norfloxacin 20mg/kg/day or ofloxacin I0mg/kg/day for 3-S 
days), the remainder of the criteria for admission to the study were comparable, children 
were eligible for enrolment to the study if consent was given and they were aged less 
than 14 years. The obvious variation in the enrolment for this study was that children 
were enrolled on the basis of having any diarrhoeal syndrome, rather than specifically 
targeting those with dysentery and suspected shigellosis. One hundred and fourteen 
Shigella isolates were recovered during this period; clinical data was available for 
analysis on 113 patients. 
(iii) The fmal period (referred to as Period C) in which data was combined in this 
retrospective assessment was a trial conducted at the HTD and at DTP between June 
2006 and March 2009. This was a randomized controlled trial comparing ciprofloxacin 
(30 mg/kg/day for 3 days) with gatifloxacin (10mg/kg/day for 3 days) for the treatment 
of dysentery in Vietnamese children. The inclusion criteria were as Period A. One 
hundred and three isolates were collected during this period and clinical data on all 
admitted children were available for analysis. All three studies were approved ethical 
assessment by the Scientific and Ethical Committee of the Hospital for Tropical 
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Diseases, Oxford University Tropical Ethics Committee (OxTREC) and Dong Thap 
Provincial Hospital. 
Microbiological methods used were described in section 2.3 of chapter 2. 
Clinical data was recorded on specialized clinical report forms for all three studies by 
clinical staff involved in the studies. The data collected included basic demographic 
details of the patient, age (months), sex, location of residence and weight (kg). A history 
from all patients was also recorded, including; duration of illness prior to admission to 
hospital (days), fever (defined as a prolonged temperature > 37.5°C), abdominal 
discomfort, vomiting, watery diarrhoea (defined as three or more loose bowel 
movements during a 24-h period), bloody or mucoid diarrhoea (defined as >3 loose 
stools with obvious blood or mucus), estimated number of episodes of diarrhoea before 
attending hospital, convulsions believed to be related to fever and/or infection and if 
there was any known pre-treatment with antimicrobials. 
43 Results: 
Over the duration of the three studies spanning 14 years (1995-2009), 297 strains of 
Shigellae were isolated. 
4.3.1 Epidemiological characteristics: 
Spatial distribution of Shigella strains: 
Among 297 strains of Shigellae, 228 were from children living within the districts that 
constitute Ho Chi Minh City. These children, who were treated as in-patients for 
shigellosis, came from 13 different districts in Ho Chi Minh City (Figure 4.1). 
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Figure 4.1 The distribution of household residences of cases of childhood shigellosis 
admitted to the Hospital for Tropical Diseases in Ho Chi Minh City. 
Whilst the distribution of the location of the residences of these patients is biased by 
referral patterns and people attending the local hospital (HTD is one of several hospitals 
in the City where children may be treated for gastrointestinal infections), the majority of 
children attending HTD with culture confirmed shigellosis came from the three districts 
within the locality of the Hospital (districts 5,6 and 8), which constitutes a total 
population of approximately 800.000 people. In total, the majority of patients resided in 
district eight (n = 88) within approximately 6 Km of the hospital. There was no 
significant change in the locality of patients over the three studies, or any relationship 
between serotype and location of the residence of the patients (including in those 
residing outside Ho Chi Minh City). 
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Age distribution: The median age of children with culture confirmed shigellosis from all 
the combined data was 24 months, the interquartile range from 16 months to 36 months 
(Figure 4.2). More than 75% of patients in this series are 36 months of age or younger. 
These observations are consistent with other epidemiological findings of Shigella 
infections in Viet Nam and other Asian countries, which show that the majority of the 
burden of shigellosis is in children under the age of 3 years (von Seidlein et al. 2006). 
Sex distribution: There was no dominant gender in shigellosis, the female to male ratio 
is 1 (145 female : 152 male). 
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Figure 4.2 The combined distribution of sex and age of 297 children with shigellosis in 
southern Viet Nam. Graph depicts the combined age and sex distribution (female-red, 
male-grey). The black line represents the total number of cases per age group specified. 
Seasonal variation of Shigellu infection: The combined data from studies A, B and C 
demonstrated some seasonality related to the times of peak infection, with the majority 
of cases (> 60 %) occurring in the wet season (May and September) (Figure 4.3). 
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Figure 4.3 The seasonal distribution of shigellosis in southern Viet Nam. Data represent 
the average number of cases, rainfall and temperature per month for Ho Chi Minh City. 
Red bar: total number of cases, grey bar: average monthly temperature and black line: 
average monthly rainfall. 
4.3.2 Microbiology and antimicrobial susceptibilities: 
Shigella species and serotype distribution: Among 297 Shigella strains isolated from 
studies A. B and C three were S. boydii. 136 S. flexneri and 149 S. sonnei, and nine were 
un-typable. There was no S. divsenteriae isolated in this series. There was a significant 
species shift from S. flexneri to S. sonnei between study A (29 % S. sonnei) and study C 
(78 % S. sonnei) with an approximate 1: 1 ratio of S. flexneri to S. sonnei in the 
intermediate period of study B (Figure 4.4). The most commonly isolated S. flexneri 
serotype was serotype 2a representing 43% of all the S. flexneri strains isolated (Table 
4.1). 
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Figure 4.4 Distribution of Shigella species and serotypes from three childhood 
shigellosis studies in Southern Viet Nam over fourteen years. The distribution of 
Shigella species from study A (1995 - 1996) n= 80, study B (2000 - 2001) n= 114 and 
study C (2006 - 2008) n= 103. The percentages of organisms that are S. sonnei, S. 
flexneri are coloured red and grey respectively. Other Shigella species are coloured 
black. The p value was calculated using a chi - squared test. 
Table 4.1 S. flexneri serotypes isolated in southern Viet 
Nam 1995-2008 
S. flexneri serotpye No. of (%) 
la 00 
lb 00 
lc 4 2.9 
2a 59 43.4 
2b 8 5.9 
3a 13 9.6 
3b 2 1.5 
3c 16 11.8 
475.1 
4a 5 3.7 
4x 00 
5a 00 
6 13 9.6 
x00 
y00 
Not typed 8 5.9 
Total 136 100 
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Antimicrobial susceptibility: There was a significant change in the profile of the 
proportions of organisms demonstrating resistance to the seven antimicrobials 
tested (Figure 4.5). 
- Resistance rate unchanged during the 3 periods: The proportion of organisms 
that were resistant to trimethoprim-sulfamethoxazole and tetracycline was high 
throughout the three periods (all greater than 95% resistance in all groups) 
(Figure 4.5). 
- Resistance rate decreased during the 3 periods: There were significant decreases 
in the proportions of organisms resistant to ampicilIin from 75 % to 48 % (p = 
0.0003) and of chloramphenicol from 66 % to 30 % (p = <0.0001) between 
period A and period C. 
- Resistance rate increased during the 3 periods: The number of Shigellae isolated 
that were resistant to nalidixic acid increased from 8% in study A to 68% in 
study C. There was only one S. lexneri strain isolated in September 2008 in 
Dong Thap Province which was fully resistant to fluoroquinolones 
(ciprofloxacin MIC =6 mg/L, ofloxacin MIC =16 mg/L, gatifloxacin MIC =8 
mg/L). 
- Occurrence of ceftriaxone resistance: Shigella strain resistant to ceftriaxone was 
not recognized until the first case in February 2001. After a silent period, 
ceftriaxone resistant strain was also identified in May 2007 and then increased 
rapidly reaching 23 % of all Shigella strains in Period C (Figure 4.5). 
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Figure 4.5 The changing antimicrobial resistance patterns of Shigella spp. Graph 
shows the percentage of resistant (red) and sensitive (grey) organisms isolated from 
period A, B and C. Statistical significant changes were calculated using a chi squared 
test. 
There was an overall increase in the number of antimicrobials that the organisms were 
resistant to (Figure 4.6). In study A, 62 % of all Shigellae were resistant to three or more 
of the seven antimicrobials tested, this percentage increased to 87 % in study B and 
decreased slightly to 83 % in study C; the increase was statistically significant when we 
compared period C with period A (p = <0.0001, Chi squared test). 
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Number of antimicrobials (from seven) to which organisms were resistant 
Figure 4.6 The increasing antimicrobial resistance of S. sonnei and S. flexneri during a 
fourteen year period. Sflexneri strains (red lines) were significantly more likely to be 
resistant to more antimicrobials than S. sonnei (black lines) over both collection periods. 
S. sonnei and S. flexneri were significantly more likely to be resistant to more 
antimicrobials when period C (2006-2008) (lines with triangles) was compared to 
period A (1995-1996) (lines with squares). 
Difference in antimicrobial resistance pattern between S. flexneri and S. sonnei: 
There was a significant change in sensitivity patterns over time related to the 
type of Shigella sero-group isolated (Table 4.2). S.. flexneri was significantly 
more likely to be resistant to ampicillin in study A, study C and when combined 
over all three studies. S. flexneri was also significant more likely to be resistant 
to chloramphenicol in study B, study C and overall (Table 4.2). The combined 
data demonstrated that S. sonnei was significantly more likely to be resistant to 
both trimethoprim--sulfamethoxazole and ceftriaxone. The overall pattern of 
reversion of sensitivity to ampicillin and chloramphenicol was mainly observed 
with respect to S. sonnei isolates. The reversion of S. sonnei sensitivity to older 
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generation antimicrobials may account for the overall sensitivity patterns of S. 
flexneri being different to S. sonnei. 
Table 4.2 Comparison of resistance patterns between three collections of Shigella 
serotypes flexneri and sonnei isolated in southern Viet Nam between 1995 and 2008 
Cdleetlon Serotype (n) Pbenohpe b AMP CHL SXT TET NAL OFX CRO 
A (1995 -1996) Sonnei ( 24 )R 11 8 23 23 000 
S 13 16 11 24 24 24 
Flexneri (56) R 54 10 53 53 900 
S2 46 33 47 56 56 
p Value' <0.0001 0.1287 0.8102 0.8102 0.0371 
B (2000 - 2002) Sonnei ( 54 )R 50 10 53 52 901 
S4 44 12 45 54 53 
Flexneri (50) R 46 38 44 49 21 00 
S4 12 61 29 50 50 
p Value 0 0.9316 <0.0001 0.0415 0.5577 0.0052 - 0.329 
C(2007-2008) Sonnei (71) R 17 5 71 69 51 0 12 
S 54 66 02 20 71 59 
Flesneri (30) R 25 28 28 30 19 11 
S5220 11 29 29 
p value' <0.0001 <0.0001 <0.0001 0.3696 0.4619 0.297 0.076 
Combined Sonnei (14R) R 78 23 147 144 60 0 13 
S 70 125 14 88 148 135 
Flezneri (136 )R 125 76 125 132 49 11 
S 11 60 11 4 87 135 135 
p Value <0.0001 <0.0001 0.001 0.613 0.365 0.478 0.002 
An increase in the number of organisms resistant to multiple antimicrobials over 
time was seen in both Shigella species. However, between study A and study C, 
S. flexneri was more likely to be resistant to more antimicrobials than S. sonnei 
(p = <0.0001). Resistance to multiple antimicrobials increased from two to three 
out of the seven tested from study A to C for S. sonnei and from four to five 
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from the seven antimicrobials tested from study A to C for S. flexneri (Figure 
4.5). 
MIC of Ciprofloxacin in Nalidixic acid resistant versus Nalidixic acid 
susceptible Shigella spp.: The median of MIC of ciprofloxacin is 10 times higher 
in Nalidixic acid resistant strains than in Nalidixic acid susceptible strains 
(0.125ug/mL versus 0.012ug/mL). The hospital stay was longer in patients 
infected with Nalidixic acid resistant Shigella than patients with Nalidixic acid 
susceptible strains (Table 4.3). 
Table 4.3 The ciprofloxacin MIC and duration of hospital stay in 2 groups of 
children infected by Nalidixic acid-resistant or -susceptible Shigella spp. 
Nalidixic acid - Nalidixic acid -P 
resistant n=83 susceptible n=161 values' 
Ciprofloxacin MIC 
(µß)b 
0.012 (0.008-0.012) 0.0001 All cases 0.125 (0.094-0.190) 
S. flexneri 0.190 (0.125-0.190) 0.012 (0.012-0.016) 0.0001 
S. sonnei 0.094 (0.094-0.125) 
0.012 (0.008-0.012) 0.0001 
Hospital stay (days)' 
All cases 5 (4-6) 3 (2-5) 0.005 
S. flexneri 5(4-6) 4(2.5-5) 0.01 
S. sonnei 4.5 (4-5) 3(2.5-5) 0.0003 
FCT°(hrs) 23.5 (12-36) 24 (12-41) 0.07 
DCTd (hrs) 48 (30-72) 48 (29-74) 0.07 
'P values calculated using the Mann-Whitney U test test 
b Value were median (interquartile range) CFCT: Fever clearance time 
dDCT: Diarrhoea clearance time 
4.3.3 Clinical features associated with Shigella infection: 
The clinical observation data was combined and analyzed from all three studies; this 
permitted a comparison of clinical characteristics of the patients with confirmed 
shigellosis over the three periods. Data was available for analysis from 279 patients: 63 
patients from study A, 113 patients from study B and 103 patients from study C (Table 
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4.4). These data demonstrated several changes in disease profile over the three studies, 
particularly between study A and study C, which is more than 12 years apart. 
- Change in age of patients: 
There was a statistically significant increase in age, which corresponded with an 
increase in weight of the children from study A to study C (Table 4.4). 
- Patients were admitted earlier in study C than in study A: 
There was decrease in the number of days of history of the disease symptoms prior to 
admission to hospital (decrease in median days from 2 to 1). 
- More indicators of severity in patients of study C: 
There was a statistically significant increase in the number of children with watery 
diarrhoea (44 % to 71 % from study A to C), abdominal pain (52 % to 76 % from study 
A to C) and febrile convulsions (4 % to 20 % from study A to Q. 
These clinical features combined all suggest progressively more severe illness in 
patients being admitted to hospital between 1995 and 2008. Additionally, patients in 
study C had higher white blood cell counts, higher density of white cells in their stool 
and had longer stays in hospital (an increase from 3 to 5 median days from study A to 
study Q. The combined duration of disease (days of history + duration of stay in 
hospital) was significantly increased from study A to study C (Table 4.5). 
The increase in the severity of the disease coincided with a change in the dominant 
Shigella species isolated (S. sonnei becoming more common) and a change in 
antimicrobial resistance profile of the organisms. 
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Table 4.4 Clinical results and observations of Shigella infections in southern Viet Nam 
Pateints 
A (1995 - 1996) B (2000 - 2002) C (2006 - 2008) Combined p value' 
n=63 n=113 n=103 n=279 
Age (months) d 23(17-48) 21(14-29) 30(19-42) 24 (16 - 36) < 0.001 
Weight (Kg) 10(9-13) 10(9-12) 11.5 (10 -15) 10.5(9-13) 0.004 
Male Sex (%) 31(49) 50(44) 61(59) 184 (59) 0.085 
Patient History 
Days 2(1-7) 2(1-9) 1(1-4) 2(1-9) <0.001 
Fever (%) 62(98) 104 (92) 100(97) 266 (95) 0.09 
Abdominal Pain (%) 33(52) 41(36) 79(76) 153 (54) < 0.001 
Vomitting (%) 24(38) 64 (56) 51(49) 139 (50) 0.062 
Watery Diarrhoea (%) 28(44) 67(59) 74(71) 169 (60) 0.002 
Bloody/ Mucoid Diarrhoea (%) 63 (100) 60(53) 98(95) 221(79) < 0.001 
Diarrhoeal episodes per day NA 8(5-10) 8(5-10) 8(5-10) 0.595 
Convulsions (%) 4(6) 7(6) 20 (19.4) 31(11) < 0.001 
Known pretreatment (%) 3(5) 8 (7) 4(4) 14(5) 0.543 
Clinical Details 
Serotype Sonnei (%) 21/ 63(33) 55/113(49) 71/103(69) 153/279(55) <0.001 
White Cell Count (x 103 / mm) 10(8.3-15) 10.1(7.7-12.8) 13.1(10.1-17.3) 11.3(8.7-15.4)<0.001 
Red Cells in Stool b NA 1110.715 
White Cells in Stool b NA 3330.02 
Mucoid Duration (hrs) 31.5 (24 - 53.5) 36(24-54) 28(18-48) 30 (19.5 - 48) 0.113 
Diahorrea duration (hrs) 48.5 (29.25 - 87) 48(24-72) 48(30-72) 48 (26.75 - 72) 0.402 
Duration of Illness 
Hospital stay (days) 3(1-12) 4(1-15) 5(2-14) 40-15) < 0.001 
Disease duration (days) ` 4(2-15) 6(3-18) 6(3-15) 6(2-18) < 0.001 
'p Values calculated using either Chi-square test or Kruskal-Wallis test 
° Cells in Stool assessed over a range from not seen to highly prevalent (0 - 4) 
Disease duration calculated by addition of history of disease and stay in hospital 
° Interquartile range values in brackets unless stated 
The data presented in Table 4.5 demonstrates only subtle differences between the 
syndromes synonymous with the two differing species. S. flezneri is associated with an 
increase in the number of days of illness prior to admission in hospital, the number of 
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episodes of diarrhoea, an increase in the duration of mucoid/bloody diarrhoea and the 
duration of stay in hospital. 
Table 4.5 Clinical presentation of S. flexneri and S. sonnei infections 
Pateints 
S. flexneri S. sonnei p value' 
n=123 n=147 
Age (months) d 25(12-42) 23(14-36) 0.105 
Weight (Kg) 11(8.5-14) 10(9.9-13) 0.558 
Male Sex (%) 55 (44.7) 83 (56.5) 0.055 
Patient History 
Days 2(2-3) 1(1-2) < 0.001 
Fever (%) 117 (95) 141(96) 0.761 
Abdominal Pain (%) 64(52) 84 (57.1) 0.48 
Vomitting (%) 60 (48.8) 74 (50.3) 0.78 
Watery Dirrhoea (%) 78 (63.4) 86 (58.5) 0.41 
Bloody / Mucoid Diarrhoea (%) 97 (78.9) 117 (80) 0.88 
Diarrhoea! episodes per day 10(5-10) 8(5-10) 0.051 
Convulsions (%) 9(7.3) 21 (14.3) 0.07 
Known pretreatment (%) 7(5.7) 7 (4.8) 0.585 
Clinical Details 
White Cell Count (x 103 / mm3) 10(8-13.6) 12 (10.5 -15.5) 0.029 
Red Cells in Stool b110.056 
White Cells in Stool b330.173 
Mucoid Duration (hrs) 36 (24 - 53.5) 25(18-48) 0.054 
Diahorrea duration (hrs) 48(39-72) 48(27-72) 0.088 
Duration of illness 
Hospital stay (days) 5(4-5) 4(3-5) 0.276 
Disease duration (days) ` 7(6-8) 5(4-7) 0.009 
'p Values calculated using either Chi-square test or Kruskal-Wallis test 
"Cells in Stool assessed over a range from not seen to highly prevalent (0 - 4) 
`Disease duration calculated by addition of history of disease and stay in hospital 
°Interquartile range values in brackets unless stated 
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4.4 Discussion: 
Our findings demonstrate that the epidemiology of shigellosis infection is similar in 
southern Viet Nam to other locations in Asia. The main burden of infection is in those 
under three years of age (Agtini et al. 2005; Chompook et al. 2005; von Seidlein et al. 
2006; Wang et al. 2005). The median age of patients in this investigation was 24 
months; this is slightly less than a previous study in Nha Trang, Central Viet Nam (von 
Seidlein et al. 2006). A discrepancy in age in the two settings may be related to the 
epidemiological study in Nha Trang being performed with ongoing community 
surveillance, rather than those admitted to a paediatric ward of the hospital for treatment 
as in this study. 
We also found a pattern of infection which correlated with the rainy season. The 
observation that Shigella infections generally coincide with the wet season in a tropical 
setting has been noted before in an urban setting in North Jakarta, Indonesia (Agtini et 
al. 2005). Transmission of Shigella has been linked to waste water and river water in 
Viet Nam in two independent locations in Viet Nam, Hanoi and Nha Trang respectively 
(Hien et al. 2007; Kim et al. 2008). An increase in faecal contamination of the water 
supply due to increased ground water may account for this pattern as distance to a water 
source/river was found to be associated with higher risk of shigellosis in Nha Trang 
(Kim et al. 2008). The majority of patients enrolled in the studies combined here resided 
in District 8 of Ho Chi Minh City. Although we are unable to draw strong conclusions 
from the residences of these patients owning to referral and catchment areas of the 
HTD, District 8 represents the area of the city with the greatest density of canal 
networks and waterways. 
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Our observations from 1995 to 2008 recognized for the first time a shift of dominant 
Shigella species from S. flexneri to S. sonnei at the turn of the 21S` century in Ho Chi 
Minh City and adjacent provinces in southern Viet Nam (Figure 4.3). The shift in 
dominant Shigella species has been recognized previously. In Japan, where the 
prototype Shigella was first described, S. dysenteriae type I was the most common 
species in the latter half of 19th century and early 20`h century. But after that most of the 
Shigella strains isolated in hospitalized patients in Tokyo were Sflexneri. The 
percentage of S. sonnei increased gradually from 10% in 1953 to 50% in 1963 (Hiroshi 
1964) and in recent years S. sonnei is the most prevalent Shigella species in Japan. In 
Britain and Europe during the 1920s S. flexneri and S. sonnei were of approximately 
equal prevalence, but the former gradually faded and after the Second World War 
S. sonnei has accounted for the majority of the endemic shigellosis in these areas. 
Similar trends have also been observed in the United States. (Skirrow M. B. 1996). 
Statistics in Korea showed that S. sonnei constituted 4.8% of all Shigella isolated in the 
1961-1968 period, increased to 23.6% in 1980-1987, and then became the most 
prevalent species in 1991-1997 period with 77.1% of all isolates (Lee 2006). This 
change has also been seen recently in many newly industrialized countries including 
Thailand, Turkey, Israel (Ashkenazi et al. 1993; Ceyhan et al. 1996; von Seidlein et al. 
2006). The cause of the shift of Shigella species is not fully understood but probably 
reflects the expanding economies in these countries because there is a significant 
correlation between the Gross Domestic Product (GDP) and the frequency of S. sonnei 
isolation (Ram et al. 2008). 
In addition to the shift in the dominant Shigella species over time, there has also been a 
shift in antimicrobial resistance with a marked increase in resistance to nalidixic acid 
and ceftriaxone. We have previously reported the alarming increase in ceftriaxone 
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resistant Shigellae in southern Viet Nam (Vinh et al. 2009a). This is important as 
ceftriaxone is an alternative drug for the treatment of shigellosis and often used in 
patients with severe illness and in those in whom the first line drugs have not been 
successful (WHO 2005). However in these studies patients with shigellosis caused by a 
ceftriaxone resistant Shigellae strain still responded well to ciprofloxacin (Vinh et al. 
2009a). 
Whilst nalidixic acid is no longer recommended for use in the treatment of Shigellosis, 
resistance to nalidixic acid increases the MIC to fluoroquinolones (ciprofloxacin or 
other drugs in the class), which do remain recommended drugs for the treatment of 
Shigella infections (WHO 2005a). Therefore, resistance to nalidixic acid may delay 
recovery in those treated with fluoroquinolones, as showed in Table 4.5. 
Shigellae circulating in Ho Chi Minh City would seem to be under drug selective 
pressure in this population, an idea supported by the sequential decrease in resistance to 
older antimicrobials, such as ampicillin and chloramphenicol which are rarely used in 
the community to treat gastrointestinal infections. The uncontrolled use of 
antimicrobials in this setting may fuel the spread of multiple drug resistant organisms. 
However, due to the promiscuous nature of the Shigellae it is likely that resistance 
genes are transferred regularly to and from other enteric bacteria and maintained by 
continued selective drug pressure in the community. 
Currently there are several potential Shigella vaccines undergoing development, of 
which some have already been tested in early phase clinical trials (Coster et al. 1999; 
Katz et al. 2004; Kotloff et al. 1995b; Kotloff et al. 2000; Launay et al. 2009; Levine et 
al. 2007). The development of Shigella vaccines may be hindered by the number of 
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different species and serotypes circulating in one setting and in differing locations. For 
example, S. flexneri serotypes are known to fluctuate over time as shown in India, 
Indonesia, Bangladesh, and Pakistan (Dutta et al. 2002; von Seidlein et al. 2006). Here, 
we have demonstrated a significant longitudinal transition of species from S. flexneri to 
S. sonnei. Vaccine development for shigellosis is challenging as primary infection offers 
only serotype specific immunity (Kotloff et al. 1995a). A study concerning a cohort of 
Chilean children found infection conferred 76% protective efficacy against re-infection 
with the same serotype (Ferreccio et al. 1991). An option for controlling shigellosis 
would be the development of a series of single serotype vaccines which could be 
implemented in individual locations with a known serotype profile. Alternatively, the 
most cost effective method of control would be the development of a polyvalent vaccine 
offering protection to a number of known dominant serotypes, this approach may aid in 
tackling the global burden of shigellosis. The transition of dominant Shigella species in 
southern Viet Nam has occurred on a background of economic development and may 
predict a continuing cycle in other areas under going similar rapid economic changes. 
In summary, on the basis of data collected from three studies covering 14 years from 
1995 to 2008, a transition in dominant Shigella species from Sflexneri to S. sonnei has 
been recognized for the first time in Viet Nam, and an increase of antimicrobial 
resistance overtime, particularly resistance to ceftriaxone and nalidixic acid, which 
appears to predict a more severe clinical disease presentation and prolonging the illness 
course. 
92 
Chapter Five: ESBL-producing Shigella 
Chapter Five 
Extended-Spectrum ß-Lactamase Producing Shigella 
spp. in Southern Viet Nam 
5.1 Introduction: 
Enterobacteriaceae that have the capability to express CTX-M (so named because of 
their hydrolytic activity against CefoTaXime) a family of extended spectrum beta- 
lactamases (ESBLs) have emerged as a major public health threat worldwide 
(Livermore et al. 2007; Rossolini et al. 2008). Most of the research in this area is 
conducted in industrialized countries, where organisms such as Escherichia coli and 
Klebsiella spp., mostly from urinary tract infections, are the commonest source (Pitout 
and Laupland 2008; Valverde et al. 2008; Heffernan et al. 2009). Relatively little is 
known about the distribution of such genes in organisms found in developing or 
countries undergoing economic transition, where the circulating pathogens may differ. 
Enterobacteriaceae capable of producing ESBLs have been described previously in 
South East Asia (Cao et al. 2002); Kiratisin et al. 2008; Ruppe et al. 2009). Ho Chi 
Minh City in southern Viet Nam is typical of many cities where patterns of infectious 
diseases are changing due to rapid economic growth, better access to health care and 
improving infrastructure. Le recently showed that 42% of healthy people carried ESBL 
producing bacteria as part of their regular intestinal flora (Le et al. 2009). This work 
suggested that commensal organisms may play an important role in the dissemination 
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and maintenance of such antimicrobial resistance genes in the population. Furthermore, 
the uncontrolled use of antimicrobials in the human population and in livestock rearing 
may lead to further problems with drug resistance and more limited treatment options 
Shigellosis is a gastrointestinal infection caused by members of Shigella spp and 
transmitted by the faecal-oral route. Children less than five years old and living in 
developing countries bear the brunt of the disease (Kotloff et al. 1999; Kim et al. 2008). 
In our hospital in Ho Chi Minh City, shigellosis is the commonest cause of paediatric 
admission in those with a confirmed bacterial aetiology (See Chapter Three). Although 
diarrhoeal diseases caused by S. sonnei is generally mild and self-limited in healthy 
adults in industrialized countries, antibiotic therapy is necessary for the treatment for 
severe forms of dysentery caused by Shigella spp. (Christopher et al. 2009). Infection 
with any Shigella species can be lethal to children in developing countries, particularly 
the very young, malnourished or immuno-compromised. Without effective antibiotic 
treatment, mortality due to Shigella infection, especially from infection with 
S. dysenteriae type 1 may exceed 10% (Bennish and Wojtyniak 1991). Antibiotics 
shorten the duration of symptoms, prevent severe complications and eradicate Shigellae 
from the stool more quickly and hence prevent the spread of the disease in the 
community (Salam and Bennish 1991; Vinh et al. 2000). 
Fluoroquinolones are the drugs of choice to treat Shigella infections in both adults and 
children (WHO 2005). However, as with many other members of the 
Enterobacteriaceae, mutations in the genes encoding the target proteins for 
fluoroquinolones are common in Shigella (Chao et al. 2007; Hu et al. 2007). Our recent 
findings have shown that patients with shigellosis remain in hospital for longer periods 
compared with ten years ago and the disease severity has concurrently increased (Vinh 
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et al. 2009b). Interestingly, at the same time there has been a significant species shift 
from Sllexneri to S. sonnei isolated from patients (Vinh et al. 2009b). Patients are 
treated with fluoroquinolones; however, those patients that do not respond to the 
standard therapy are treated with third generation cephalosporin (mainly intravenous 
ceftriaxone). The intravenous third generation cephalosporins are amongst the most 
commonly used antimicrobials in hospitals in Ho Chi Minh City and the oral second 
and third generation cephalosporin are also widely available without prescription in the 
community. Antimicrobial resistance in the Shigellae is common; these organisms are 
closely related to E. co1i and are readily transformed by exogenous DNA (Bratoeva and 
John 1994; Dutta et al. 2002; Iversen et al. 2003). The distribution of antimicrobial 
resistance is, however, often different depending on the species. A multi-centre study 
across Asia demonstrated that S.. lexneri were more likely to be resistant to ampicillin, 
whilst S. sonnei were more likely to be resistant to cotrimoxazole (von Seidlein et al. 
2006). Resistance patterns and species dominance are variable depending on the specific 
location and can vary with time (Anh et al. 2001; Lartigue et al. 2005; Kuo et at. 2008). 
Shigellosis caused by third generation cephalosporin resistant Shigella in Viet Nam had 
not been previously reported. In this chapter, I report the clinical and epidemiological 
aspects of shigellosis caused by ESBLs producing Shigella spp. In addition, the 
transferability and molecular characteristics of ESBLs genes in clinical Shigella strains 
is also described. 
5.2 Materials and methods: 
The work described in this chapter was conducted at 2 sites: (i) The Paediatric Ward B, 
Hospital for Tropical Diseases (HTD) in Ho Chi Minh City, Viet Nam, and (ii) 
Infectious Diseases Ward, Dong Thap Provincial Hospital (DTP). 
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All the Shigella spp. strains described in this chapter were isolated from patients 
enrolled into a randomized controlled trial comparing treatment with ciprofloxacin and 
gatifloxacin as described in Chapter Six. 
Microbiological culture, antimicrobial susceptibility testing and molecular techniques 
were described briefly in chapter two. The detailed procedure is described here. 
Procedure of bacterial conjugation experiment: 
Step 1: Revival of parental strains: Sub-culture donor and recipient strain onto Nutrient 
Agar (NA) plates. Incubate at 37°C overnight. 
Step 2: Pick single colony each from the donor and recipient plate and inoculate into 
separate 15-m1 Falcon tube containing 4 ml of Luria-Bertani (LB) broth. Incubate at 
37°C (tilt 30*) ovemight with gentle shaking. 
Step 3: Mating experiment: Inoculate 0.5 ml of donor and 0.5 ml of recipient broth 
culture into a 50-m1 Falcon tube containing 4 ml of LB broth. Also inoculate 0.5 ml of 
donor and 0.5 ml of recipient into 2 separate 50-ml Falcon tube containing 4 ml of LB 
broth as control. Incubate all tubes at 37°C (tilt 30°) 12-16 hours without shaking. 
Step 4: Culture of mating broth and control donor and recipient onto selective LB agar 
plate containing sodium azide 100mg/L and ceftriaxone 6 mg/L: 
- Centrifuge Falcon tubes 4000 RPM at 4 
°C, in 5 minutes. 
- Discard supernatant. 
- Re-suspend sediment of each Falcon tube with 1 ml NaC10.9%. 
- Spread 100 gL of mating culture onto separate selective LB agar plate 
containing sodium azide 100mg/L plus ceftriaxone 6 mg/L firstly without 
dilution, then at 10" dilution, 10'2 dilution, 10'3 dilution with NaC10.9%. 
- Spread 100 itL of donor as well as recipient control onto separate selective LB 
agar plate containing sodium azide 100mg/L and ceftriaxone 6 mg/L. 
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- Incubate the plates at 37°C overnight. 
Step 5: Checking plates for transconjugants: 
Nothing grew on donor and recipient control plate 
Spread one colony from mating plate onto LB agar plate containing sodium 
azide 100mg/L and ceftriaxone 6 mg/L. 
Step 6: Re-identify transconjugant by API 20E. 
Performe antibiogram and ESBL confirmation test for transconjugants. 
Procedure of plasmid extraction: 
1. Inoculate pure culture of ESBL negative Shigella isolates, ESBL positive 
Shigella isolates, their transconjugants, E. coli 39R861 and E. coli J53 AzR strain 
each into 3m1 of LB broth. Leave overnight at 37°C (gentle shaking). 
2. Centrifuge to harvest cells. To the cell pellet, add l50µ1 of E buffer and re- 
suspend. 
3. Add 300µ1 of lysis buffer and mix gently. The solution should begin to clear 
quickly. 
4. Heat sample to 55°C for 1 hour precisely. 
5. Add 600µl of Phenol/Chloroform and mix gently until the solutions have 
emulsified. 
6. Centrifuge for 30 minutes to separate layers. 
7. Remove a 35 to 45µl aliquot from the middle of the top layer and add final 
sample buffer (treat as a 5x concentrate) 
8. Load samples onto 0.7% agarose gel. Run gel at 90 volts for 3 hours. 
9. When Blue dye is near bottom of gel, remove to a box containing Ethidium 
Bromide solution (5µ1 of aI Omg/ml stock per 100mis of water) to stain 
10. Leave 45 minutes to stain gel. 
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11. Rinse in distilled water and visualize under UV light. 
12. Photograph and save as digital files. 
ESBL gene PCR amplification and characterisation. 
Genomic DNA was isolated from strains that were subjected to PCR from 1 ml of a5 
ml overnight bacterial culture using the wizard genomic DNA extraction kit (Promega, 
USA), as per the manufacturer's recommendations. 
Genomic DNA was subjected to PCR amplification targeting known classes of bla 
genes using, initially, primers that would recognize sequences encoding ESBLs: 
SHV (F; 5' TCTCCCTGTTAGCCACCCTG, 
R; 5'; CCACTGCAGCAGCTGC), 
TEM (F; 5' TGCGGTATTATCCCGTGTTG, 
R; 5' TCGTCGTTTGGTATGGCTTC), 
CTX-M (F; 5' CGATGTGCAGTACCAGTAA, 
R; 5' TTAGTGACCAGAATCAGCGG). 
Further characterization of the various sub-classes of blame ESBL genes was 
performed using primers 
CTX-M-1; (F 5' ATGGTTAAAAAATCA CTGCG, 
R 5' TTACAAACCGTCGGTGAC), 
CTX-M-2; (F 5' TGGAAGCCCTGGAGAAA AGT 
R 5' CTTATCGCTCTCGCTCT GT); 
CTX-M-9 (F 5'ATGGTGACA AAGAGAGTGCAAC, 
R 5' TTACAGCCCTTCGGCGATG) 
in previously outlined PCR amplification conditions. 
All sequencing reactions were performed twice to ensure correct sequencing and 
sequences were verified aligned and manipulated using Bioedit software 
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(http: //www. mbio. ncsu. edu/BioEdit/bioedit. html). All ESBL gene sequences were 
compared to other ESBL sequences by BLASTn at NCBI. The DNA sequence of 
various classes of blame were downloaded and aligned with the produced sequences. 
5.3 Results: 
5.3.1 The rapid occurrence of Ceftriaxone-resistant Shigella spp. in Ho Chi Minh 
City and adjacent provinces: 
During a 24 month period between April 2007 and March 2009 we isolated 94 Shigella 
strains from the stools of children admitted with dysentery. Of these 94 strains, 24 were 
S. Jlexneri and 70 were S. sonnei. There were 35 ceftriaxone-resistant strains: 33 
S. sonnei and 2 Sfexneri. 
Timing of occurrence: The first isolation of a ceftriaxone resistant organism during the 
transitional period occurred in May 2007. The numbers of Shigellae isolated that were 
resistant to ceftriaxone fluctuated over the following months. However, there was 
increase in the proportion of resistant to sensitive isolates from 19% to 41% (5 / 11 
strains) between the periods from April 2007-September 2007 and April 2008- 
September 2008, respectively. This trend peaked in March 2009, with six out of seven 
Shigella strains isolated resistant to ceftriaxone (MIC >256). The rate of resistance to 
ceftriaxone between September 2008 and March 2009 was 75%. The increasing 
proportion of ceftriaxone-resistant to sensitive isolates in the late period from April 
2008 to March 2009 (23 / 22 strains) was significantly increased in comparison to the 
earlier period from April 2007 to Mar 2008 (12 / 33 strains) was statistically significant 
(pß. 02, Fisher exact test, Figure 5.1). 
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ApriA My07 JniA J007 hp07 SeDOI 0007l4e07DecL7x+0B FeoOBMrw Apr139 MM-09 LnW AltB hgw Sep18 OdOB Nova Dec-0BJm09FeD09Mr119 
Month of Isolabon 
Figure 5.1 Graph depicting an increase in number and proportion of ceftriaxone- 
resistant Shigella spp. isolated between April 2007 and March 2009 at The Hospital for 
Tropical Diseases in Ho Chi Minh City. 
The overall number of strains in this period is 35. While tracking back our Shigella 
collection in period 2000-2002, one strain of S. sonnei (strain DE0611) isolated in 
February 2001, which had high MIC for ceftriaxone (MIC>256mg/L), was confirmed as 
ESBL-positive, and we now believe this to be the first ESBL-producing Shigella isolate 
in our 1995-2009 series, and the first ESBL producing S. sonnei to be confirmed in Viet 
Nam. 
Location of cases with ceftriaxone-resistant Shigellae: 24 strains were isolated from 
patients living in Ho Chi Minh City, 6 in Long An Province (which has a border with 
Ho Chi Minh City), 5 in Dong Thap Province, and I from Vinh Long Province. 
Owing to the rapid increase in the isolation of such organisms we hypothesised that an 
individual dominant strain had began circulating in one area of Ho Chi Minh City from 
May 2007. However, residence data procured on the time of admission showed that 
such strains were circulating over a wide area of the city and not purely limited to an 
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isolated outbreak (Table 5.1). Twelve patients were resident in surrounding provinces, 
some 150 km from the hospital. 
5.3.2 The clinical features of shigellosis caused by ceftriaxone resistant strains: 
The median age of patients harbouring third generation cephalosporin resistant 
Shigellae was 32 months (range 8 to 120 months), the median age of shigellosis patients 
during the same period was 24 months (Vinh et al. 2009b). The percentage of patients 
presented with fever, vomiting, mucoid diarrhoea or seizure did not differ when 
compared with those patients infected by ceftriaxone-susceptible Shigella strains in the 
same period. The white cell count in blood was not different between the two groups. 
The presence of faecal leukocyte was higher in patients with ceftriaxone-resistant 
Shigella. All patients were treated with fluoroquinolones (ciprofloxacin or gatifloxacin) 
and responded well irrespective to the susceptibility status to ceftriaxone. As a result of 
treatment, the fever clearance time was the same in two groups, but the diarrhoea 
clearance time is shorter in patients infected by ceftriaxone-resistant strains. There were 
no deaths in our series (Table 5.1). 
5.3.3 The combined resistance patterns of ESBL producing Shigella spp.: 
Between 2007 and 2009,35 (34 %) Shigella isolates cultured were resistant to 
ceftriaxone. Of these strains, 33 were S. sonnei and the other two isolates were S. 
flexneri. The remaining strain was a solitary sporadic S. sonnei isolate previously 
cultured in 2001 (strain DE 0611). 
Resistance to 3rd generation cephalosporin: All the 36 ceftriaxone resistant strains were 
examined by the combination disc method to identify ESBL producing organisms 
(CLSI, 2007). Thirty four S. sonnei strains and one S. flexneri strain (35 from 36 
ceftriaxone resistant Shigella) produced the characteristic ESBL pattern on 
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investigation, whereas the hydrolysing activity of the other S. flexneri (strain EG0419) 
was not inhibited by clavulanic acid (Table 5.2). 
Table 5.1 Clinical features of childhood shigellosis caused by ceftriaxone-resistant 
versus ceftriaxone-susceptible Shigella strains 
Febrile (cases / total) 
Vomiting (cases / total) 
Bloody diarrhoea (cases / total) 
Seizure (cases / total) 
Number of stool daily" 
Blood white cell count (103/mm3) # 
Stool white cell (score 0-3) 
Fever clearance time (hours) # 
Diarrhoea clearance time (hours) " 
Death 
Ceftriaxone- 
resistant 
N=34 
32 / 34 
24 / 34 
29 / 34 
8/34 
6 (5-10) 
14.75 (11.4- 
17.5) 
3(1-4) 
18 (12-30) 
36(12-48) 
0 
* Fisher exact test, 
** Mann-Whitney U test 
"Number are median (interquartile ranger) 
Ceftriaxone- P value 
susceptible 
N=60 
59 / 60 0.6* 
45 / 60 0.9* 
56 / 60 0.36* 
10 / 60 0.4* 
8.5 (5-10) 0.1** 
13.35 (9.95- 044** 17.25) 
1 (0-3) 0.007** 
20 (10-30) 0.89** 
48 (30-70) 0.03** 
0 
Combined resistance to other antibiotics: Along with ceftriaxone, all strains were 
examined for resistance to an additional five antimicrobials by disc diffusion method 
and MIC measurement (Table 5.1). As predicted, all strains demonstrated co-resistance 
to ampicillin. Thirty five of the 36 strains (97 %) were resistant to trimethoprim- 
sulfamethoxazole and tetracycline, whilst 33/36 strains were resistant to nalidixic acid. 
Only three isolates: DE0611, EG0419 and EGO471 were co-resistant to 
chloramphenicol, of which two S. flexneri strains EG0419 and EG0471, were resistant to 
five of the six antimicrobials tested (Table 5.1). 
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5.3.4 The transferability of ceftriaxone resistance in Shigella spp. 
The rapid rise in the prevalence of Shigella spp. which are resistant to third generation 
cephalosporin lead us to hypothesise that this resistance pattern arose by plasmid- 
transfer (Vinh et al. 2009a). Conjugation experiments were conducted to try transfer the 
ESBL genes from wild-type ESBL-positive Shigella strains to laboratory E. coli strain, 
and then from transconjugant back to ESBL-negative wild-type Shigella strains. 
Transfer of ESBL genes from wildtype ESBL-positive Shigella strains to laboratory 
E. coli J53 (Sodium Azide resistant) strain: All 36 ceftriaxone resistant strains were 
subjected to conjugation experiments with the laboratory E. coli J53 (AziR). Thirty five 
Shigella strains gave positive results (Table 5.3). The exception is strain EG1020 where 
conjugation experiment was not successful. 
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Table 5.3 Characterisation of blac-rx_M genes and the corresponding plasmids of ESBL 
expressing Shigela spp. Strain EG0471 was SJlexneri, the rest were S. sonnei. 
Strain 
ID 
D 
EG0162 
EGO 187 
EG0204 
EG0250 
EG0250a 
EG0356 
EG0373 
EG0384 
EG0390 
EG0395 
EG0421 
EG0424 
EG0430 
EG0471 
EG0472 
EG 1007 
EG 1008 
EG 1009 
EG1010 
EG101 I 
EG1012 
EG1013 
EG1014 
EG1015 
EG1016 
EG1017 
EG1018 
EG1019 
EG 1020 
EG1021 
EG1022 
EG1023 
EG1024 
EG1025 
Ceftazidime bla CTX_M Plasmid size Conjugative 
zone size (mm) 
28 
18 
27 
19 
19 
19 
28 
18 
20 
22 
20 
20 
21 
21 
20 
20 
22 
20 
21 
21 
21 
20 
19 
19 
22 
20 
20 
20 
20 
20 
21 
21 
21 
20 
20 
CTX-M-24 
CTX-M15 
CTX-M-24 
CTX-M 15 
CTX-M 15 
CTX-M 15 
CTX-M-24 
CTX-M 15 
CTX-M 15 
CTX-M15 
CTX-M 15 
CTX-M 15 
CTX-M 15 
CTX-M 15 
CTX-M 15 
CTX-M15 
CTX-M15 
CTX-M 15 
CTX-M 15 
CTX-M15 
CTX-M15 
CTX-M15 
CTX-M 15 
CTX-M15 
CTX-M15 
CTX-M15 
CTX-M 15 
CTX-M 15 
CTX-M15 
CTX-M15 
CTX-M15 
CTX-M15 
CTX-M15 
CTX-M 15 
CTX-M15 
(kbp) (+1-) 
70 + 
100 + 
70 + 
100 + 
100 + 
100 + 
70 + 
100 + 
100 + 
100 + 
100 + 
100 + 
100 + 
100 + 
100 + 
100 + 
100 + 
100 + 
100 + 
100 + 
100 + 
100 + 
100 + 
100 + 
100 + 
100 + 
100 + 
100 + 
100 + 
100 _ 
100 + 
100 + 
100 + 
100 + 
100 + 
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There was I plasmid transferred from each wildtype Shigella donor to the recipient 
(Figure 5.2). 
Figure 5.2 Transferability of ESBL containing plasmids from wildtype Shigella 
strains to E. co1i J53 AAR. L: plasmids of E. coli 398861 with known size of 7,36,63 
and 147 kbp; numbers in upper row denote ID number of wildtype Shigella strains, the 
letter C denotes the corresponding transconjugants of those strains. Solid short arrow 
indicates the -100 kbp plasmid; the long arrow indicates the -70 kbp plasmid. 
The S. fexneri (strain EGO419) which was not confirmed as ESBL-producing in 
combination disc test did transfer the ceftriaxone resistant gene to the laboratory strain 
E. co1i J53 (AziR) also (Figure 5.3). 
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Figure 5.3 Plasmid transfer in 2 S. flexneri strains EG419 and EG471. Upper row: 
ID number of Shigella strains, the letter C after ID number denotes the corresponding 
transconjugants of those strains. E. coli J53 was the plasmid-free laboratory strain used 
as a receiver in the experiment. Ladder: plasmids ofE. coli 39R861 with known size of 
7,36,63 and 147 kbp. 
Transfer of ESBL genes from transconjugant back to ESBL-negative wildtype Shigella 
strain: The transconjugant EG 187c (which is a result of the mating between wild-type 
ceftriaxone-resistant S. sonnei strain EG 187 and the laboratory ceftriaxone-sensitive 
sodium azide-resistant E. coli J53, hence ceftriaxone-resistant but nalidixic acid- 
sensitive) was used as donor, and the wild-type ceftriaxone-sensitive nalidixic acid- 
resistant S. sonnei strain EG211 as a receiver. The conjugation was carried out in LB 
media containing ceftriaxone 6mg/L plus nalidixic acid 30mg/L. The final 
transconjugant (named EG187c-211tc) was a S. sonnei strain which was resistant to both 
ceftriaxone and nalidixic acid. The plasmids from these strains were extracted using a 
modification of Kado and Liu method- and the DNA separated on a 0.7% agarose gel 
and photographed (Kado and Liu 1981). The plasmid sizes calculated in agarose gel 
electrophoresis of the transferable plasmid in the clinical isolate S. sonnei EGO 187, in 
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the transconjugant EG 187c and in the final transconjugant (EG 187c-211 tc) were the 
same (Figure 5.4). 
Figure 5.4 Transfer of ESBL-carrying plasmid from the Wildtype S. sonnei EG187 
(D) to E. coli J53, then from the transconjugant (Tc) to a Wildtype S. sonnei. The 
wildtype S. sonnei EG187 (D) as the donor to the laboratory E. coli J53, then from the 
transconjugant (Tc) to a wildtype nalidixic acid resistant ceftriaxone susceptible 
S. sonnei receiver (R); the resulting final transconjugant (fTc) was a S. sonnei strain 
which was resistant to both nalidixic acid and ceftriaxone. The size of ESBL-carrying 
plasmid in this case was -70 kbp; the ESBL in this strain was CTX-M-24. L: plasmids 
of E. coli 39R861 with known size of 7,36,63 and 147 kbp. 
5.3.5 Characterisation of bla genes: 
Genomic DNA of all ESBL producing Shigella strains were extracted, this DNA was 
subjected to PCR amplification to characterise the ESBL genes. Primers were selected 
specific for blaTEM, blaSHV and blacrx. M classes of ESBL genes. All ESBL-positive 
strains (34 S. sonnei and I S. flexneri) strains produced CTX-M primer-specific 
amplicons. No amplicons were observed from PCR with the blaTEM and blasHV primers. 
Further PCR amplifications were performed on DNA from all strains that produced 
amplicons with the blacrx. M. Primers specific for the three major CTX clusters, blacTx- 
M-9, blacrx-M-, and b/a . M. 2 
(Bonnet 2004) were selected. Three strains (DE0611, 
EG0356 and EGO 187) produced amplicons with the blacTX. M_9 primers and the 
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remaining 32 isolates produced amplicons with the blacrx_M_1 primers (Table 5.3). The 
amplicons were cloned into cloning vector pCR 2.1 (Invitrogen, USA) and sequencing 
reactions were carried out on an ABI 3700 sequencing machine (ABI, USA) at the 
Sanger Institute, UK. All ESBL gene sequences were compared to other ESBL 
sequences by BLASTn at NCBI. The DNA sequence of various b1aCTX-M ESBLs 
were downloaded and aligned with the produced sequences. 
Sequence analysis demonstrated that there were two different types of b/acTx. M present 
in the S. sonnei population, blacrx. M-24 (n=3,8 %) and blacTx. M_15 (n=32,92 %). The 
only S. flexneri strain (EG0471) possessed blacTx_M. 15 genes (Table 5.3). Both genes 
(blacTx. M. 24 and b! acrx. M. 15) share 74 % DNA homology with each other; bla(. rx. M-15 
and blacrx. M. 24 differ by 12 and 6 nucleotides from their parent group (blacrx. M. 1 and 
blaCrX. M. 9) respectively. The first ESBL producing S. sonnei strains in our series (strain 
DE0611) harbouring blacrx. M. 24 was isolated in Ho Chi Minh City in February 2001 
and 6 years later the second strain (EG0356, isolated in May 2007) was also found to 
harbouring the blacTx_M_24 and also from a resident of Ho Chi Minh City. Although the 
possibility of an outbreak of ceftriaxone resistant Shigella was a concern, in fact the 
next strain of ceftriaxone resistant Shigella was isolated in June 2007 and showed a 
different phenotype. These strains had less activity against ceftazidime when compared 
with the first two strains. The third S. sonnei possessing blacTx. M. 24 was isolated from 
Dong Thap Province in January 2008. Thereafter, all the ESBL-producing Shigella 
strains harboured the blacrx. M. 15 genes (Table 5.3). 
Plasmid size estimation (calculated from comparing with plasmids of known sizes of the 
strain E. coli 39R861) demonstrated that the blacTx-ear-u was consistently carried on a 
large plasmid (-100 Kbp), whilst the blacTx_M_24 gene was carried on a smaller (-70 
Kbp) plasmid. The differing plasmid sizes and ESBL genes correlated precisely with 
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two distinct zone clearance areas when strains were susceptibility tested with 
ceftazidime. The strains expressing CTX-M-24 demonstrated less activity against 
ceftazidime when compared to CTX-M-15 (median zone size, CTX-M-24: 28mm, 
CTX-M-15: 20mm respectively) (Table 5.2). 
5.4 Discussion: 
Multi-drug resistance is a well-known phenomenon in Shigellae. Almost all oral 
antibiotics used for the treatment of shigellosis have become useless after widespread 
use (David A. Sack et al. 2001). Resistance to currently recommended antibiotics such 
as ciprofloxacin, azithromycin has also been recognised (Boumghar-Bourtchai et al. 
2008; Kansakar et al. 2007; von Seidlein et al. 2006). Members of the 
Enterobacteriaceae that carry CTX-M group ESBLs have been isolated from many 
parts of the world since the mid-1990s (Bonnet 2004). CTX-M genes were also detected 
in Thailand, Cambodia and Singapore (Cao et at. 2002; Kiratisin et al. 2008; Koh et al. 
2004; Ruppe et al. 2009). 
In Viet Nam CTX-M-14 and CTX-M-17 genes have been previously identified from 
pathogenic Kpneumoniae causing hospital-acquired infection (Cao et al. 2002). Work 
in our institution has shown that ESBLs are commonly expressed in organisms which 
constitute the "normal" gastrointestinal flora in the general population living in Ho Chi 
Minh City (Le et al. 2009). Such data predicts that intestinal flora may be a considerable 
reservoir of ESBL encoding genes carried on transposable genetic elements (plasmids 
and transposons) permitting transfer to pathogenic counterparts intermittently carried in 
the gastro-intestinal flora. 
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5.4.1 Increasing trend of ESBL-producing Shigella spp. but without increasing 
severity of the disease: 
The occurrence of ESBL-producing Shigella strain (majority are S. sonnei) increased 
sharply from 2007 to 2009. The spatial distribution of 36 ESBL-producing Shigella 
strains in our series suggested that there was not a common-source outbreak of disease. 
The clinical features of children infected with ESBL-producing Shigella strains were 
not more severe when compared with those infected by ESBL-negative Shigella strain. 
All patients responded favourably to fluoroquinolone treatment and there were no 
severe complications or deaths in this case series. 
5.4.2 Two types of CTX-M genes in Shigella spp. in southern Viet Nam: 
Different CTX-M genes in the Shigellae have been reported from Argentina (CTX-M-2) 
(Radice et al. 2001), Korea (CTX-M-14) (S. Kim et al. 2004), China (CTX-M-14) 
(Xiong et al. 2007), Lebanon (CTX-M-15) (Matar et al. 2007) and from a Czech 
traveller returning from India (CTX-M-15) (Hrabak et al. 2008). More recently, Nagano 
et al described a novel CTX-M-64 hybrid from a shigellosis patient infected with S. 
sonnei after returning to Japan from China (Nagano et al. 2009). Our data showed that 
there are 2 ESBL genes circulating in Shigella strains in southern Viet Nam, the blame. 
M-15 and blacTx. M. 24 genes. The blacTx. M-24 gene was first detected in S. sonnei strain 
DE0611 in February 2001 and re-appeared in May 2007 in Ho Chi Minh City. The last 
time this strain was isolated was in January 2008 in a patient resident in Dong Thap 
Province. The presence of the blacTx_M. 15 was detected in June 2007 and has gradually 
become the dominant gene (comprised of 92% of all ESBLs) in S. sonnei strains isolated 
through 2009. The single S, flexneri strain that harboured the blacr M-15 gene was 
isolated in September 2008 from a4 years old boy resident in Ho Chi Minh City. 
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5.4.3 Epidemics of CTX-M carrying plasmids in Shigellae. 
Our findings demonstrate a switch from 0% to 75% ceftriaxone resistance in Shigella 
spp. over a two year period in the key age group (1 to 3 years) for this disease. By 
sampling across the Ho Chi Minh City area, covering approximately 150 sq kilometres 
of southern Viet Nam and a population of approximately 15 million people, we have 
shown that the genetic explanation for this resistance pattern is the dissemination of two 
novel plasmids that carry two distinct ESBL genes: 
(i) The -70Kbp plasmid first appeared in 2001, harbouring the blacrx. M-24 gene, 
and re-appeared in May 2007 in Ho Chi Minh City and was last identified in 
January 2008 in Dong Thap Province, and has not been detected since then. 
There are only 3 Shigella strains carrying the -70 kbp plasmid in our series. 
The presence of the blaclx. M. 24 gene has been previously reported in only 
one SJlexneri strain from Hong Kong (Cheung et al. 2005). 
(ii) The second plasmid, which is -100kbp and harbours the blacTX_M. 15 gene, 
first detected in June 2007 in Ho Chi Minh City and later- in October 2007 
Dong Thap Province, has replaced the -70Kbp plasmid and has become the 
dominant plasmid carrying blacTX-M-Is gene. The total number of Shigella 
strains we have identified which carry this plasmid is 32, including 1 
S. flexneri and 31 S. sonnei. 
The Shigellae are closely related to E. coli (Wirth et at. 2006), and similar to E. coli, are 
capable of rapid population changes by the acquisition of extraneous DNA. Shigella 
spp. are capable of carrying multiple plasmids with an array of phenotypes including 
virulence and antimicrobial resistance (Dutta et al. 2002; Iversen et al. 2003). The 
presence of Shigella in the gastrointestinal tract of humans is an ideal environment to 
acquire horizontally transferred genetic material via conjugation. Highly transmissible 
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plasmids that impinge on the fitness of the host may be rapidly disseminated under 
appropriate conditions. 
The detection of the plasmid-transferable b! aCTX-M-15 in Shigella strains in southern 
Viet Nam is important in terms of the shifting pattern of the epidemiology of the 
disease. Our data suggests an increase in the prevalence of the CTX-M-15 carrying 
plasmid circulating in Shigella community in Ho Chi Minh City and surrounding 
provinces in the southern part of Viet Nam. CTX-M- 15 was first detected in E. coli in 
India in 2001, then was rapidly distributed globally mainly through the ST 131 clone of 
E. coli. Over the intervening nine years this has become the dominant transposable 
ESBL. CTX-M-15 has now been reported from all continents except Antarctica (Pitout 
2010). CTX-M-15 belongs to the CTX-M-1 cluster and is derived from CTX-M-3 by 
one amino acid substitution at position 240 (Asp- Gly). The beta-lactamase CTX-M-15 
has been detected in S. sonnei in France and Lebanon (Lartigue et al. 2005; Matar et al. 
2007). 
Shigellosis is primarily a community-acquired infection, the presence of CTX-M 
ESBLs in Shigella spp. may indicate that CTX-M-carrying plasmids are circulating not 
only in the hospital environment but also in the community. Characterizing the 
molecular nature of ESBL-carrying plasmids in other bacteria in the Enterobacteriaceae 
family such as E. coli and Kpneumoniae may help to address this question. Moreover, 
there is a dominant presence of CTX-M in Shigella isolates causing symptomatic 
disease and their rapid spread suggests that these organisms are under strong selection 
pressure either through drug pressure or other biological advantages. The use of third 
generation cephalosporins, such as oral cefpodoxime and cefixime in the community is 
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common in Viet Nam, and places the even the short term usage of ceftriaxone and other 
broad-spectrum cephalosporins in jeopardy. 
Viet Nam is a country that is in many respects a microcosm of the rapidly changing 
developing world. The Vietnamese economy is developing rapidly and the country is 
undergoing transition with an increasing population, urbanisation and shifting patterns 
of infectious diseases. In the past decade there has been a transition in species from S. 
flexneri to S. sonnei in the southern provinces of Viet Nam (Vinh et al. 2009b). With 
this shift has come the emergence of ESBL-producing Shigellae, mainly S. sonnei, 
between 2007 and 2009. These findings from the Vietnamese population should serve 
as a warning for other countries encountering the same economic transition. The 
progressive evolution of pan-resistant Shigella makes vaccine development an 
increasingly important objective. 
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Chapter Six 
A Randomised Controlled Trial of Gatifloxacin versus 
Ciprofloxacin for the Treatment of Bacillary Dysentery 
in Children 
6.1 Introduction: 
Shigella infection is a commonly seen enteric infection world-wide. In industrialized 
countries, small outbreaks of shigellosis may occur in infant day-care centres or nursery 
where optimal personal hygiene is difficult to maintain. Travellers from industrialised 
countries may get shigellosis during or short after their travel to developing countries. 
The Center for Disease Control and Prevention recently estimated that there are more 
than 440,000 cases of shigellosis per year in the United States (Mead et al. 1999). In 
developing countries, Shigella infection remains the most important bacterial cause of 
diarrhoeal diseases in children (Hien et al. 2008). The annual number of Shigella 
infection episode was estimated to be 163.2 million in developing countries, with 1.1 
million deaths; a total of 69% of all episodes and 61 % of all deaths attributable to 
shigellosis involved children less than 5 years of age (Kotloff et al. 1999). Despite the 
recently decrease in the case fatality rate Shigella infections remain an important public 
health issue (Sansonetti 2006). 
The treatment of shigellosis includes providing water and electrolytes rehydration and 
nutrition in addition to the administration of appropriate antibiotics. Antimicrobial 
therapy is important for the treatment of shigellosis. Without antimicrobial treatment, 
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the case fatality rate associated with S. dysenteriae type 1 infection may exceed 10%, 
particularly in the young and the older patients (Bennish and Wojtyniak 1991). 
Antimicrobials shorten the duration of symptoms, eradicate Shigellae from the stool 
more quickly, and may prevent severe complications (Salam and Bennish 1991). The 
choice of antibiotics to use as first line against Shigella infection should be based on 
knowledge of the antibiotic susceptibility patterns of locally circulating strains. 
Currently, the World Health Organisation guidelines have recommended ciprofloxacin 
as the drug of choice for all patients with shigellosis, irrespective of their age. 
Pivmecillinam (amdinocillin pivoxil), ceftriaxone and azithromycin are considered as 
alternatives for the treatment of multi-resistant strains of Shigella in all age groups 
(WHO 2005a). Unfortunately, strains of Shigella developed resistance to ciprofloxacin 
and other antibiotics have been reported (Taneja et al. 2005). 
Although drugs in the quinolone class have been reported to cause arthropathy in 
immature laboratory animals, the risk of joint damage in children treated with short 
course of fluoroquinolones appears to be minimal (Bethell et al. 1996; Sansone et al. 
2009) and is clearly outweighed by the value of these drugs for treatment of potentially 
life-threatening disease (Leibovitz 2006). 
Gatifloxacin is a new 8-methoxy-fluoroquinolone antibiotic. The presence of a methoxy 
group at position 8 in gatifloxacin increases the antibacterial activity of the drug against 
Streptococcus pneumoniae in addition to Enterobacteriaceae spp., and also a structural 
advantage that decreases the likelihood of emergence of resistance (Leibovitz 2006). 
The drug is distributed extensively into tissues. The MIC90 for Shigella spp. is 0.01- 
0.03mg/L (Douglas 2001). Gatifloxacin actively penetrates into phagocytic cells in 
vitro. Its significant accumulation in these cells (intracellular: extracellular 
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concentration ratios are between 5-7 times in macrophages and neutrophils) may result 
in enhanced activity against susceptible intracellular pathogens such as Salmonellae and 
Shigellae (Douglas 2001). In Viet Nam gatifloxacin has showed an excellent efficacy 
and safety for the treatment of typhoid fever caused by multidrug and nalidixic acid 
resistant organisms in both children and adults (Dolecek et al. 2008). 
As a result of increasing multidrug resistance (including nalidixic acid and 
ciprofloxacin) in Shigella strains circulating in Viet Nam (von Seidlein et al. 2006), we 
conducted a controlled trial comparing the efficacy of gatifloxacin, a third generation 
quinolone, versus the currently recommended drug ciprofloxacin, of the second 
generation quinolone (Leibovitz 2006), in the treatment of childhood shigellosis in 
southern Viet Nam. 
6.2 Materials and methods: 
The study was conducted from June 2006 to March 2009 at two places in southern Viet 
Nam: The Paediatric Ward B at the Hospital for Tropical Diseases (HTD) of Ho Chi 
Minh City and The Infectious Diseases Ward, Dong Thap Provincial Hospital (DTP) 
(see section 2.1.3 and 2.1.4 chapter two). 
The study protocol was approved by the Scientific and Ethical Committee of the 
Hospital for Tropical Diseases, Ho Chi Minh City, of Dong Thap Hospital and by The 
Oxford Tropical Research Ethics Committee (ref: OxTREC 010-06) and registered at 
International Standard Randomized Controlled Trials Registry (ISRCTN55945881). 
Inclusion criteria to the randomised clinical trial (Code name EG): 
Patients 3 months to 14 years old of either sex, who were admitted to the study wards 
with acute dysenteric syndrome (i. e. bloody stools, or mucoid stools accompanied by 
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abdominal pain and/or tenesmus) of less than 72 hours were eligible to be included in 
the study provided their parents or caregivers gave fully informed written consent. 
Exclusion criteria: 
Patients were excluded from the study if 
-They had documented been treated with any quinolones for this illness, 
-Their clinical states were severe enough to require parenteral antibiotics (based on 
treating physician's decision) 
-They had coexisting illnesses requiring antimicrobial therapy, 
-There were trophozoites of Entamoeba histolytica observed in stool microscopic 
examination. 
-Informed consent was not obtained 
Random allocation of patients to the clinical trial (code name EG study): 
A computer-generated randomization list for two study drugs in blocks of 10 was 
prepared by a person not involved in the care or evaluation of the patients or in data 
analysis. Whenever a patient fulfilled the entry criteria, a consecutively numbered 
sealed opaque envelop containing a small piece of paper (folded 4 times) printed the 
name of one of the study drugs was open to allocate her/him into one of two study arms: 
- (1) Ciprofloxacin (OPV manufacturer, Viet Nam) 15 mg/kg by mouth every 12 hours 
for a total of 6 doses in 3 days, 
- (2) Gatifloxacin (Stada Pharmaceuticals, Viet Nam) 10 mg/kg per day (orally in a 
single dose) in 3 days. 
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In case the clinical condition did not improve or worsened requiring parenteral 
antibiotics, ceftriaxone 50mg/kg of body weight per day in a single dose was used for 5 
days. Other treatment included fluid and electrolytes (WHO Oral Rehydration Solution, 
or parenteral Lactated Ringer solution) and antipyretics were given to the two groups at 
the discretion of the treating physician. Seizures were treated with diazepam 0.25 mg/kg 
of body weight intravenously. 
Clinical examination: 
Study day 1 (D 1) began with the first dose of the study drug and continued for the next 
24 hours. The clinical history and physical examination of the patients were 
documented on standardized case record forms (CRF). Vital signs and stools 
characteristics (bloody, mucoid or watery) were recorded every 6 hours, and the number 
of bloody or watery stools recorded every 24 hours. 
Haematology and biochemistry tests: 
Full blood count and microscopic examination of the stools for red blood cells (RBC), 
white blood cells (WBC) and parasites including Entamoeba histolytica were done for 
all patients. Serum electrolytes, ultrasound examination of the abdomen, and other tests 
were done at the discretion of the treating physician. 
Assessment parameters: 
For the purpose of the EG study, outcome parameters were as follows: 
Primary outcome: 
Failure rate: percentage of patients who suffered from either clinical failure or 
microbiological failure: 
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(a) Clinical failure: the patient still had symptoms (fever and/or diarrhoea) at day 5 
following treatment. 
Diarrhoea was defined as: 
Watery diarrhoea: passing 3 or more of liquid (un-formed) stools in the past 24 
hours; 
Bloody diarrhoea: passing at least one stool with visible blood; 
Mucoid stool: visible mucus in stool; 
Fever was defined as axillary temperature of >37.5°C. 
Patients re-admitted to the hospital because of diarrhoea within 1 week of discharge 
were classified as clinical failure. 
(b) Microbiological failure: Shigella was recovered from patient's stool after day 5 
following treatment. 
Secondary outcomes: 
(a) Fever Clearance Time (FCT): time from the start of treatment to when the axillary 
temperature fell below 37.6°C and remained there for more than 24 hours. 
(b) Diarrhoea Clearance Time (DCT): the time until the first formed stool. 
(c) Bloody diarrhoea Clearance Time (BDCT) the time until the last stool containing 
visible blood was passed. 
(d) Bacteria Clearance Time: the time from the start of treatment until the first culture 
negative stool (in cases where Shigella had been isolated on enrolment). 
(e) Hospital stay: from admission to discharge (days); 
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6.3. Results: 
6.3.1 Patients: 
A total of 500 cases of childhood acute dysentery were included into the study, 200 
cases at The Hospital for Tropical Diseases at Ho Chi Minh City and 300 cases at Dong 
Thap Provincial Hospital at the Mekong Delta. Half of these patients (250 cases) were 
allocated to the ciprofloxacin arm, and 250 cases in the gatifloxacin arm. Five patients 
in the ciprofloxacin arm and I child in the gatifloxacin arm were withdrawn from the 
study before taking study drug because their parents wanted to transfer them to other 
hospitals for their convenience. Shigellae were isolated from 108 admission stool 
culture (46 in Ciprofloxacin arm and 62 in gatifloxacin arm). Four hundred and thirty 
three patients returned to the hospital for follow-up 7-10 days after discharge, including 
35 Shigella culture positive cases in ciprofloxacin group and 47 Shigella culture positive 
in gatifloxacin group (Figure 6.1). 
The baseline characteristics of the patients enrolled in the two study arms were similar, 
except the number of cases with Shigella in admission stool in ciprofloxacin was lower 
than in gatifloxacin arm (46 versus 62 patients). The median age of patients was 19 
months old, and the median weight 10 kg. The patients were ill for a mean of 24 hours 
before admission to the hospital. The percentage of nalidixic acid resistant Shigella 
strains was the same in two groups (72% in ciprofloxacin arm versus 68% in 
gatifloxacin arm); so was the percentage of patients had follow-up visit (Table 6.1). 
S. sonnei was the dominant species with 73 out of 108 Shigella strains isolated, equal to 
68%. Sfexneri constituted 30% with 33 strains (12 in ciprofloxacin arm and 21 in 
gatifloxacin treatment arm). There were only 2 S. boydii strains, both in the gatifloxacin 
arm. 
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The Participants Flow Diagram 
Assessed for eligibility 
(n=551) 
Enrollment 
(n=500) 
Allocated to Ciprofloxacin arm 
(n= 250) 
Received allocated intervention 
(n= 245) 
Did not receive allocated intervention 
(n- 5) 
(Transfer to other hospital for 
parents' convenience ) 
IV 
Lost to follow -up (n= 29) 
(Family busy) 
Discontinued intervention (n 0) 
I 
r- Analyzed (n= 216) 
Excluded from analysis (n= 0) 
--I- 
Allocation 
Un Follow- 
M Analysis 
Shigella in stool culture (n= 46) 
Lost to follow -up (n= 11) 
i 
Analyzed (n= 35) 
Excluded from analysis (n= 0) 
PP Analysis 
Figure 6.1 Participants flow diagram in the study. 
Excluded (n=51): 
Not meeting inclusion criteria 
(n=22) 
Refused to participate 
(n=15) 
Other reasons (research doctor 
not available in holidays) 
(n=14) 
Allocated to Gatifloxacin arm 
(n= 250) 
Received allocated intervention 
(n= 249) 
Did not receive allocated intervention 
(n=1) 
(Transfer to other 
hospital for parents' convenience) 
Lost to follow -up (n= 32) 
(Family busy) 
Discontinued intervention (n= 0 
I 
Analyzed (n= 217) 
Excluded from analysis (n= 0 
Shigella in stool culture (n= 62) 
Lost to follow -up (n= 15) 
Analyzed (n= 47) 
Excluded from analysis (n= 0) 
Of particularly interest, there was one S. flexneri strain from a patient in gatifloxacin arm 
which was not only resistant to nalidixic acid but also to both ciprofloxacin and 
gatifloxacin. This patient responded uneventful to gatifloxacin treatment and was 
discharged healthy. 
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Table 6.1 Baseline clinical and laboratory characteristics of 494 children 
with acute dysentery. 
Parameters 
Age (month)* 
Weight (kg)* 
Boy/Girl (No. ) 
Duration of Illness before 
admission (hrs)* 
Body Temperature (°C* 
White cell count (/mm )* 
Total Shigella strains (No. ) 
S. sonnei 
Slexneri 
S. boydii 
Nalidixic acid resistant 
Shigella (No. of strains (%)) 
Follow-up (No. of cases (%)) 
Shigella culture positive 
* Median (interquartile range) 
Ciprofloxacin 
N=245 
19.0 (11.0-33.0) 
10 (8.4-12.0) 
148/97 
24 (16-48) 
38.5 (37.5-39.0) 
11,450 (8,595-15,700) 
46 
34 
12 
0 
33/46 (72%) 
216 (88%) 
35 
Gatifloxacin 
N=249 
19.5 (10.0-32.0) 
10 (8.2-12.5) 
146/103 
24 (16-48) 
38.5 (37.5-39.0) 
11,150 (8,645-14,200) 
62 
39 
21 
2 
42/62 (68%) 
217 (87%) 
47 
6.3.2 Efficacy: 
All children receiving antimicrobial treatment responded well to the treatment; there 
were no death or severe complications during the course of treatment. There was 1 child 
in each treatment arm who received rescue treatment with intravenous ceftriaxone 
because their clinical status did not improve after 3 days of treatment. They all 
recovered and were discharged healthy. 
Among 494 patients allocated to 2 treatment arms, there were 433 children who 
attended for follow-up 7 to 10 days after discharge from the hospital; the data of these 
patients was analysed on an intention-to-treat basis. The failure rate (the primary 
outcome) of the 2 treatment arms was 7.4% in ciprofloxacin arm versus 6.9% of 
gatifloxacin arm. This different was not statistically significant (OR=0.93,95%CI- 
0.42-2.05, pß. 9, Fisher exact test). The median time to first formed stool (diarrhoea 
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clearance time) was 67 hours in ciprofloxacin treated patients in comparison with 64 
hours in gatifloxacin treated group (pß. 7) (Table 6.2 and Figure 6.2). 
Other secondary outcome measures (bloody diarrhoea clearance time and fever 
clearance time) were also not different between the two treatment groups (Table 6.2). 
Table 6.2 Responses to treatment with ciprofloxacin and gatifloxacin in 433 
children with acute dysenteric syndrome attending follow-up. 
Parameters Ciprofloxacin Gatifloxacin P values 
(n=216) (n=217) 
Failure, cases (%) 16 (7.4%) 15 (6.9%) p=0.9 
Clinical failure 11(5.1%) 11 (5.0%) 
Relapse 5 (2.3%) 4 (1.8%) 
Microbiological failure 00 
Fever clearance time (hrs)* 24 (12-36) 24 (12-37) 0.5 
Bloody diarrhoea clearance time (hrs) * 30 (21-54) 29(21-48) 0.5" 
Diarrhoea clearance time (hrs) * 67 (42-93) 64 (42-93) 0.74 
Median (Interquartile range) 
t Chit test 
r Mann-Whitney U test 
There were 82 children among 108 Shigella positive patients attending follow-up, 35 in 
the ciprofloxacin arm and 47 in the gatifloxacin arm. The analysis of these patients (per 
protocol analysis) showed that the failure rate was 8.5% in both treatment arms (Table 
6.3). 
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Figure 6.2 Comparison of diarrhoea clearance time in 433 dysentery patients treated 
with ciprofloxacin (continuous line) versus gatifloxacin (broken line) (p=0.7 Mann- 
Whitney U test). 
There were 75 cases caused by nalidixic acid resistant Shigel/a strains, 33 in the 
ciprofloxacin arm and 42 in the gatifloxacin treatment arm. The fever clearance time as 
well as the diarrhoea clearance time did not differ significantly in the ciprofloxacin arm 
versus the gatifloxacin arm (Table 6.3 and Figure 6.3). 
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Table 6.3 Responses to treatment with ciprofloxacin and gatifloxacin of 82 
Shigella positive patients attending follow-up (per protocol analysis). 
Parameters 
Failure, cases (°o) 
Clinical failure 
Relapse 
Microbiological failure 
Fever clearance time (hrs)* 
Nalidixic acid resistant strains 
Bloody diarrhoea clearance time(hrs)* 
Diarrhoea clearance time (hrs) * 
Nalidixic acid resistant strains 
Bacteriological clearance time (hrs) 
" Median (Interyuartilc range) 
Fisher exact test 
Mann-Whitney U test 
log rank test 
io1 ý ý 
Ciproflotacin Gatifloxacin p 
(n=35) (n=47) values 
3 (8.5%) 4(8.5%) p=1' 
12 
22 
00 
19(12-36) 24 (12-48) 0.5 
18(12-30) 24(12-36) 0.4 # 
24(18-48) 24(23-42) 0.64 
54 (30-76) 54 (36-77) 0.9 # 
47 (24-70) 45 (24-70) 0.81 
1.0 (1.0-1.0) 1.0 (1.0-1.0) 0.11 ## 
Drug 
17 Ciprofloxacin 
_ ."I Gatifloxacin 
17 
0 "0 OC ' SC 200 250 300 
Diarrhoea clearance time (hrs) 
Figure 6.3 Comparison of diarrhoea clearance time in shigellosis caused by nalidixic 
acid resistant strains, ciprofloxacin versus gatifloxacin. 
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633 Adverse effect: 
This study was not designed to compare adverse effects of the 2 study drugs. All 
patients revealed no joint pain during the course of treatment and on follow-up visit one 
week after discharge. The concern was that dysglycaemia (hypoglycaemia and 
hyperglycaemia) has been recognized in elderly patients treated with gatifloxacin. We 
compared glycaemia levels on day 1 (just before taking gatifloxacin) and day 3 (at the 
same time of day) in patients in the gatifloxacin arm. In 234 patients whose pair 
glycaemia data were available, the means of glycaemia in D1 and D3 was 100.7 mg% 
and 98.4 mg% respectively. Of 61 patients with Shigella in stool culture the glycaemia 
was 108 mg% versus 102 mg% in D1 and D3. Using paired-samples T-test the 
difference between glycaemia of D1 and D3 was not significant in both intended-to- 
treat (p=0.18) and per-protocol analyses (p=0.09) (Table 6.4). There was no mortality in 
this study population. 
Table 6.4 Glycaemia levels at day 1 and day 3 of gatifloxacin treatment in 
dysentery patients. 
All Dysentery cases 
(n=234) 
Shigella positive 
cases (n=6 1) 
* paired-samples T-test 
CI: Confident interval 
Mean Mean Mean Paired P value 
Glycaemia Glycaemia difference (2-tailed)* 
Dayl (mg%) Day3 (mg%) (95% Cn(mg%) 
100.7 98.4 2.28 (-1.1 - 5.6) 0.18 
108 102 6.0 (-0.8 - 2.9) 0.09 
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6.4. Discussions: 
An effective antimicrobial is important for the management of shigellosis. It shortens 
the course of the illness, prevents the occurrence of severe complications, and reduces 
the transmission of the bacteria to close contacts, such as household members, 
classmates or neighbour (Traa et al. 2010). A 3-day course of ciprofloxacin is the 
current recommendation treatment for shigellosis including those caused by 
S. dysenteriae type 1 (WHO 2005a). The results of our study showed that gatifloxacin 
was as effective as ciprofloxacin in the treatment of childhood dysentery including 
culture-confirmed childhood shigellosis. 
In this study, 494 children hospitalized for acute dysentery (in which 108 cases with 
positive faecal culture for Shigella) were treated by either the WHO recommended 
treatment of ciprofloxacin for 3 days or gatifloxacin once a day for three days. There 
were 433 patients who attended for follow-up at 7-10 days after discharge and were 
eligible for primary outcome comparison. The failure rate was not different between the 
two treatment groups (7.4% in ciprofloxacin group versus 6.9% in gatifloxacin group). 
Time to become afebrile and time to first normal stool were also similar in the two 
groups (Table 6.2). In the subset of children with Shigella cultured on admission stool 
the failure rate, fever clearance time and diarrhoea clearance time were not significant 
different in both treatment groups (Table 6.3). The duration of faecal excretion of 
Shigella following antimicrobial treatment was slightly longer in the ciprofloxacin 
group (means 1.2 days in ciprofloxacin group versus 1.05 days in gatifloxacin group), 
but this was neither a clinically important difference nor was it significant statistically 
(pß. 11, log rank test, Table 6.3). 
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The treatment failure rate of 8.5% in the culture confirmed shigellosis in this study was 
much lower than the 31 % to 35% reported in the treatment of dysentery caused by 
S. dysenleriae type I (ZimBaSA Dysentery_Study_Group 2002). The difference may 
reflect the fact that the main serogroup of Shigellae in our study was S. sonnei, which is 
considered to cause a more benign illness than S. dysenteriae type 1. In a study in 
Bangladesh the failure rate in adults treated with ciprofloxacin was 18% (Khan et al. 
1997). In our previous study at the same institution in Ho Chi Minh City, in which 
S. flexneri was the dominant sero-group, the failure rate was 10% in the ofloxacin group 
(Vinh et al. 2000). One possibility is that shigellosis has become a more benign illness 
over time (Sansonetti 2006), or the patients admitted latterly were seen and admitted 
earlier and the case management at health facilities was better than in previous years. 
Although gatifloxacin is a newer fluoroquinolone, it's efficacy in the treatment of 
shigellosis did not appear to be superior to the older fluoroquinolone ciprofloxacin. 
However, because of its long half-life, the once-a-day administration is simpler and 
more convenient than the twice-a-day needed for ciprofloxacin. In this series 70% of 
Shigella strains were nalidixic acid resistant, but both study drugs cleared Shigella from 
stools effectively (Table 6.3). Of interest in this study is that one child was infected with 
a gatifloxacin-resistant S. flexneri strain (MIC of gatifloxacin was 8 gg/ml) but 
responded very well clinically to treatment with gatifloxacin. The bacteria were cleared 
from the patient's stool after one day of gatifloxacin treatment. Possibly the clinical 
response to treatment depends on a variety of factors of which antibiotics are only a 
part. 
The use of fluoroquinolones in children has been controversial for many years because 
of the fear of causing arthropathy, an adverse effect observed in immature laboratory 
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animals during the pre-clinical testing of this class of drugs. However, the 
overwhelming clinical evidence suggests that these fears are unfounded. A two year 
follow-up children treated with short course ciprofloxacin or ofloxacin for typhoid fever 
in Viet Nam did not showed any adverse effects on the children's growth nor did it 
reveal any evidence of arthropathy (Bethell et al. 1996). Recent studies in young lambs 
have shown that ciprofloxacin and gatifloxacin did not affect growth velocity in ovine 
model when administered in a dose regimen similar to that used in paediatric 
populations (Sansone et al. 2009). The World Health Organisation, after considering the 
potential risks and benefits, has recommended ciprofloxacin as the drug of first choice 
for the treatment of shigellosis in both adults and children (WHO 2005a) as well as the 
use of fluoroquinolones in the treatment of enteric fever. 
One other issue with gatifloxacin has been the association with dysglycaemic episodes 
both in pre-clinical studies and retrospective studies in the elderly. The propriety drug 
"Tequine" (Gatifloxacin manufactured by Bristol Myers Squibb) was voluntarily 
withdrawn from the market in May 2006 because of concerns about dysglycaemic. 
Although hypoglycaemia and hyperglycaemia were reported rarely in clinical trials with 
gatifloxacin, dysglycaemic events (mainly involved elderly patients with diabetes) were 
reported during the post-marketing period and published in medical literature (Park- 
Wyllie et al. 2006; Yadav and Deopujari 2006). In 1504 patients > 18 years old treated 
with either gatifloxacin or ceftriaxone for up to 5 days for acute community-acquired 
pneumonia or acute exacerbation of chronic bronchitis in the United States, the risk of 
dysglycaemia with gatifloxacin was not as high as previously reported in ambulatory 
patients (Onyenwenyi et at. 2008). Dysglycaemia was not reported in the pre-clinical 
testing in younger animals and it has not been reported in younger patients treated with 
gatifloxacin. Gatifloxacin maybe a very important drug both for enteric fevers in the 
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setting of high rates of nalidixic acid resistance and fluoroquinolone reduced 
susceptibility or resistance and for tuberculosis. Further work on its efficacy and its 
adverse event profile is needed before this drug is potentially lost from our potential 
therapeutic options. This is particularly true when most of the time we are using this 
drug to treat young adults and children in whom problems with dysglycaemia have not 
been reported. 
The design of this study may confound our interpretation. The study was not double- 
blind, the treating doctors and nurses knew the drugs their patients received, although 
neither the patients nor their parents did. However, because the randomization was 
prepared by individuals unrelated to the allocation or treating patients, none of the 
treating clinicians or nurses knew which drug the patients received before the envelop 
was opened, so treatment allocation was concealed. 
Another potential weakness of the study is that because gatifloxacin was withdrawn 
from the market by the primary manufacturer after the start of this trial, the future of 
gatifloxacin remains unclear. However, there are plans to prepare a dossier to submit to 
the World Health Organisation bringing together all the clinical experience of the use of 
this drug in enteric fever and tuberculosis and assess whether its continued production is 
required (C. Dolecek personal communication). 
In conclusion, gatifloxacin was as effective as ciprofloxacin in the treatment of acute 
dysentery, specifically shigellosis, in Vietnamese children. A simple once-a-day oral 
administration may lead to better adherence. Acute dysglycaemia episodes were not 
seen in children treated with the 3-day course of gatifloxacin in this study. With the 
131 
Chapter Six: Gatfoxacin versus Ciprofloxacin 
increasing trend of quinolone-resistance in Shigellae, it is worth to consider other 
antimicrobials for the treatment of shigellosis. 
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Chapter Seven 
Summary and Directions for Future Research 
Acute diarrhoea is a clinical syndrome every paediatrician sees in their daily practice. 
The case fatality rate of acute diarrhoeal disease has been decreased substantially in 
recent years presumably due to better case management at health care facilities. 
Shigellosis remains a significant global public health problem particularly affecting 
disadvantaged children. 
In Viet Nam, studies on the prevalence and antibiotic susceptibility of Shigella infection 
have been conducted in Ha Noi in northern Viet Nam and in Nha Trang in the central 
part of the country. There has been much less data on childhood Shigella infection in 
southern Viet Nam. This has been the focus of my thesis. 
This thesis focused upon the epidemiology, clinical features, antibiotic resistance and 
treatment of Shigella infection in Vietnamese children and aimed to address four 
questions: 
(i) What is the magnitude of Shigella infections as a causative agent of 
childhood acute diarrhoea in southern Viet Nam? Is clinical picture specific 
enough to differentiate acute diarrhoea caused by Shigella from that caused by 
other agents including rotavirus? 
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(ii) What have been the changes in the epidemiology, antibiotic susceptibility 
and clinical features of childhood shigellosis in southern Viet Nam in the last 15 
years? 
(iii) What are the molecular characteristics of the ESBL genes in the Shigella 
population circulating in southern Viet Nam? What transferable genetic 
elements have mediated the transmission of ESBL genes between bacteria? 
(iv) Is gatifloxacin an effective drug for the treatment of Shigella infection in 
children? 
In this chapter the key findings from my thesis are summarised, the limitations of the 
studies identified and some personal thoughts on the areas of research that demand 
further investigations are discussed. 
7.1 Research questions revisited: 
Question 1: What is the magnitude of Shigella infections as a causative agent of 
childhood acute diarrhoea in southern Viet Nam? Is the clinical picture specific enough 
to differentiate acute diarrhoea caused by Shigella from that by rotavirus? 
The study to answer the above question was described in Chapter Three. A total of 556 
children admitted to the hospital because of acute diarrhoeal illness were included in a 
12-month study during the period 2000-2001. Standard microbiology methods were 
used to detect enteropathogenic bacteria and parasites. The negative-stain electro- 
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microscopy was performed for detecting potential enteropathogenic virus in stools. 
There was no enteropathogen detected in 210 samples (38% of all samples) and at least 
one enteropathogen was detected in 62% of samples. Among the enteropathogens, 
rotavirus was the most important agent (46%) and Shigella ranked second with 9% of 
all cases. This result was similar to that reported from other developing countries. The 
most frequent genotype of rotavirus strains was G1 [P8] and its variants (20/49) and of 
interest genotype G2 [P4] ranked second with 16 strains. These data should be 
considered when choosing the type of rotavirus vaccine (monovalent or polyvalent 
vaccine) for this community in Viet Nam. Next to these pathogens norovirus and 
Campylobacter spp. were frequently identified. 
To answer the second part of the question I compared the clinical features of cases of 
acute childhood diarrhoea in which a single enteropathogen were isolated in admission 
stools, either rotavirus or Shigella spp.. There were 234 cases with rotavirus and 99 
cases with Shigella. Rotavirus caused diarrhoea in a younger age group (peaked in 7-12 
months old group) than that of Shigella (peaked in 13-24 months old group). Shigellosis 
in children less than 6-months was very rare but 8% of rotavirus diarrhoea cases were in 
this very young group. A typical case of rotavirus diarrhoea is a child 7-12 months old, 
admitted to hospital with the triad of "fever-vomiting-watery diarrhoea", the blood 
white cell count is within normal limits and with no white cells in the stool. A typical 
shigellosis cases presented with "fever-mucoid diarrhoea-abdominal pain" with 
leukocytosis and the presence of white blood cells in stool. In practice of course there is 
significant overlap in the clinical and laboratory signs of these two diseases. Data from 
this study showed that 46% of children with shigellosis passed only watery stool and not 
mucoid stools. In addition 32% of rotavirus infection cases had white blood cells in 
their stool and 10% of all rotavirus diarrhoea cases had red blood cells in their stools. 
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These findings underscore the difficulty in making the clinical diagnosis of cases 
presented with acute diarrhoea in children. More studies using simple clinical and 
laboratory tests would be useful to help clinicians answer this issue. It has major 
implications for which microbiological tests to order in a financially constrained 
environment and what treatment to offer. 
Question 2: Are there changes in epidemiology, antibiotic susceptibility and clinical 
aspects of childhood shigellosis in southern Viet Nam in the last 15 years? 
This question was answered in Chapter Four. I had a chance to look at a collection of 
Shige/la spp. strains isolated from hospitalised children over 3 time periods: 1995-1996, 
2000-2002 and 2006-2009 with clinical data recorded. A prominent change in dominant 
Shigella species was seen: Sflexneri was the dominant species in 1995-1996 (-70% of 
all strains) while S. sonnei was the most frequent in 2006-2009 (-70%), in the 
transitional period 2000-2002 the proportion of S. flexneri and S. sonnei was mixed. The 
second important change in the 15 year time period was the sharp increase of Shigella 
strains which were resistant to nalidixic acid from -7% in 1995-1996 to -70% in 2006- 
2009. The third change was the clinical features of in-hospital shigellosis cases 
suggested that the clinical presentation had become more severe; the body temperature 
and the blood white cell counts were higher and the hospital stay was longer than seen 
previously. However there was no fatality in the 3 periods. Lastly of note was the 
identification and rapid development of ESBL-producing S. sonnei strains as the 
dominant species. The details of these strains were described in Chapter Five. 
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Question 3: What is the molecular characteristic of ESBL genes in Shigella population 
circulating in southern Viet Nam? What transferable genetic elements mediated the 
transmission of these ESBL genes? 
The occurrence of ESBL-producing Shigella strains in southern Viet Nam was 
discovered by chance. In HTD, ceftriaxone has been used as an alternative treatment for 
cases of acute bacterial diarrhoea which did not respond to oral antibiotic treatment or in 
patients in whom the clinical state was severe enough to require intravenous antibiotic 
treatment. As a result of this practice a ceftriaxone disc was placed on the susceptibility 
test plate for all Shigella strains from the year 2000. The first cefiriaxone-resistant 
S. sonnei was detected in May 2007 and further strains were identified at approximately 
one strain per month. I subsequently checked the susceptibility results of all strains in 
the period 1995-1996 and 2000-2002 and found only one S. sonnei strain isolated from a 
child in February 2001 which had a high MIC to ceftriaxone. This was the first reported 
ceftriaxone-resistant Shigella strain detected in southern Viet Nam. Approximately 
60% of Shigella strains were ceftriaxone-resistant in the last 6 months of the the study 
(Oct. 2006- Mar. 2009. The combination disc test and double disc synergy test were 
used to confirm the ESBL production of these strains. The test was positive in 35/36 
strains. The conjugation experiment was carried out to confirm the plasmid- 
transferability of bIaESBL genes. The conjugation experiment was successful in 35/36 
strains. The plasmid extraction was performed using a modified Kado & Liu procedure. 
In the majority of cases there was only 1 plasmid transferred to the laboratory plasmid- 
less E. coli J53 AzR along with the ceftriaxone resistance. Among 35 strains the ESBL- 
producing genes were transferred by a plasmid of -100kbp in 32 strains. In the other 3 
strains the transferable plasmid was -. 70kbp in size. The bacteria genomic DNA was 
subjected to PCR amplification to identify the molecular nature of the ESBL genes. 
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Firstly primers were selected to be specific for blaTEM, b1aSHV and blaCTX-M 
classes of ESBL genes. Then primers specific for three major CTX clusters, blacTx-M-9, 
blacTX. M. i and blacTx. M. 2 were used to characterise the molecular nature of ESBL genes. 
All ESBL-positive strains (34 S. sonnei and 1 S.. lexneri) strains produced CTX-M 
primer-specific amplicons. 
Sequence analysis showed that there were two different types of bIaCTX-M present in 
the S. sonnei population, bIaCTX-M-24 (n=3,8 %) and b/aCTX-M-15 (n=32,92 %). 
The only S. lexneri strain (EG0471) possessed b1aCTX-M-15 genes. The blaCTX-M- 
24 was carried by the --70kbp plasmid, while the b/aCTX-M-1 5 gene was carried on the 
-100kbp plasmid. The 3 S. sonnei strains containing the b/aCTX-M-24 genes were 
isolated in February 2001, May 2007 and January 2008 consecutively. The b/aCTX-M- 
15 gene occurred in June 2007 and from February 2008 has become the sole b/aCTX-M 
gene in Shigella strains circulating in southern Viet Nam until the end of the study in 
March 2009. 
Based on the scatter spatial distribution and variable plasmid profiles of ESBL- 
producing strains, the occurrence of ESBL-producing Shigella strains was unlikely to be 
the result of an outbreak of a single ceftriaxone resistant Shigella clone. This is the first 
time the b1aCTX-M-15 was detected in Viet Nam. The presence of a blaCTX-M-15 
carrying transferable plasmid in the Shigellae circulating in southern Viet Nam is of 
particular interest because this bIaESBL gene has been detected recently in all 
continents and lead to difficulties in the treatment of community acquired as well as 
health care associated infections caused by Enterobacteriaceae globally. 
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Question 4: Was gatifloxacin an effective treatment for Shigella infection in children? 
The randomised controlled trial described in Chapter Six attempted to answer this 
question (registered at International Standard Randomised Controlled Trials Registry, 
ID number ISRCTN55945881). Five hundred patients age 3 months to 14 years were 
consented by their parents/care-givers to participate in the study. Six of them were 
withdrawn from the study soon after allocation before taking the study drug because the 
parents/care-givers changed their mind and decided to transfer them to other hospital. 
Among 494 children still in the study 245 were in the ciprofloxacin arm, 249 in 
gatifloxacin arm. After 5 days treatment in hospital, a total of 433 patients came back 
for follow-up (216 in ciprofloxacin arm and 217 in gatifloxacin arm). In this population, 
stool culture positive for Shigella spp. were 35 in ciprofloxacin arm and 47 in 
gatifloxacin arm. The primary outcome in this study was the failure rate (presence of 
diarrhoea or fever or Shigella in stool after 5 days from the start of drug treatment; or 
was relapse or had Shigella in stool culture on follow-up). In the intention-to-treat 
analysis, the failure rate was not different between the two treatment groups (7.4% in 
ciprofloxacin group versus 6.9% in gatifloxacin group, p=0.9). Time to become afebrile 
(median time were 24 hours in ciprofloxacin group versus 24 hours in gatifloxacin 
group, p=0. S) and time to first normal stool (median time were 67 hours in ciprofloxacin 
group versus 64 hours in gatifloxacin group, p=0.7) were also similar between the two 
groups. 
In the per protocol analysis of the subset of children with Shigella cultured from the 
admission stool, the failure rate (8.5% in both treatment groups), fever clearance time 
and diarrhoea clearance time were not significant different in both treatment groups. 
The duration of faecal excretion of Shigella following antimicrobial treatment was a bit 
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longer in ciprofloxacin group (means 1.2 day in ciprofloxacin group versus 1.05 days in 
gatifloxacin group), but it was not significant statistically (p=0.11, log rank test) nor of 
clinical relevance. The dysglycaemic state seen in the elderly treated with gatifloxacin 
was not seen in our 3-day treatment course of gatifloxacin The results of this 
randomised controlled trial lead to the conclusion that gatifloxacin was comparable to 
ciprofloxacin for the treatment of acute bacillary dysentery in children, including those 
caused by Shigella spp. 
7.2 Limitations of the studies and future directions: 
There were limitations which may lead to bias need to be considered in the 
interpretation of studies included in this thesis. 
The main limitation was the hospital-based design of the studies. This will inevitably 
miss mild (self treated or a self limiting illness) or the most severe patients who may 
have died before reaching the hospital for treatment. The failure rate in the in-hospital 
treatment may not reflect that of community health station where the diagnosis and 
management facilities may not as good as hospital-based treatment. 
This thesis has described paediatric patients only (people under 15 years old who are 
defined as children in Viet Nam). That limited the generalisability of the conclusions to 
older populations in whom there is a second peak of Shigella infection in those older 
than 40 years of age (von Seidlein et al. 2006). 
The diarrhoea aetiology study described in Chapter Three had limitations including the 
lack of E. coli identification, and of an appropriate control group. These lacking data 
may over-emphasise the magnitude of Shigella as well as other enteropathogens 
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infection. The clonality of ESBL-producing Shigella strains was not studied in sufficient 
detail and the molecular nature of bIaESBL-carrying plasmids was not described. 
More works need to be done in the future to expand our understanding about Shigella 
infection in children. I would suggest that these include: 
1. A comprehensive study on aetiology of diarrhoeal diseases in children using 
classic clinical microbiology techniques plus multiplex-PCR technique. Such a 
study will not only help to monitor the change of the magnitude of rotavirus, 
norovirus, Shigella, Salmonella, Campylobacter spp. as the cause of acute 
diarrhoea but also help to clarify the role of diarrhoeagenic E. coli in Vietnamese 
children. This study has already been started in my hospital and 2 children 
hospitals in Ho Chi Minh City. The control group included healthy children in 
baby day care centre and kindergarten. 
2. The sero-group distribution and susceptibility of Shigella strains in different part 
of Viet Nam (Ha Noi in the northern part, Hue City and Nha Trang City in the 
central part, and Ho Chi Minh City of the southern part of Viet Nam) should be 
monitored. 
3. The molecular nature of the plasmids carrying the b1aCTX-M genes should be 
characterised. The -70kbp plasmid which carried the b/aCTX-M-24 has been 
characterised, the -I OOkbp plasmid are being studied (Nhu et al. 2010). A study 
on the ESBL-producing E. coli and K. pneumoniae in community-acquired and 
hospital-acquired infection may define the magnitude of the b/aCTX-M-15 and 
b/aCTX-M-24 genes in southern Viet Nam. 
4. Either a newer antimicrobial drug or a combination of an antimicrobial and an 
anti-diarrhoeal product may be compared with the current standard treatment in 
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a randomised controlled study in order to decide which treatment is the best for 
childhood shigellosis. 
5. Lastly is the development of a simple, inexpensive, and reliable predictive score 
or algorithm which based on simple and easy available clinical and laboratory 
data that would assist clinicians in identifying patients with acute diarrhoea who 
to be treated with antibiotics and who not to. 
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Rapid emergence of third generation cephalosporin 
Shigella spp. in Southern Vietnam 
ý'ý r P- s ýýý ý'ý ý: C 
resistant 
Uiarrhocal dixasc caused bs third 
generation c halosporin rc istant Shigella 
%pp. has been described in the past. but it 
remains a relativcly infrequent dcxasc. 
Ilere. we report II cases of childhood 
shigeflosis causal by ctiitriaaunr-resistant 
organisms isolated in Sotthcm Vietnam 
between May 200: and January 2008. We 
predict that the emergence of such strains 
may berme more frequent and will 
hamper effective treatment. lmprcwed 
microbiulogial szuveillancc and cknkal 
investgatiors are required for an accurate 
assessment of the problem. 
There are an estimated 165 million 
shigellusis episodes annul' worldwide. of 
which 64'4o of the patient burden is in 
children under the age of 5 gran 
(Kntlu f 
er al.. 1999). Transmission tit Shtgdka 
follows the faae1-oral mute, hence. 
Shigdk infertiorn arc commonly 
associated with poor sanitation and limited 
accts, to clean water. Antimicrobial 
therapy of Shi(ella infections hastens the 
dinical recovery. prevents complications 
and stops the dissemination of the bacteria 
back into the community. The emergence 
of multiple-drug resistant (MDR) strains 
of Sbigefa spp. over the last two dttades 
clearly highlights the pmhlem of \1L)R 
pathogenic enteric bacteria and makes the 
selection of treatment fur shigellosis more 
pnohlcmatical. The World I health 
Organration (A%'110) currently 
recommends ciproflosacin (or oilier 
fluor quinolonrs) as the drug of dhoise for 
the therapy of Shigdla infections in both 
adults and children. In addition. 
ecftriaxcnc, pivmcetllinam Iamdinoc 
lin 
pivoxilI and azithnomycin are considered 
as alternative drugs suitable for Shiy, Yla 
treatment (WI 10,2005). Ilowever. similar 
to other pathogenic enteric bacteria like 
Salmencla ((-7tau es al., 2007), strains of 
Shpdh spp. that are resistant to 
eipmfoxacin have lien described in Asia 
(Von Seidkin et al., 2(8)6). Additional)), 
strains of Slrigdla spp. that produce 
cstenukd spectrum ß-Lutamases (ESBU. 
inferring resistance to third generation 
cephalonlurins have also 
been reported 
R, rtineau ei aL. 2001). 
In Vietnam. MDR strains of Sitigdla spp. 
have been reported (Is-nbargur et at, 24812; 
\'inh et at., 2000) but shigellnsis caused by 
Shtella spp. that are resistant to third 
generation cephaloosporins was, previously, 
unknown During the course of a clinical 
shigellosis treatment trial conducted in 
Southem Vietnam from tune 20416, we 
have identified several children infected 
with ceftriaxone-resistant Shigdla. here, 
we report the clinical. epidemiological and 
microbiological asp--s of shigollosis in 
these patients. 
The study was carried out at two locations 
in Southern victnam between tune 2(816 
and January 2(818. These locations were the 
I lospital for Tropical Diseases, I In Chi 
Minh City, and Lkmg Thap Provincial 
Hospital, Dontg Thap Province, in the 
Mekong Delta, appn, ximately 180 kill 
font Ito Chi Minh City. The criteria for 
enrolment in the clinical trial was: the 
patients had to be children under IS years 
ofagc, of either sex, who were hospitalized 
because of asvte dysentery (this was 
defined as passing blonds diarrhoea or 
mucuid stools with additional abdominal 
pain or tenesmus). Only those patients 
with written consent, given 
by parents or a 
guardian. were eligible to take part in the 
study. the clinical deaiLs were recorded in 
a study form. 
stool samples were taken 
from the patients 
on arrival in hospital. prior to the 
first 
administration of antimicrol 
iaLs, then 
daily for the next 3 days, and additionally 
on a follow-up visit I week after being 
di charged from hospital. 
The stool 
samples were cultured by standard 
procedures in order to 
isolate Shigella spp. 
A ntibiotic susrptibaity testing was carried 
out using the disc diffusion method, 
according to Qinical and Liboratory 
Standards Institute (CLSI) guidelines. The 
MIC was measured using 
Etest strips (AB 
DOI 1Q1099fjmm. Q002949-0 ® 2009 SGM Ain. 'ed in Great &Cein 
Bitdisk). the susceptibility of Shigela 
strains to ccftriawine was used to ascertain 
strains that could generate LSBLs. Those 
strains that were identified as resistant to 
ceftriaxone using the disc diffusion 
susceptibility test were further subjected to 
the 'combination disc method' to confirm 
ESBL production. The combination disc 
method utilized discs containing 
cefotaxime (30 µg) alone, ceftazidime 
(30 µg) alone, and either antimicrobial 
combined with clavulanic acid (10 pg). All 
antimicrobial testing was performed on 
Mueller-Ilinton agar according to CLSI 
guidelines (CLSI, 2007). 
The clinical study was initiated in June 
2006; in the period from June 2t9)6 to 
Januarys 2008 we isolated 72 Shil ella strains 
in total, of which 1I (15.3 %), were 
ceftriaxonc resistant. 'Ihtse strains were 
isolated on admission from the stools of II 
children (7 boys, 4 girls) aged between 17 
and 48 months. Eight of the patients came 
from I to Chi Minh City, one carte from 
Long An (near I to Chi Stith Cit)) and 1m) 
from Dong Thep Prosince in the Mekong 
delta. The first GSBI. -prod ucing 
ce triaxonc-resistant Shigella onaei strain 
was isolated from a Bocal sample taken 
from a child from I to Clti Minh City, who 
had sevcte dysentery, in May 2007. We 
then identified new ceftriaxone-resistant 
strains at a rate of one per month, until 
January 2008, when we isolated three 
strains. S. sound accounted for the 
majority ofthe ccftriaxonc-nsistatt strains 
isolated (1011). All of the . so nei were 
confirmed to produce EMIL due to an 
increase of ?5 mm in zone diameter 
around crInaximelclavulanic acid disc 
compared to the zone around the 
celotaxime disc, using the combination 
disc test. ShigdIa flecneri accounted for the 
remaining ceftriaxone- resistant strain 
(1; l I). The S. fletseri isolate was found 
not to be ESBL producing its it only 
exhibited limited zone clearance with the 
combination disc test. This obsen"ation 
was corroborated by the lack of a 
281 
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charrteristic hell-shaped rust of clearance 
between the two discs when the strain was 
Koval on plates containing ceftrsrxone 
and amoxicithn/cdavulauc acid discs. All 
putsnts returned I wtrl after dixhargr for 
a follow-up caanunation and wcrc in pmo d 
)rakh. Faccal samples from 10 dtidren 
were taken on the follow-up visit. all trstcd 
ctrture nrgatise got ShigeUa. 
Additioxtally. we retro sp . tis'eh" analysed a 
culkati on of 114 SJgrlla strains isolated 
between 2000 and 2002 fur chnaaunc 
resistance . %m We identified one strain of S. 
sormei that displayed E. S1IL-mediated 
ceftriaxutr resistance. This strain was 
isolated from a 10-month-old bus treated 
fox acute watav diarrhoea in the llospital 
for Trop" al Utsea ci in February 2001. 
This. potential) . is the 
first recorded strain 
of third generation ecphaluspwrin resistant 
S. sonrri in Vietnam. 
Antimicrabwl resistance is a will described 
phemomcnrn in the prtsw Shigdfa, but 
diarrhocal disuse caused by third 
grrscratiun c phabsporin resistant Shigrlla 
spsp. is still uncommon. the first 
occurrence of third pmeration 
crphabsporn rsrstant S. 
"ctnen was tram 
the stool sample of a 16-month-old 
Alprrian chid husptuliand in Paris. 
France. in 1995: the microhiololtical details 
of this strain were ptislishe d in 21101 
(Furtincau er aL. 2001). Since that time 
many strains of Shigrfla spp. hartsouring 
different types of f_SBLs have been 
reported in developed and developing 
countries in Asia (('htung er ad., 1_005: 
(7tuang er al.. 2(06; Kim et al.. 2200.1; 
Pai 
er al.. 2001; t(ahman er A. 20M; Xiong 
er al_ 2007). l lovvevcr, to the 
best of our 
kruwvletlge this is the first report of LSBL- 
producing Shgd(o spp. in Vietnam. 
'the clinical patens of these casts were 
typical of dysentery caused by a Shigella 
infection. Ucspitc 9110 S. sarinei strains in 
this series elcm onstratigt co-ressurre to 
rsslidivic rid. Al patients responded to 
oral f)uuruyuinnlotss (ctprofloxacin, 
ptifloxacin or norioxacin). None of the 
patients had any clinical signs or 
symptoms of Shigrlla infection within 
3 days of the octet of treatment. 
Additionally, 41 (anal samples from the 
patients taken after treatment and on 
follow-up visits were negative for Shigda. 
these data show that resistance to third 
282 
gernrration ccphalotsporins did not prolong 
the shedding of Shtgd6r provided the 
appropriate antimicrobials were 
administered. The niok"cular 
duractcnstics of the ESBL-encoding genes 
ha toured hs the S.. onnd strains in these 
nulates are currently- Ixng investigated 
and will be reported elsewhere. Ilowever, 
lydiminars" data suggest that ceftriax ne 
ress anu in these strains is mediated l. y a 
plan nid-Lorne Cl: X-M cLtss ESBL- 
encoding gene. The mule ular ntcchanisnt 
d the ESBL ncg,. tivc, ccftriasortr-resistant 
S. Norrrri is also under investigation. 
Our otssen"ations demonstrate that 
emergence of ccttrt&sone-resistant 
slugdLic in Southern Vietnam has not 
accurnd 1y chance and the ability of thew 
strains Ia produce ESBI-s appears to be 
escl. tiemarih advantageous. The simple 
availability of antibiotics in Vietnam 
predicts that drug resistance in the 
community is rife. It is also known that 
E l. -encoding genes can 
be carried on 
llasmids by non-gathogenic, commensal 
organisms. suggesting that spread of 
r? astatce genes to pithottertie 
bacteria 
may enc, rr at a significant rate. The genetic 
transfer of drug resistance genes may not 
be of immediate concert 
for the treating 
Jinicians, but will lxtsc a potential 
problem in the future. We predict that the 
isolation of cefiriasonc-resistant shigellae 
and other biterobactrriacrae will 
become 
imcreasingk common in Vietnam in the 
coming years. Currently, we have effective 
optional therapies; however. ceftriasunc is 
used in the hospital here in Vietnam as an 
alternative when the patient does not 
respond to fluorgiiinolonc treatnienl A 
marked increase in resistance to nalidiaic 
acid and newer fluontquinukmas. 
combined with FBI: mediated third 
generation cepltakisporin resistance would 
leave limited treattnent options for those 
with life-threatening tactrrial infections. 
the majority of studies published in recent 
)rays on E'CBI: producing Shigdla 
have 
described mainly the transfer mechanisms 
and the mde,. ular types of the /1- 
Li Camases produced In order to have a 
comprehensive perspective on the clinical 
manifestations and outcomes of the 
illness 
caused by f_SEIL-producing shigellac more 
patient-oriented easc series reports are 
required. Moreover, ESBL-producing 
strain of Sitigdla may he overlooked if 
Appendices 
screening for FS13Ls is not routine in 
diagnostic microhitittgv laboratories. 
Therefore, more vigilance is required in 
detecting FSBL-prtxiucing Shigdla strains 
and a wt, rldwale rapid reporting %vuem 
will allo% the monitoring of the 
dissemination oi'such strains and whether 
diarrhoeal diseases caused by third 
generation cephalosporin rtsistant Shigella 
is an emerging trend muridwidc. 
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Abstract 
Background: Shigellosis remains considerable public health problem in some developing 
countries. The nature of Shigetloe suggests that they are highly adaptable when placed under 
selective pressure in a human population. This is demonstrated by variation and fluctuations in 
serocypes and antimicrobial resistance profile of organisms circulating in differing setting in endemic 
locations. Antimicrobial resistance in the genus Shigella is a constant threat, with reports of 
organisms in Asia being resistant to multiple antimicrobials and new generation therapies. 
Methods: Here we compare microbiological, clinical and epidemiological data from patients with 
shigelosis over three different periods in southern Vietnam spanning 14 years. 
Results: Our data demonstrates a shift in dominant infecting species (S, fkxneri to S. sonnei) and 
resistance profile of the organisms circulating in southern Vietnam. We find that there was no 
Page 1 of 12 
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srmßcant variation in the syndromes associated with either S. sonnei or S Heinen, yet the clinical 
features of the disease are more severe in later observations. 
Conclusions: Our findings show a change it clinical presentation of shigelosis in this setting, as 
the disease may be now more pronounced. this is concurrent with a change in antimicrobial 
resistance profile. These data highlight the socio-economic development of southern Vietnam and 
should guide future vaccine development and deployment strategies. 
Trial Registration: Current Controlled Trials ISRCTNSS94S88I 
Background 
Shigcllosis is an onguing global public health problem. 
Due to the fecal-oral transmission route of the organisms, 
the over itciming burden of shigellosis is found in 
resource-poor settings with inadequate sanitation 
11.21. 
With an estimated number of episodes exceeding 90 mil- 
lion per annum in Asia alone, shigellosis represents a sig- 
nificant proportion of the total number of bacterial 
gastrointestinal infections worldwide (3). Unlike other 
related bacteria which can cause a particular 
disease syn- 
drome in specific locations (e. g. SalmondlaTyphi)14) it is 
a disease which 'bridges the gap' between industrialized 
and developing countries. A report from the National 
Center for Infectious Diseases in the United States of 
America found the incidence of shigellosis to be 7.6 cases 
per 100,000 persons in 1993 (51. 
The ShiSMae are gram negative, non-motile bacilli of the 
larger bacterial family fnwerob, eriacae. S. fearrert are 
regarded to be the most abundant globally and are 
known 
to predominate in developing countries 
(3). S. wnel is 
the most commonly isolated species in developed coun- 
tries, representing over 70% of the total isolates in the 
United States of America and Israel ( 5,61. The disease syn- 
drome associated With these organisms includes fever, 
headache. malaise, anorexia and occasionally vomiting, 
followed by excretion of profuse watery diarrhea proceed- 
ing bloody and/or mucoid diarrhea 171. All the members 
of the genus ShiSella arc pathogens restricted to infecting 
humans and exert their effects on the gastrointestinal 
mucosa via the production of a multitude ofvirulcnce fac- 
tors, including enterotoxins and effector proteins (6,91. 
In a recent publication by von Seidlein et at. the authors 
found a change in dominant Shigeffa species related to the 
location in Asia (S. sunnei predominated in Thailand, S. 
le, meri was dominant in other Asian countries) and 
fluc- 
tuations in S. Jlexneri serotypes in the same location over 
the duration of the study (101. The authors concluded that 
'Shiged! r appears to be more ubiquitous in Asian impov- 
erished populations than previously thought and antibi- 
otic-resistant strains of different species and serotypes 
have emerged' 1101. Such findings have important impli- 
cations for treatment and prevention strategies of shigel- 
losis. 
On a larger scale, the Shigellae are a group of dynamic 
organisms, in which the overall bacterial population 
appears to be adaptable with a high recombination rate 
and a large amount of imported genetic material in the 
genome architecture 1111. These organisms are highly pro- 
miscuous regarding their ability to accept horizontally 
transferred genetic material. Like E. coli the Shigcllae are 
successful recipients of numerous plasm ids, which maybe 
transferred from other enteric organisms in the gastroin- 
testinal tract 112. This is supported by evolutionary evi- 
dence that the Shigellae arc a branch of the E. col; family, 
having developed a pathogenic phenotype by the acquisi- 
tion of a virulence plasmid and other gene loci and 
genomic compensatory mechanisms 113,141. 
It is known that the circulating species and serotypes may 
be considered a marker of the socio-economic climate in 
an individual setting 1151. It is clear that Vietnam has 
undergone rapid economic development since the early 
199o's. To understand the nature of bacterial and clinical 
nature of shigellosis in southern Vietnam we have 
amassed and compared microbiological and epidemio- logical data on childhood shigeliosis over three periods 
spanning 14 years, from 1995 to 2008. 
Methods 
Study sites and settings 
The primary location was the pediatric gastrointestinal 
infections ward at the hospital for tropical diseases (IITD) 
in Ho Chi Minh City in southern Vietnam. The H TD is a 500 bed tertiary referral hospital treating patients from the 
surrounding provinces and from the districts within Ho 
Chi Minh City. The secondary location was Dong Thap 
provincial (DTP) hospital in Dong Thap province, 
approximately 120 km from the HTD in Ito Chi Minh 
City. 
Studios contributing data for analysis 
Data from three independent studies were combined and 
compared. All patients enrolled in the three studies were 
treated as inpatients and there were no fatalities. The ini- 
tial period (referred to as period A from here onwards) 
was a study performed at the pediatric wand at I iTD from January 1995 to August 1996. The enrollment and clinical 
observations for this randomized controlled trial are as 
Page 2 of 12 
(papa nwneernat fiu dWw popvses) 
176 
Appendices 
BMG Mfecuojs Dseases 2009.9"204 
described previously II bi Briefh-, children that were aged 
>3 months and < 14 tears. admitted to l iD with fever and 
bloody diarrhea (bloody diarrhea defined >3 loose stools 
with obvious blood) for e5 days were entered into the 
study provided that their parents or guardian gave fully 
informed consent. Additional strains for microbiological 
assessment only ( nine in total) were collected for compar- 
ison within the same period of the study duration from 
DTP. Overall &0 strains were isolated from enrolled chil- 
dren over this period, clinical data was available for anal- 
ysis on 63 patients with cultwc confirmed shigdlosis. 
The secondary period (referred to as period B from here 
onwards) was conducted only at the FIM, between March 
2000 and December 2002. This period was a clinical and 
microbiological imcstigation of the etiology of diarrhea 
in the pediatric population admitted to the 14TD in Flo 
Chi Minh City Whilst the treatment criteria for this 
descriptive study were not controlled (> 900% of patients 
received treatment with fluroquinolones (norfloxacin or 
ofloxacin)), the remainder of the criteria for admission to 
the study were comparable, children were eligible for 
enrollment to the study if consent was given and they 
were aged less than 14 years. The obvious variation in the 
enrollment for this study was that children were enrolled 
on the basis of having any diarrheal syndrome, rather 
than specifically urgcting those with dysentery and sus- 
pected shigellosis. One hundred and fourteen Shigello iso- 
lates were recovered during this period; clinical data was 
available for analysis on 113 patients. 
The final period (referred to as period C from here 
onwards) in which data was combined was a trial con- 
ducted at the F1TD and at DTP between June 2006 and 
December 2008. This was a randomized controlled trial 
for comparing the treatment of dysentery with cipro- 
floxacin and gatilloxacin in Vietnamese children (control- 
led trials number 1SRCTN55945881) (HV and SB, 
unpublished data). The inclusion criteria were as period A. 
One hundred and three isolates were collected during this 
period and clinical data on all admitted children was 
available for analysis. 
All three studies were approved ethical assessment by the 
Scientific and Ethical Committee of the hospital for trop- 
ical diseases and Oxford University tropical ethics com- 
mittce (OXTREC) number 010-06 (2006). 
MicrobloloVcd methods 
From all studies, stool samples were collated from 
patients and cultured directly on the day of sampling. Ini- 
tial isolation was as below, however, all bacterial isolates 
were stored in glycerol at -80°C and re-scrotyped and 
checked for consistency with the original antimicrobial 
susceptibility profile for the purposes of this work. All 
hrip: llwww. Womedcenhal. rnm/1471-2334/9? 2D4 
specimens were processed and checked in the microbiol- 
ogy laboratory of the FRU. 
Samples were cultured overnight in selenite F broth 
(Oxoid, Basingstoke, LIK) and onto MacConkey and XLD 
agar (Oxoid) at 37 ° C. Colonies suggestive of Salmonella or 
Shigella (non-lactose fermenting) were sub-cultured on to 
nutrient agar and were identified using a 'short set of 
sugar fermentation reactions (Kliger iron agar, urea agar, 
citrate agar, SIM motility-indolc media (Oxoid)). After 
incubation for 18 - 24 
h at 37°C, the test media were read 
for characteristic Shigella reactions and API 20E test strips 
of biochemical reactions (Biomerieux, Paris, France) were 
used to confirm the identity of Shigella spp. Serologic iden- 
tification was performed by slide agglutination with poly- 
ralent somatic (0) antigen grouping sera, followed by 
testing with available monovalent antisera for specific 
scrotype identification as per the manufacturers recom- 
mendations (Denka Seiken, Japan). 
Antimicrobial susceptibility testing of all Sbigelln isolates 
against ampicillin (AMP), chloramphenicol (CHL), tri- 
methoprim- sulfamethoxazole (SXT), tetracycline (IET), 
nalidixic acid (NAL), ofloxacin (OFX) and ceftriaxone (CR0) was performed by disk diffusion following stand- 
ardized Clinical and Laboratory Standards institute meth- 
ods 1171. The minimum inhibitory concentrations (MICs) 
were additionally calculated for all isolates by E-test, 
according to manufacturer's recommendations (AB Bio- 
disk, Solna, Sweden) and were compared to control strain E. cols ATCC 25922 and an in house fully sensitive E. coli 
control. 
Clinical observations and statistical analysis 
Clinical data was recorded on specialized clinical report forms for all three studies by clinical staff involved in the 
studies. The data collected was related to basic details of 
the patient, age (months), sex, location of residence and 
wwight (kg). A history from all patients was also recorded, including; duration of illness prior to admission to hospi- 
tal (days), fever (defined as a prolonged temperature > 
37.5°C), abdominal discomfort, vomiting, watery diarrhea (defined as three or more loose bowel move- 
ments during a 24-h period), bloody or mucoid diarrhea 
(defined as >3 loose stools with obvious blood or mucus), 
estimated number of episodes of diarrhea before attend- 
ing hospital, convulsions believed to be related to fever 
and/or infection and if there was any known pretreatment 
with antimicrobials. A white blood cell count was per- 
formed on all patients and stools were examined by 
microscopy (HPF (. 400)) to identify white and red blood 
cells, these observations were scored on scale from zero to 
three, scale 0-0 cells/1-IPF, scale I-I to 10 cells/HPF, 
scale 2- 11 to 20 cells/HPF and scale 3- >20 cells/HPF, Time in hours (from initial investigation in hospital) to 
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the ceasing of hloodvjmucoid and tsatcry diarrhea was 
recorded Duration of hospital stay was recorded in days 
post admission, patient, were only discharged when all 
clinical symptoms had rcwl"ed completely 
Data were douhlc entered Into Microsoft Excel for storaF; c 
and manipulation Mapping 
data tyas cntcretil, an. 
+zcd 
and draw in Maplnfo software (Citncv Rotycs Maplnlo 
(w. rporauon, USA) For Intergroup comparisons, Chi- 
square Icsts were used f,, r comparison of categorical van- 
ahles for the analysis of continuous vanahk'. \Vilcoxon 
rank sum. and Kruskal-Wallis test were used 
for non-nor- 
http: i: Www. biomedcentral com! 1471-2334? 5? 204 
malls distributed data A p-valuc of less than o or (tvvo 
tailed) was considered significant Statistical analysis vas 
pcrfimncd in R hup : Itvww r-proIC, T rg 
Results 
Epidsmiological findings 
(h-ct the duration of the three periods spanning 14 years, 
228 5h I!, te tsrre isolated from children living -ithin 13 
districts that c<. nsu(utc 11.. ( hi Minh (city (I igurc 1) 
1Vhilst the distribution of the location of the residences of 
these patients is hissed by referral patterns and people 
attending the local hospital (I I IT) is one of several hospi- 
Figure I 
The distribution of the residences of cases of childhood shigellosis admitted to the hospital for tropical dis- 
eases in Ho Chi Minh City. Over the three periods we were able to positively identify infecting 
Shigella serotypes in the 
stools of 297 children with symptoms consistent with shigellosis. 
Of these patients. 228 (76.8%) children lived in the 23 dis- 
tricts that constitute Ho Chi Minh City. This figure represents the 
distribution of the homes of patents reporting to the hospi- 
tal for tropical diseases with Shngela isolated from stool. 
by district. The percentage of cases reporting from each ward is 
distinguished by gradual shading. The location of the hospital for tropical 
diseases is shown by a yellow scar. Large waterways 
(rivers and canals) are shown in dark grey shading. 
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uls in the ( ny wh rt children may be treated for gastroin- 
testinal infections). the rtutonty of children attending 
I III) with culture conform d shyxllosis came from the 
three districts within the locality . >< the 6-pital (distr. -t% 
S, t, and R), which constitutes a u4a1 population of os cr 
RiA). ttt>tt ptoplc In ttal, the matonty .d the patients 
n%tdcd in drstnsi eight (n - A$) within appwximatcly t, 
km of the h. sptul (here was no, significant change in the 
k. caliry of patients rs-cr the three pern. ds. or any relation- 
ship Ixtween scmhju and kxation of the residence of the 
pat tents 
1}sc median agc of chtldren with rulturc confirmtd shtgcl- 
Iost. from all the comhtrtcd data w"as 24 months, the age 
range was from i to 1 C4 months (Filzurc 2) the number 
of children rtqutnng hospital treatment as inpaucnts for 
ship llosn declined stgnifi, antly after it, months of age 
Ibc c<omhnsd data fn. m pcnod A. B and C dcmonstratcd 
srsmc waxinale"" rclatcd to the tim, -. of peak tnfcction, 
with the rnaponty of caws (> (. 00. ) occurring in the w"ct 
season (hen. cvn \fap. tnd 4wptcmhcr) (Figure ;) 
Microb/olo" end enWn/creWel suscept/blNtfes 
In at. il. : 'r- +tr. unsLrrr rlatcd from lxri.. 
ds. A. 
9 Ind tI hrrr Ircrr ý1', i, I, rrc ' tý, 'I 149 
71 
fI 
! 
{ 
1 
I 
http: ilWww. tromedcentral. com? 1471-2334/91204 
% -re S coroner and nine swcrc unt peahlc '['here was a sig- 
nificant spccres shift from S jlexnc.. r to S amrer between 
pcncd A (29 S nonnsti) and period C "unn. y) 
with an approximate II ratio of S jlexnerr to S. ionnei in 
the intermediate period (I igurc 4) Apart from S tletnen 
wrotype one Fatly being 6-und in period A, there was no 
evident fluctuauons in S Heinen populations between the 
three periods the most commonly isolated S Retneri 
wrotypc twat serotypc 2a. rcprt cnting 4 i"° of all the S. 
llexnen strains (7 ahk I) 
%Vc idcntiGed a significant change in the prof tc of the pru- 
pontons of organisms demonstrating resistance to stw"cn 
antimicrobials (Figure S) there teas a sequential increase 
in the number of Shntfat isolated that were resistant to 
nalidixic acid, ofloxacin and cchriaxonc In period l, 2 fi3o 
of strain, were resistant to ccftrilronc and were 
resistant to nalidixtc acid (Figure S) -I he« was an addi- 
tional overall increase in the number of anti rin irrobials to 
which the organ isms were resistant C)uringperiodA. 62°o 
of all "higel!, tc were resistant to three or more of the seven 
antimicrobials tested, this increased to 8o in period R 
and decreased to 8 i''r. in period ( (I igure S) the propor- 
tion of organisms that were resistant to trimcthoprim- cul- 
tamethoxazolc and tctracvcline was unchanged between 
\ 
ý \ / \ y 
________ , 
\ u j; r -I 
j l 
M 
N 
je 
N 
ý ý u. uiw 1ºbn 2&30. i 31310 37-42M 
Apr Ora* (w , momM) 
*mm 4w2. 
Figure 2 
The combined sex and age distribution of childhood shigellosis patients 
in southern Vietnam. Graph depicts the 
combined age and sex distribution (female - red, male - grey) of 
297 children with shigellosis. The black line with boxes repre- 
sents the total number of cases per Age group specified. The overall age range was 
from 3 months to 154 months, with a 
median of 24 mont s. There was no significant relationship of shigellosis with gender; in total, 152 patients were male (S 1.2%) 
and 14S were female (48.8%). 
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MlorrA 
Figure 7 
the seasonal distribution of shigellosis in southern Vietnam. southern Vietnam has two distinct seasons, wet and dry. 
The combined data were averaged by calculating the number of months represented to get an overall number of cases per 
month Red bars: total number of cases. grey ban: average monthly temperature and black line with boxes: average monthly 
rainfall. The seasonal data represents the average rainfall and temperature per month for Ho Chi Minh City. 
the thnt" pcnods (Ilguic S) Between pcnod . and (-. 
thcrc tsrrc significant dccrcaxs in the proportions of 
organisms rcsiuant to ampicilhn. dccrcasing from 75"o tv 
4t °., and chksramphcnicol decreasing from et, 'v to 
1kre 
lhcre was a Jtsccmtble change in %nsitivity patterns rn"cr 
time. which was also related to ýi, lndki apccics (Iahlc 2) 
s was significantly more likely it, be res, sunt to 
amptctlhn in pcnods A and ( and when comhtnsd over 
all three studies t flvren was Am, significantly more 
likely it, be rsrsunt to chloramphenicol in periods R. C 
and overall (lable 2) 1}tc combined data demonstrated 
that a srnn., was significantly more likely to be resistant 
to trimcthopnm" sulfamethox. tzolc and celtriaxone, 
despite echnaxone resistance not becoming evident till 
period( 1he . 5srall pattern u(resrrsion ul s nsuotity to 
ampictlhn and chlorimphenicol was mainly observed 
with respect to . x, nnn isolates An increase in the 
number of organisms resistant to multiple anti micr, biah 
over time was seen in both >hi«. 1a species Iluwever. 
between period A and period l. Ilcs-rk-n was more likely 
to be resistant to more anttmtcrohtals than S xonnct (I ig- 
ure 6) Resrsunce to multiple antimicrobials increased 
from two to three out of the sewn tested from periods A 
to l for S xm, r, and from four to fnt from the seven anti- 
microbials tested from periods A to C for C Res', en (figure 
Clinical features associated with shigellosis 
(. Ilnli al data was combined and . 111A-zed 
from all three 
stuJtes this permitted a comparison of some of the fca- 
tures of the patients with confirmed shtgellocis over the 
three studies Data were available for analysis from 2') 
patients, 63 patients from period A. 113 patients from 
Table 1: 5higelb flexnen serotypes isolated in southern Vietnam 
between 1995 and 200d. 
S. /leinen serotype Number Percentage (1) 
ho 
lb p 
Ic 4 
2a 
2b 
4b 
4x 
sa 
6 
x 
0 
0 
13 
0 
0 
0 
29 
43 4 
59 
96 
15 
118 
SI 
37 
07 
0 
0 
96 
0 
0 
59 
ro 
Not typed $ 
Tool 136 100 
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Figure 4 
The distribution of Shigelb species from three child- 
hood shigellosis studies in southern Vietnam over 
fourteen years The distribution of Slrrllu species 
from 
period A (n = 90). period B (n = 114) and period 
C (n = 103). 
The percentage of S somei and S (lexnen are colored red and 
trey respectively, other ShIe1o species are colored 
black. 
}, e p value was calculated using the e chi - squared test. 
period R and I0 i patients 
from period ( (l able 3) These 
data demonstrated several changes in disease profile over 
the three pen-. l% (here was a statistically significant 
m: r. " i in age, which corresponded with an incr. aw 
in 
weight of the children from period A it, period (, (l able 
4) There seas decrease in the number of day" t history of 
the disease symptoms prior to admission to 
hospital 
Ilxye seas a sutturcill-v significant increase in the number 
of children with wjtcry" 
diarrhea, abdominal pain and 
febrile cunsulsiuns Thane clinical features combined sug- 
geststl a progn%snrly more severe infection cvvndrome 
between 1995 and 2008 AJdrttonallyr patients in penod 
(:. had higher white blood cell counts Over the 14 year 
pernxi, patients had a 
higher density of white cells in their 
stool and had h. ngrr stars in 
hospital 
nttp: r-'. 'Nww btomedcentral corn; 1471-2334191204 
the increase in the severity of the disease was concurrent 
with a change in antimicrobial resistance profiles of the 
., rganisms and a change in the dominant shi eUa species 
, slated Ihereforc, these data suggestcd a more severe dis- 
ca%pattern may he related to antecuon with S s. r. rci To 
account for any variation in disease syndrome that may he 
species specific, the data were analyzed to compare the 
clinical syndromes related to species the data presented 
in lablc 4 demonstrates only subtle differences between 
the syndromes synonymous with the two differing spe- 
cies S /lath, i shows an increase in the numherof Ja)s of 
illness prior to admission in hospital. the number of epi- 
s,, Jes of diarrhea. an increase in the duration of mucoidr 
bloody diarrhea and the duration of stay in hospital 
Discussion 
our findings demonstrate that the epidemiology of shig- 
ellosis infection is similar in southern Vietnam to other 
locations in Asia 'the main burden of infection in chil- 
dren is in those under three years of age I 10.15.18.19 
IN: median age of patients in this investigation was 24 
months, this is slightly less than a prc-vious study in Nha 
Irang. ( entral Vietnam 101 A discrepancy in age in the 
two settings may he related to the epidemiological study 
hang performed with ongoing community surveillance. 
rather than those admitted to hospital for treatment We 
also found a pattern of infection which correlated with the 
rainy season 'I11e observation that Sili'efia infectionsgen- 
eralkcoincide with the wet season in a tropical setting has 
been noted before in an urban setting in Jakarta, Indone- 
sia I I81 1"tansmission of chilyd! i has been associated with 
wastewater and river neater in Vietnam in two independ- 
ent locations in Vietnam 120.211 An increase in fecal con- 
tamination of the neater supply due to increased ground 
water may account hoe this pattern as distance to a water 
source was found to be associated with higher risk of shig- 
ellosis in Nha Trans The majority of patients enrolled in 
the studies combined here resided in District 8 of I to Chi 
Minh (: itv Although we are unable to draw meaningful 
conclusions from the residences of these patients owning 
to referral and catchment areas of the 1 rITI, district 8 rep- 
resents the area of the city with the greatest density of 
canal nets, -,, rk, and avatenvays 
In addition ta species shift over time, there was coin- pined effect on antimicrobial resistance. there was a 
narked increase it resistance to ccftnaxone and nahdixic 
acid \Ve have previously reported an alarming increase in 
ceitriaxone resistant Shijc? l. ie in southern Vietnam 1221 
Whilst nahdixic acid is no longer used therapeutically, 
resistance increases the , NIl(; to fluoroyuunohun-s, which 
are recommended for the treatment of 5h: gelb infections 
12; I our thcon- that antimicrobial resistant organisms 
are under selective pressure in this population is sup- 
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Antimicrobial and Period 
Figure S 
Changing antimicrobial resistance patterns of Shigello spp. All organisms were tested for susceptibility to seven anumi- 
crobial agents by the disc d«lusron and E-test methods The antimicrobials tested were as 
follows. AMP. Ampicillin. CHL; Chlo- 
rampherocol. SXT. Trenechopom- 
Sulfamethoxazole. TET; Tetracycline, NAL Nalidixic Acid. OFX; Ofloxacin and CRO; 
Ceftnaxone. Graph shows the percentage of resistant (red) and sensitive (grey) organisms isolated from periods A. B and C. 
statistical srgndicance was cakulated using a chi squared test. 
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Table 2: Compm4son of resistance patterns between Shi(dJa fleanen and Shtaefo sonnet isolated in southern Vietnam between 199$ 
and 211t. 
C. 16c6.. Sw. qi. (-) /fiýwotyp. ý AM CHL SXT TET HAL OFX CRO 
A IIMS I0KI ý«.. ý 12O RIID 2) 2) 000 
S I3 14 11 24 21 24 
ýIS<1 R 54 10 53 53 900 
S2 46 33 47 56 56 
0 Yrw" < 0.0001 0.1207 0.9102 0,0102 0.0371 
B ., m 2802, IS4ý 
50 10 53 52 90I 
S4 44 I2 45 54 53 
, eiurriSOi 
R 16 36 44 19 21 00 
Sý 12 fI 29 50 50 
p vJw' 09314 <0.0001 00415 05577 00052 0.329 
C (j007 - 20011 wr (71) 
R 17 5 71 69 sl0 12 
S 54 66 02 20 71 59 
. 
4ý130) R 2S 29 29 30 19 11 
5S220 II 29 29 
p yAW 0.0001 0.0001 0.0001 0.3696 0.4619 0.297 0.076 
Ce, i+ud +err 141h R 71 23 147 144 60 0 13 
S 70 125 14M 140 135 
M.. JIM) R 12S 76 125 132 49 II 
5 11 40 II 4 97 135 135 
p VA. - < 0.0001 < 
0.0001 0.001 0.613 0.365 0.178 0.003 
vr ,. <ýnrs. d rt w. dN. a*r. d wi 
R... n. K Oki « S., umw (51 
A11P MTnN. CHL Ctib.. wpr... cd. S7fT. T, wrdagnn. SJ`, wMxmoM. TET. T. v. ryd... NAL. Ndd.. c Aöd. OFX ORmc. on. CRO. C. lo-w, an. 
i I 
f 
,a 
R aaýsi 
i 
\ 
t 
t ý 
` 
/I '7\ _- -ý- -ý :-r,, ý 
39 
0 
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Figure 6 
The increasing proportions of antimicrobial resistant S. sonnei and S. ffexneri during a fourteen year transition. 
The distribution of the proportion of S sonnet and S. ) exnen isolates that were resistant to one or more of seven antimicrobials 
tested 5 lernen strains (red lines) were significantly more 
likely to be resistant to more antimicrobials that S sonnet (black 
lines) over both collections compared. S sonnet and S jkxnen were significantly more likely to be resistant to more antimicro- 
buis when period C (2007 - 2008) (lines with triangles) was compared to period A (1995 -1 996) (lines with squares). 
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Table 3: Clinical results of SbKelb infection between 1995 and 2008. 
Paoeints 
A (1995 - 1996) d (2000 " 2002) 
n=63 n= 113 
Age (rnondnM 23(17-48) 21 (14-29) 
We4gAt (kg) 10(9 -1 3) 10(9-12) 
Male sex (X) 31 (49) 50(44) 
Packnc hFsovry 
Days 2(1.7) 2(1.9) 
Fe. er (%) 62 (n) 104(92) 
Abdominal pain (%) 33 (S2) 41 (36) 
Vormmng (%) 24 (38) 64(56) 
Watery darrfiea (%) 28 (44) 67(59) 
Blood/'mucoid diarrhea (%) 634100) 60(53) 
Dwhorreal epnodes per day NA s (S-10) 
Convulsions (%) 4(6) 7(6) 
Known precreannent (%) 3 (5) 
8 (7) 
Ciniul detaii 
Serorype sonne. (%) 
WMte cell count (' 1030mn)) 
Red cells in stoot 
White cells in scoot 
Mucotd duration (hrs) 
Durrhea duration (hrs) 
Ouradon of ilness 
21163 (33) 
10(8.3-IS) 
NA 
NA 
31.5 (24 - 53.5) 
48.5 (29.25 - 87) 
Hosed scar (days) 3 (1 - 12) 
Dwease durxan (days)' 4(2- IS) 
551113 (49) 
10.1(7.7-128) 
1 
3 
36(24-54) 
48(24-72) 
4(1 -15) 
6(3.18) 
ap Vakses calculated using either Chi-square test or the Kruskal-Wallis test 
b Cclk in Stools assessed as described in methods 
c Disease duration calculated by addition of history of disease and stay in 
hospital 
s Intergsartr1e range values in brackets udess stated 
ported by a sequential decrease in resistance to older anti- 
microbial therapies. such as ampicillin and 
chloramphenicol which are now rarely used in the com- 
munity to treat gastrointestinal infections. Inc uncon- 
trolled use of antimicrobials in this setting may 
fuel the 
spread of multiple drug resistant organisms. However, 
due to promiscuous nature of the Shir4Iae it is likely that 
resistance genes arc transferred regularly to and from 
other enteric bacteria and maintained by selective pres- 
sure. The change is species and antimicrobial resistance 
pattern reflects a change occurring in the Shiged1a popula- 
tion over time in this setting. Locality and time of isola- 
tion data suggest that entrance to all studies was sporadic 
and there was no evidence of transient epidemics. 
Currently there are several candidate Shigella vaccines in 
development of which some have already been tested in 
initial clinical trials 124-271. The development and 
htip_; lwww. biomedcentral. com11471-23341912D4 
C (2007 - 2008) Combined p value- 
n=103 n=279 
30(19-42) 24(16.36) <0.001 
11.5(10-15) 10.5(9- 13) 0.004 
61 (59) 184 (59%) 0.085 
1 (1-4) 2(1.9) <0.001 
100(97) 266(95) 0.09 
79(76) 153(S4) < 0.001 
51 (49) 139 (50) 0.062 
74(71) 169(60) 0.002 
98 (95) 221 (79) < 0.001 
8(5.10) o (S-10) 0.595 
20 (19.4) 31 (11) < 0.001 
4(4) 14 (5) 0.543 
71/103(69) 153/279 (55) < 0.001 
13.1 (10.1.17.3) 11.3 (8.7.15.4) < 0.001 
1I0.715 
330.02 
28(18-48) 30 (19.5.48) 0.113 
48(30-72) 48 (26.75 - 72) 0.402 
S(2- 14) 4(1 
-IS) <0.001 
6(3- IS) 6(2- IB) <0.001 
deployment of Shigdla vaccines may be hindered by the 
number of different species and serotypes circulating in 
one setting and in differing locations. For example, S. 
flirneri serotypes are known to fluctuate over time, this 
has been observed in India, Indonesia, Bangladesh, and 
Pakistan, 110,281.1 lere, we have demonstrated a signifi- 
cant longitudinal transition of species from S. flerneri to S. 
srntnei. Vaccine development for shigellosis is challenging 
as primary infection offers only scrotype specific immu- 
nity 1291. A study concerning a cohort of Chilean children found infection conferred 76% protective efficacy against 
re-infection with the same scrotype 1301. An option for 
controlling shigellosis would be the development of a 
series of single serotype vaccines which could be imple- 
mented in individual locations with a known serotype 
profile. Alternatively, the most cost effective method of 
control would be the development of a polyvalent vaccine 
offering cross protection to a number of known dominant 
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Table 4: The clinical pn+ent&tion of Slwgifa fieanef and Shlaelia sonneI infections. 
S. Pkxneri 
Iatclntf 
Age (mondn)e 
Week (he 
MYe sex (X) 
n= 123 
25(12-42) 
II(ßS-14) 
S5 (44.7) 
httpJhvww. tromedcentraLcom, 1471-2334,91204 
S. ioenei p value 
e= 147 
23 (14.36) 0,105 
10(99.13) 0.558 
83(s6.5) 0.055 
Paöert kkco. y 
Dan 
Fe+er (%) 
Abdomwal pain (Y4 
Vomrtvn: (x) 
WaKry &Ar+bea (X) 
Blood)+nwcod durrhea (i) 
Uaanhea epwdes per dar 
Conwkbro (1) 
Known preveauwsnc (X) 
2(2-3) 
117(9S) 
64 (52) 
60148, S) 
78 (63.4) 
97 (78.9) 
I0(5-10) 
9(7.3) 
7(5.7) 
1 (I"2) <0.001 
141 (96) 0.761 
84 (57.1) 0.48 
74(50.3) 0.78 
86 (58S) 0.41 
117(00) 0.88 
8 (5 - 10) 0.051 
21 (14.3) 0.07 
7(4, S) 0.585 
Clinical details 
White cer count (  Ipllnuns) 
14d celh n acooP 
White cels in scooP 
Mucod duraoon (Ms) 
Dur*+w duraoon (Ms) 
1018-13,6) 
1 
3 
36 (24 " S3. S) 
48(39-72) 
12(10.5-1S5) 0,029 
1 0.054 
3 0.173 
25 (18.48) 0.054 
48(27-72) 0.088 
Durnri«+ of ianess 
H-pmW uay (days) 
Doom duraoon (days)` 
S(4-5) 
7(6.8) 
4(3-5) 0.276 
5(4-7) 0.009 
ap values cakulated using eider the Ch -square test or the 
Kruskal-Wal is test 
a Celk in Stool assessed as described in methods 
t Disease dtration ca culated by addkion of history of disease and stay in hospisa 
4 kiter*artfe note wlaa in brackets u+less stated 
urotypcs. this approach may aid in tackling the global 
burden of shigellosis. The transition of dominant Shigrlln 
species in southern Vietnam has occurred on a 
back- 
ground of economic development and may predict a con- 
tinuing cycle in other areas under going similar rapid 
economic changes. 
Conclusions 
what we are unable to specifically ascertain from this 
study is the overall incidence and greater epidemiological 
picture of shigellosis in this setting. On the basis of these 
data a thorough epidemiological assessment of burden is 
warranted to calculate the financial and health implica- 
tions of any potential future routine vaccination against 
shigellosis that may become available. Hower, here we 
have shown a significant transition in Shigella species and 
antimicrobial resistance dominance overtime and a con- 
current change in the clinical disease presentation. 
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Abst fact 
Racitynonwid' Plas+nid mediated antimicrobial resistance in the tnterobocrerioceae is a global problem, The rise of CTX-M 
class extended spectrum beta lactamases lES8ls1 has been well documented in Industrialized countries. Vietnam is 
representative of a typical transitional middle Irxome country where the spectrum of infectious diseases combined with the 
W read of drug rrststance is iihiftng and bringing new healthcare challenges. 
AM/Andorbyr: We collected hospital admission data from the pediatric population attending the hospital for tropical 
diseases in Ho Chi Minh City nwth Shgefkta nft! ctions Orgawsms were cultured 
from all enrolled patients and subjected to 
antrnkrobral tusuptblity testing Those that were ESal positive were subjected to further investigation These 
tnvestrgaoons nduded Pt: R anpatcation for common ESBL genes. plasmld Investigation, conjugation. micro ray 
hybridization and VHA sequenKng of a bbcrx-#r encoding plasmid. 
Priicijvaffindnigs we show that two different blacrx+. genes are circulating in this bacterial population in this location. 
Sequence of one of the ESOL piasmids shows that rather than the gene 
being integrated into a preexisting MDR 
plasmid. the blq,... gene is located on relatively simple conjugative plasmid. 
The sequenced plasmid (pLG3561 carried 
the bid(,...., 4 gene on an Ucpl elernert and 
demonstrated considerable sequence homology with other IncH 
plasmids 
Sgrnrkanrcr. The rapid dissemination spread of antimicrobial resistance and changing population of Shigella spp. 
concurrent with economic growth are pertinent to many other countries undergoing similar development. Third generation 
cephalosporns are convrrsony used empiric antibiotics in Ho Chi Minh 
City. We recommend that these agents should not be 
considered for therapy of dysentery on the setting. 
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ka.... n ahsu thr dwtnhustn ol stah trrrs in 4r>;. rtisma I4Mmd 
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bloc,  . in Stsgdla spp. 
Author Summary 
Srrgelosrs is a disease caused by bacteria belonging to 
5hrgeb spp and is a leading cause of bacterial gastroirr 
testinal infecnans in infants in unirdustriakzed countries. 
The 5hge#oe are dynamic and capable of rapid change 
when placed under selective pressure in a human 
population. Extended spectrum beta lactamases (ESBLs) 
are enzymes capable of degrading cephalosporins (a 
group of antimicrobial agents) and the genes that encode 
them are comon in pathogenic L. cob and other related 
organsms in industrialized countries. in southern Vietnam. 
we have isolated multiple cephalospoºm resistant Shigeib 
that express LSBLs. Furthermore, over two years these 
strains have replaced strains isolated from patients with 
shgelosis that cannot express LSBLs. Our work describes 
the genes responsible for this characteristic and we 
investigate one of the elements carrying one of these 
genes. These finding have implications for treatment of 
shigelosis and support the growing necessity for vaccine 
development Our findings also may be pertinent for other 
countries undergoing a similar economic transition to 
Vietnam's and the corresponding effect on bacterial 
populations. 
Materials and Methods 
Ethics statement 
I hia atwl% .. a> rtxtdta trd arrnrtiinG ut ihr print q'tlra rxlYraafd in 
the I hYLlratiul ri I IrhinkL Ihi< vudN taaa appxoArd ht the rirnritir 
. ur1 dtir. d tnnuneter tt1 the 1111) mid (hind ttvpial traranh 
ethir. tvtmminrr O\ I RP. G numt. r IIIILIN; _tNxii. \II parrrn+ of 
the etthirrt rhüdtrn NPn trrPptirrd in pmnirk" wittrn in&trntrd 
rnnaent for thr rolkrtint ti aamplrc ttttl cuhaerlttrnt . atahiý. 
Patient criteria 
I M" , ml, s.. v . tttdtM nrl nn ttrp. rdtatrig. hL"ntnraltLd 
itilrttit rt: w. rtd at the lutji a. d fin trupit-. J dtir. l4"S : II II) it I 11,, 
Chi \Iaih (av in \'i"ntam. I Ir ItI I) iv a iiNI bed iii ban rrlrnal 
hncpit. il m"atntq patirinv trim thr aut'nundinq pnvittrrv and tmm 
ihr divoin; l. ithin IIii (: hi \lath (: itl. : \II p, ni"niv front whit It tiJay+&b 
. /+r. wrrr ivnlttrd wrrr rnn. lkd iuu, a randrtnvrd rnnunikd trial 
rtxnp. tratq uramunt . rith rpr. 6n\m in aryl g. uilirsi at as dt arr Fw d 
prrvir. u+h I I3ý : trial unmhrr I1N(: I '05441M I, 1kir8v . dl 
rhikdrrn iqt-d it 14 wart, l. ith divrntrn drtinrd is p. iamig hinxil 
rlGnhtr"a r. r nnttnid a. wd; +. ith adrlitamal adtd. rotitt. d pain or 
u"rrnnuvl whose parrnt or qturdi. m Gacr hdk attninrrI l. reu"n 
t rnsrnt wrrr rliqildr let admiai. n it) dr vmdv. IN priuan 
utw. nrrn- nt thr trial . cav trt"atmtnt taJum. rk"lm. d . i; ihr pari-it ra" 
rlmrvtg viniptr. m, ahrt lily da% v. d antani rnl. i. tl trrarm. tu. 
lhiqrlk, ai it a tp. tn, itrntinat nli"rtixt ra. w"d hs In"mhrn hs 
. 4iyal, 
'u y/. Dur m tM tan al aal rnutr ill tranrntisint ul der 
4kpila. rhidrrn kss than tisr scars . ild and li. it>c in drsrk, png 
rrrnirtrs tusr der hiqhrat 
in'idrnrr I, 1. I11I In r. r h. ps'saI in Ila 
lhi \Inh (: is, thiOsit is thr karlittg rautr .d parrGari 
rli. u ttr. ral a, tniiwiii with ln. trtial a. ti., krgs. 1 hr ittlr, ti, ar 
is 
rspmaffs irk liniting. alttr, ugh atttimitml>;. tl tr.: vtnrnr is 
nrrrturs la thr s, ruig and those that are srsrrrh iff t< i rrsttres 
r. m>filiati. nt and , sutail. thr rkuation a4 ific- dim-a- 1111. 
trrat l/iti'rlb l'1ua. rpunikirr. arr thr , tnrgs ill rht, i-r it, 
nlrsut, n. in both . dtik. and rhikttrn 
11: 1. Il. ns, "srr, as with mans 
tither rnrrtihrr. ., l ihr mtnatims in thr grir" 
en-din[ ihr urgri pnrrie" k. r tlutungttii, iiian air , mmeer. n in 
%, Irt. Ua II i, 1 i1.1). u reimt findings thim that lari-m, with 
ahigrfk,. ti arr aasirig it hspü. d for lotigrr prri. xh , tMip. trrd with 
i and Ill srars a(n atd ihr diar". ur . rarrits has ron. turrrnh 
n, rra. rd 1111. Iirrtr"stingls. at thr utnr titrr then- has hrrn a 
si(nili atu spn ie. . ttili town .\ 
$"ro.. n r, \ v. wrtr, ia. Litrd Irorn 
patirtrs 11.11. Patients hrrr air nraird with Ihuxsxpinolomrs, 
htr, w. "srr, or, - patirtuq ih. r dot nu rr'slr. rirt to ihc "aniLird 
thrraps arr trratrd with third grirratinn rrphal. xlsoxins maids 
, rliriamMr, I hr irrrasrn, tts third grlrratioM , eph. tispinns arr 
anrrigst it, mni nunmwtls tisr, l . ttuinicnil, 
i. tl, it hmpit. tl, in 
lit, (: hi \Inh (as and ihr rtral avtind and third qrtr"r: uion 
tr-Isb. ik.. pnri, n arr als., wid-I% asal, ililc it tFr . nmmmrin. 
\nimimliiaf msistatnr in the %tCHLr is, overtone, ui; ttrvr nsq. unsne 
arr rlnvh rrtatr-d it, /. .. i atrt arr rrarlih tr, vidornrd hs r: sop"trnis 
I)\. \ 1It., I7. IxI Ihr dturiun, n , il antmirt. >fral n"sia; urr is. 
Ir, ssrsn. ttltni dtdrrrn depending on the 4ir"ci"t. A multi. rtnir 
. rrls xns" . ý-is. 
drinutmrainl di. v A. A sr. ri wrrr in, rr, lilrls t., l. " 
rr. M. urt r, AiqwilimrL hike 
in rMrrrnn[aink 1I'11. I(r"sisatrr patients and sprc'rs d. xnaiarc 
arr, saruhk drpcrditg on ihr jtt"rifir k, catim 1_'1i;: 1,: "! 1. 
11r hasr prrsi, rnh rrp, xrrd thr rapid cnrrgrnrr ol third 
grtrauinn , rlilialrsp. rin rrstitatu . Ntn/la n\ irin, un. .. h. -rr s. r 
tntrd thr nritatr isnfatrM CA a ntmilr"r Ill 
I". 1111. pnwkr ng 
micnrirYanisre" 11 il. ltnr, wr prrrir'ilia atipr. tiigthat FM(1. 
trgaii. r o. rganisnt. 
hasr lx"rn rrpürrd stih F. tittl. p. siti, r 
organ tire". 
2 
Microbiological culture and antimicrobial testing 
Su. nl i, -Fair,; arn rnikrtrd h'nnr p. uirntc and ndturrd dirr( th 
on the- rLac of sampling. Sarnpirc "rrr rulntrrd otrtnight in 
vlrnitr F Ixrxh (knid, (Sr: ittGeutk,, l hý tnd p4nrd nun 
Var(: nnkr\ and XI. 1) agar Osnid. at 'S7 C. (: nlnnira ntggt"airr 
td Wri+lGý %iirrr cuti. nhurrd in to nn, rirnt agar and .. rrr 
Idrrttlfird ucing a'. h)n crt" td vrgar Inrtw"ntation rcartitmc 
Kliqrr iron ag. tr, urr"a agar, it atr agnr, SI\I motilin-itu4tk 
mrdia ( )xnid, t: ttitrd Kingdom.,. Srrolrrgic idrncCx-atinn crac 
prrlnrmrd its click aqghxirrar. rm rcith pnkc. tk"nt cnmatic , 
(S. 
amiqrn qrnctliiitg : rra, kllop"rd bt triting with tcaiLtllr 
montwalrnt antnrn inn cprrilic srrnnpr idrnrtlicatinn ai prr tlw" 
nian, darturrr"c rrnxnnwýrwLrtinnc Urnk. t Srikrn, Jap. trr". 
Annntirrrbial cuQrptihilin trrting it all vrgVfltr icnLan"c againct 
ampitillin A\IP, thktr. tmphrnirnl (: 111. ". trinw"drrtprim culta- 
m, ýhtr. vok "XI., u tr, wýrlitr 'l h l., nalidiýk :. id \AI. , 
olLtcu nr '( Ih\: atwf rrtwi. wrn" (: k( ). trac prrtnrnw"d In dick 
dilht. inn Ovri1, Initt"d IGngrhTni. Ihr tninimtwn irtltihiinr\ 
rotwrnnatimc , 
ýIIUcý h'-Jr artditinnalh '. 14 k1r all M h. -na, , wrording to rn. tnut. wrtrrrr+ rr"ntmm, rtdatinw AB 
ISixtick, Swt"tk"n: 
Ihocr öraitts that wrrr klrntiÄrd is rrcNtant tit rrttrimutw- 
ucing ihr dick ditluciur arc, clxihilitc wo t. rrr" further atbirttrd tn 
thr t rxnlrinatitm d: a mrtlwtd tit , anfirm 6Sül. ItnKltx lirtll 
I_'i;: ýl l hr it nnb rtatittrr dito mrtMxl ntil'vrc dia ct nnteining 
nnh rrtntacirnr (: 1 X. :; lt JAR .: mrl rcttaiidinx (:: V. ' Stt yg.. nwt both , nirimirndr'crls t nmhinrd with rlatulani, .w Id ItiUg., I'. StSI. pnwhw iug strains tcrn" idrntitird as dUt+t" tcith a grr: wrr 
than '> nIDi itw rracr in inrr with thr" 4ta; k antiui rnhial 
cnmparrd to ihr r, xnhitrd auimicrnhial, i-r. tlrmnnctrating 
I'. SIU. ürhil»tirm I_al. All anrimicmhial trsting tca: Irrkxrnrd nit 
\lurllt"r-1litnrnn aqar, data w. t. c intrr)xnrd artrtrditrg its the 
(: Ivti-al and Iattnraatsý St. tndardc Insrturr gtridt"litw"c Ishl. 
Genomic DNA isolation and DNA microarray 
hybridisation 
(: cnnntit U\: \ tr. t. iutLrtrd train) cnaitc that ttt"rr cubjrrtrd to 
Y(: R and 1)\A mirrnan'a, hchridicninn trom I ml ot ai ml 
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tnenaght hactrnal rukurr using the %uard grnomir [)\A 
mawann Li Prsanep. USA as per the manufacturer's 
recumntendationa 
For characsrsiatio dune cnattta of iolatrd 4ttiIa strains, 
grtnmu I)\A at hrhrahard to an active suMilarre of 
pothoq ns ASP. nfiRnnur 
knesdr mi"roarras" 12:. 281. The ASP 
arm contains once 6.000 firer marten. including Oct spresigttantrr 
gran. %inicare Bonn and antinrmhil resitance 
grnn front snot a hundred bacterial spreirs. This the ASP array 
per. tdn data kr attetsitg hrwurraaly tmniknrd genes, such 
data is helpful ka diap"s and for guiding aotimircohial therapy. 
'llw ASP arras utd an this studs was venato h. 2 and was 
designed and cnnsmrud as dncrihed prninush (281. Test 
samp(n were laMkd and In hrxird as described pm itu h (_w). 
Brrfls. 5 Wt grrwrrir 1)\Ik was labeled with CO and h}$wihstd 
with a frrnsatnide hard hshritisarion h4Tnr solution in a final 
odium of 48 Id at 50'C for 16 10 hours. The . ASP areas, were 
washed as Mrnhed prnisu, A- but with the initial wash at 50'C 
(141. The ASP arras were ranted seeing a 418 ntirmarrav 
Scants" Al Istria. l'. SA} and usensn tlurrice rc data 
acrpired ucint InuC. enr 7.5 hwd)ucrwnn, USA. Data s. as 
anahird as drs-rlied prsiout(ý hs Stabler dd 
(*218). Briells, a 
reporter was considered positrr if the hocºground csrrrtcrd nran 
reporter itpnai fmm duplicate spots was hoth greater than one 
standard cimisa nn d reptwr signal :r ptrtrr s ariation', and the 
mean reporter signal was greaser than the whok hackgmund 
corrected mrnwTa% mean plus one standard 
dnvcnn. as shown 
for S sawn F. (. I110) in 1)ataset tin in up[nrtint inforrrutirt 
The 
raw m -rnarray data for al isolates is presented 
in Daawt S2 in 
supporting idormuiasº 
Plasmid extraction and visualisation 
HacmiA DNA was isolated fmm FNBI. ponti. r and F-SBL 
srgatisr SkKsdu irslasn using a moelirved version of the 
tnnlrwinirsgv penaxsdý tltxntstd hv Frio and 
Liu 13111. The 
rnstitng plasnid DNA was wparatcd In clectroplinrrsh in 0.7% 
aptwr cris madr wih IxF. huf[er. Gcls wrrr run at ! )l) 
\' for 
3 It. surnrd with etlotl: sm hrrtteclr and ptrw+graphed For DNA 
sn1trnrirtg piisssid DNA containing an F: SBI. grne was t-wrted 
fron an L cob vansrmjugarr using a \urleolkrrd" \m Midi kit 
as per the rronufarnren rrrrrmrndariotn C: Innrrh, LS. ý 
E58L gene pCR amplification and characterisation 
(; rnomi DNA was suhjrrtrd to 
MR anpfifratinn targrting 
krtew. n rlasa+ of Ms genes usisS. initialh, primrn that would 
ncoRnise srrlurnres enrocän¢ S[ I\'. : F; 5' 7CTC: CCTGTT: \C; C- 
C \CXX'1(:. R: S; ( C_\(: 'It: C \GCý\C: CTGC7 TF\I : F: 5' 
i(; (: GC: LýT1 AlYY: (: G IY; TI'G, R: 5' '1'( (: 7C CI-I-I'GC- 
rAfr"cc rrc: " and C-. I: ý-\l : F: r. ' CG. \'h(? rGC_\CrACQ4r 
IAA, R. S' class ftiBls 
1"41.121. Funtrr rhrrteriucticsn of the various sssh-grrsup of 
61a,. -ta FtiBI. Rrnn wn pcrfrsrmrd using primersCI? 
C-M-1; 
A IC; (; '1'I AAAAAATG'\C. TGCG. R 5' rrAC-v-va(: r. Cr- 
(x: (: TG: u-,. ;F 5' 'IrGA. \GCCCrGG: \G. \: \4\- 
Ac: rarrlRS crlAi(: GCIT-lrccirrr; na»d(: Iý-\I-V; 
F s'. ý7'G(: If;. ýc. ýS. ýc:. \G. ºC. I GC :\ \( .R 
5' IT: \C:. %G- 
(X (: 1 rC(: G(: (; ATC; " minc presixssf\ outlined p(: R amplifra- 
thsn ranAtions 131.321. 
To idmti6 an atMrlatinn with (71. \-\t cities and the attarent 
1%1; p1 tnssprnar. a! FSdL pnstnr strains weir suhircwd 
cc) l'(: R with primers 
fi: rwart primers 7np_4F : i' CAC: - 
rC: crY-lTx: cx:. \r: \\A(x: (: (;. rnp15F 5' CCGCCG'rrr- 
(: (: (; (: A'I A(; A(; ((; (: ; frr Wa-ta as : 's and ýt-r x+t ts r'qN'r'- 
s;. rls and reverie primer 
TnpR 5' AGATATG-1'. kA'TC_4T- 
c; 
. 
\G1'I GTcGG. The Tnp24F and TnpI SF' were located 
whin the b4; ta. M..! 4 and Mas; IX. ut. le genes rttpectn'el)' and 
InpR aas located within the IS&7pl transposasr gene. 'I he bia- 
tranyxxise 1'CR was performed under the fcfiow ng eordirions. 
4i'C for I minute. 30 esrks of 45'C: for 3o second,, 56t, for 
(U ueonds. 72'C for I minute 30 seconds and 72'C for 
" miners. All PCR. s were performed utsing'Faq DNA pohmerase 
and appropriate recommended concentrations of rragentt ; ilo- 
1ire, UR}. 
Positive PCR amplicont were cloned into cloning sector pC: R 
2.1 3n itrogcn. USA} and sequencing reactions were carried out 
at recommended h% the manufacturer icing big the terminators in 
forward and merr orientation on an AIII 37(X) sequencing 
machine ',: x111. USA: i. All sequencing reactions were performed 
twice to ennnre correct sequencing and sequences were verified, 
aligned and marriptttated using Binedir software ; http:! /ssssw. 
mhin. nrat. edu/BroFidi: hinedithmml}. All 1 tBL gene sequencer 
were compared to other FSIII, sequences by BI_ it n at %CBI. 
I he DNA tegnence oft"arxu s classes of bt; tx were downloaded 
and aligned wih the prodtxrd sequences. 
Bacterial conjugation 
Bacterial conjttzacion rzXprrirnrnts Nsrrc prrfommd by combin- 
ing equal wlumes ;3 ml. of overnight Luria-Bertani cultures of 
donor and recipient strains. The donor grains ssrre ihjvIth clinical 
isolates earning brat, l\ grnes and the recipient was A. a1i )53 
; apdium azidr resistant'). Bacteria were conjugated for 12 hours at 
37 C and transronjttgants were scleeted on lima-Bertani media 
containing sodium amide ; 1(1() pg/rnlj and eeftriaconc :6 pg/mli. 
Potential transconjtgants were verified by scrottping and plainid 
extraction. 
Plasmid sequencing and annotation 
Plasmid pEG356 wai elected for DNA rgtwncintg and 
annotation as previnush drrrihed (33). The DNA rgnence is 
annotated to idcntifi coding rgucnrrs and repeat rqurnccs in 
Anemis. To identifi- plaun ids with s¢ndar rgttences. pE<; 356 was 
compared by BL1STn at NCBI. pAPEC-01-CoIBM . 
Ar. 
I)Ql8l42M )34) was downloaded and aligned with plx; 356 
and siessrd in Artemis Comparison `frail `, A(A) (35]. Schematic 
drawing of the sequence of pEG356 was constructed using 
U\Apkuter )36). Artemis, ACI' and DNAploner are freely 
asailahk at ;h top: /Jwwwsangrrar. uk/ýofiwatri. The full Se- 
gnrnce and annotation of pEC35fi was submitted to E\LBL. with 
the accession number P\544520. 
Results 
The escalating isolation rate of ESBL positive Shigella spp. 
in Ho Chi Minh City 
During a 24 month period between April 2007 and March '009 
wr icolatcd 44 57ii, {v11a strains from the stools ofchildren admitted 
with d%-xntery. (N thcr 44 strains, 24 were S. jirssvn and 70 were 
S. itmnei, ronfrtning the spines substitution ptrsiomh noted from 
isolates in this region I 15I. The general antibiotic sensitis'iry 
patients in these strains were variable, although rrsistatwc m 
nitrthnprkn - sutfamethoxaaolr, tetracycline and ltsucrh" nali" 
diuc acid were ubiquitous and there was an overall propcnsirv of 
wnsitisin" towards older trrrration antimicrobials such as 
chloramphenirol `fable 1}. A resrnion of sensrtisity to older 
therapies highlights how antimicrobial resistance genes can be 
maintained ; or othen isej by sekvrisr antimicrnhial pressure in the 
population. 
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The tint isolation ofa rrftriaxnnr resistant organism dtrrini the 
transitional period oerurrrd in May and similar strains %srrc 
isolated in kris' rntmher for the follot ing months ; Figure I ý. 'I lie 
numbers of . 
CYatv(! ae isolatrd that were resistant to rrfrriaxorr 
fhsrruated over the follnuing 18 mont, lint rrrr, their was 
increase in the proportion of resistant to stn itKe isolates 14äo to 
41% ;S to IIs hr wren the p crrnds from April 2007- Sepxrmlrr 
2007 and April 2tKt8 Srpxrmher 2018, rrsprrtisrhy. 
This trend 
peaked in Mlarrh 20(N, with six out of sm en Sizgdfa strains isolated 
resistant to reftriaxotr ;M IC>25th 7hr owrall rate of resictanre 
to reftriaxorr between Sepxcmhn 21)18 and March 2009 was 
The combined resistance patterns of ESBL producing 
Shigefla spp. 
1W r initially cultured a trfu iaxone resistant S. , mtwz strain in 
_"il ; 1)E Willi ; Table 1j. hourver. this strain was a single, 
isolated organism and a srcondanv csii: -iaxonc resistant . 
4riet'1k was 
not isolated again until : 107. Between 20X)7 and 2004,35 1: 
34ai) 
S. 4 eI a isolates cultured were resistant to crfiriaxonc I'1 able I i. Of 
these strains. : 13 were S.. conna and the other two isolates were £ 
Jk. wn. In total, we isolated 36 reftriasonr resistant organisms 
between 20(11 and 20x14. 
The mechanism of crfrriaxonr resistance was examined by the 
double disc inhibition method to identify ESBI. producing 
organimns. All the S. umnri and one S. Jlexm+i strain 35 from 36 
cefrriaxonr resistant . v. 
eai produced the characteristic LSBL 
pattern on investigation. whereas the hydrolvsiig activity of the 
other S organism was not inhibited by clasulanic acid jtemm 
1,2 U41 ; ']'able I. 
T'hr median age of patients harbouring third Generation 
crpkalnspc. in resist nt SIrges4at was 32 monde ; range: H to 120 
months), the median age of %hitdlocis patients during the came 
period was 30 months j 151. Owing in the rapid increase in the rare 
isolation of such organisms we hypothesised that an individual 
dominant strain had began circulating in one area of llo Chi 
Minh City. However, residence data procured on the rive of 
admission showed that such strains were circulating over a wide 
area of the city and riot purely limited to an isolated outbreak 
Pahl 1). 12 patients were resident in surrounding provinces, 
ionic ISO km from the hospital 
In conjunction with (eftriacone, all strains were examinrd for 
rrsistancr to an additional Ihr antimrrohials M disc difftisinn and 
MIC: 
, 
't'able I). As predicted, all strait demonstrated co-resistance 
to ampirillin. 'Ihim" for of the : 16 strain , 97'x() were resistant to 
trimethoprim - suHämerhoxazole and rerrxyrline. whilst : 33/36 
w"err resistant to nalidixic acid. Only three isolates: 1)110611, 
E; G0419 and F6047l were co-resistant to chkirantphenicol. of 
which m o. FL 0µ 19 and EG44 71 ; 6%), were resistant to five of the 
sic antimicrobials rested ; 't'able 11, 
Identifying the genetic nature of ceftnaxone resistance in 
Shigela spp. 
The most common mechanism of dissemination of E. SBI. grnes 
in the FaknthnA aarc« r pIavnid mediated transfer. Our pres"ious 
snrdrs have sun 'sted that Vietnam and other parts of South Fast 
Asia} may he hotspot for the origin and further transnicsion of 
antimicrobial resistant organisms 18.13,37,381. Ftlnahar&riarmr 
which carry . 
11tR pLlsmids are common in Vietnam and the 
isolation of M1)R , Shedla araitn has been repratrdly reported 
119.20.391. 
We h%podrsird that the E; SBI_ phenot}pr was related to the 
insertion of a transpolon carried on an Ml)R plasmid that had 
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191 
Appendices 
doRy. M in Shr9dla spp. 
ST 
I I. 
7- 
ýý 
( ý, i\ 
t' 1 
a" 
2" 
0 
pý0.024 
y. r w. r rr, or row. rorQ sr or L. w. ww uwwjww won 
Month of isolation 
Ao N1W N Mu 6... r 00 a N.. w 0.44 1.0@ p" M b4. Co 
Figure I. Graph depktlng an increase in number and proportion of ceftriaxone resistant S7siieiyarpp. Isolated between April 2007 and 
March 200 at the hospital for tropical dseasas In Ho Chi Minh Cky. The thick 
black line with circles represents the number of ceftrlaxone 
res. sont fh ydb noistes per month u asst the thin black line with tnangks represents the 
total number Of Slige/b Isolates per month (both related to 
the kill y ass) The brolen line represents the proportion of strain notated in six month periods resistant to ceftnaxone (tight y axis). The increasing 
proporton of teftnaorse reshtartt or9arssbnrs over w month periods is statistically significant 
Ip = DA24) as calculated using the chisquared test. 
don: ia 13 71 rpxnal pntd000071ug001 
Irrmrasrd into and Mar circulating within the SMkr1L popttlatinn. 
To itlrstigatr the getter nature of the I. SIII. poätiwr isolates 
compared to the FSBI. nrgame eolatn wr hýhidiscd tenanic 
DNA to an rtnr tunrillancr of pathogens ;. ASP, DNA 
micmarrar. In total. 15 isolate ; enrn )SKI. pnaithe and eight 
LSIII. trQtwr) wrrr canparrd. Ile ASP array is do 
itmd to 
senior Reny flux, genetic convent and the nartur of horiutnufy 
uamfcrrrd DNA it a hacsrrial pnpulatinn. The resulting 
hshrichatinn in them in Inter 2. l: onrtvrrnh, plasmil DNA 
was isolated and compared fmm the same hartrrtal isolates to 
asn4 pLasmil content- 
rrwr 2in a hratsssap reprrsrnutinn of the 142 ASP mlcmarray 
rrponen wftich dcnwnstratrd poitive h hridiution to 
1)\A in 
two or more of the S. i mm samples and the II rrporxen 
rrprrwtving the S seer' Ssßi6 plumid p\S_1Fki 'Ilse overall 
hrhriejation data and the namrs and predicted functions of the 
gars are presented in 
Ikausn S2 ; suppo ting ittformation. 
Tlr pattern of relater hybridisation across all arair was 
rrmrkahh Immogrnous. wihonly Wtw42/142+11p\S 1146)of 
the total propswuon of the posihr coding sequences deenotssrat- 
isR arise hhridisation patterns. The coding sequences 
sirmnrwtradnRco nm n 1»hridisatinn patterns across all 15 straits 
included a nrnher of ägnutts eF ink. %*vlla . 
yys. regions and 
arqurncrt cssrrrsxxvfng to sruirnre and antimicrobial resistance 
tgrrr 2 and ltsppnning infestation Iksarts SI and S. '1. 
'11te csnrnsn antimrcrohial resisatre gems identifrd between 
'maser included Rrtrs conferring resistance to strrptnmwrn. 
macrobdrs. tetracycline. heu larunu and also some unspecific 
; @*. *.. ploumts-M9 
antintirmbial rrtiaanrc efflux Genes. The horttogcnous nature of 
hybridisation ctrgges< that variation between isolates is limited and 
dependent on ptasinid content- All the FSHI. pr during +vaim 
dennnaratcd significant hybridisation to sequences rorrnponding 
to bh genes, highlighird in Figure 2,1). \A from the FSill. negaticr 
stratum faied to hyhridir to thew targets. 
flasmid visualisation of placmid I)NA by agarose gel clectro- 
phnrevc smith all hshxidisrd strains resealed that in contrast to the 
LSBI. nrgatise isolates, all the FSIIL producing isolates had a 
large plasnid, we mughh estimated to he greater than (3 Khp in 
size , according to the marker plasmid). Despite the F: SHI. ncgathr 
isolates Lacking a large plasmid; these straits demonstrated similar 
resistance profiles, with the obvious exception ofcef'triaxorte ; data 
not shossnl. 'l hex data suggested that the ESBL grncs mas he 
heated on simple {t»nr MDR) extrarhronxxomal c1entenn. '11his 
hspotfrvs was supported ha' r\idenre of in 'in' horizontal plasmrl 
wander; nsto strains cultured two day. ap. ut from the moor patient 
weer identical 
in srmrspc, plastnid content and \IIC: resistants 
profile, with the exception of the . secondary strain taming a large 
pltsrnid and dipla%ing resistance to ceftriaxorr data not shown). 
F'urthrrntore jrquencing of a conjugative. 
ESHI. 
encoding 
pIasmid confirmed our sup-Trion (A' a simple extrachmnncontal 
element. 
Characterisation of blo genes 
PC: K mw prrformrd to drtrrt the bintt: nt, UKitty and Mat, tx-Ai 
gcnrs. Ftuthcr PC: R amplifications wýrrr pezfornrcd on DNA from 
all nraini that produced amplirnms with the bdacix. ro primer. 
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Figure i Demonstration of the absence and presence of genes from DNA isolated from ceftriaxone resistant and ceftriaxone 
sensitive S. sound isolates using the ASParray. Red boxes indicate presence of genes: green boxes indicate absence of genes. BLAST indicates 
reporter DNA dersory rat to the S some SsO46 genome. DNA was hybridized from isolates (left to right= DE01 15, DE0477, DEO6B5, DE0891, DEl 150, 
()EI 199 DE1256. DE0611. EG0201. EG0373 EG0395. EGO43D. EG 1007. EGID08 and EG1009. 
doi 10 1371 'ioumai. pntd. 00007019D l2 
Prirrtrr. that wee TrdYtr for the diem major (: 1. X-\1 clusters, 
bdts; ta. µs. Ui -m. rt. t and b14: ý. w.; sKre ulrctrd 144)j. 'ihrre 
"rains DF1kO I. F. (; 0187 and FI; 03i6, produced amplicom with 
the º/'m. u. primer% and tlr remaining 32 isolates produced 
atrgtlir. ttts with the bLy-to-µi prirnrn labe _t All Ti PCR 
amplrrm s. rrt srmtrrrrd. 
Sequence anah"ös of the PCR amphrons demonstrated that 
there arrr two difering 6! ae. tr, At genes present in the %, gvPa 
poptiluinn. thew were, b1a(ix nt . mot 
`n = 3, $°e; and dlat-rx t t. ts 
:n= 32,420o) Table Both genes : clae- x. M-a4 and hli4: tx-ns-t 
share 74% DX-IL hontolo ' with each other: hlat-tý, st-ts and 
bly; tatt_y differ by 12 and 6 nucleotides from the pnxursor 
Table Z Chaactensatbn of bAacTx. genes and the correspondng plasmids of ESEL expressing Shigella spa 
Iitr. ii D c. RaddY.. Rege tMJ 
DM 1n 
11 GO'e: +e EGtnN 27 
LG@02 19 
EG02S0 19 
LGO25b 19 
EG1H3t 28 
LG0773 i9 
EG03M 20 
Mß790 22 
EGO" 20 
LG0421 20 
EG0L24 21 
LG0130 21 
EGOt71 20 
LG0/72 20 
EG1007 22 
LGM09 20 
EG1009 21 
LG1010 21 
EG1011 21 
(G1012 20 
EG10tJ 19 
LG101t 19 
EG101S 22 
LG1016 20 
EG10t7 20 
LG1011 20 
EG1019 20 
L61020 20 
EG1021 21 
LG1072 21 
M10» 21 
LG102N 20 
E6102S 20 
bMrn   Plasmid size fkbp)* 
CTX-M-x 70 
CTxMis 100 
CTX-M-It 70 
crx Mis too 
CTx-M1s 100 
CTx M 1S 100 
CTX-M-Ir 70 
CTX M i5 100 
CTX-M-IS too 
CTx M1S 100 
CTX-M-1S 100 
CTx M is 100 
CTX-M-1S 100 
CiXM1S 100 
CTX-M-1S 100 
CTXMis 100 
Ox-M-15 100 
CTX M15 100 
CTXM-1S 100 
CTX M is 100 
CTX-M-15 100 
Ox m is 100 
CTX"M"IS 100 
CTX M 15 100 
CTX-M-IS 100 
Ox Mis 100 
CTX-M-1S 100 
CTxM is 100 
CTX-M-IS 100 
CTX M is 100 
CTX-M-IS 100 
CTx M is 100 
CTX-M-IS 100 
CTXMis 100 
CTX-M-1S 100 
'Ernmed PVYnId *e br egro`e gel elea-ophorbe whh inoM n maßtn. 
`CoMqatwn hapuengr akuwed pen donoý odl km the mean o( two rapicam& 
dott Ot 3i VtwmipntdD000 A2100i 
www. pbsntds. vy 8 
Conjuyetion haquenq° wa lranspown VCR (+l-) 
{A3x 10 -ý 
2.711,10 
258x10 ' 
4 
4.43,84 -: + 
4D0,. 84 -z f 
2.41x10-ý + 
150,. 10 -_ + 
2.92.10 -ý + 
138.10'ý 
233x10 
183"10-I 
327.10'1 + 
2D0,10 -" 
138.10-1 + 
3.59,10 - 
1.60x10-2 + 
1.43-. 10-1 
3.11x10-' + 
182.10-ý 
Sb8x10 `+ 
231x 10'2 
4ß8x10- 
2S0x 10 -1 
275x10 
3D0x10-' 
+ 
+ 
310x10'1 f 
1s5,10- 
290x10-° 
0 
r 
iBSx10-s f 
3.7Sx10 . 
8S7x10-1 + 
343x10 
236x10-' + 
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Roes srahm their reipeetive parent grourA, dlacix. m-t and 
blat-n, u. si 
Plasnud sizing. by sisualisatiso of the pre. ixn a arose gel 
eke ihnreti denumstrated that the estimated plaanid size 
coerrsprxxkd with either the bias-ha. u Gene Table b44: ha-u-Is 
was en naacntN, located on a plasmid larger than that associated 
with bfaet a-m 4. ilttsr ohrnations were confirmed 
1w Southern 
hlnnirng hs hridisannm of ptasmil DNA evrartions data not 
ahnw'ný. The ditirritc platmid teens and Etißl- net correlated 
prrciseh with two distinct zone clearance area; when strains sere 
sstsreptihitity trued w ih refiazislime. 
The strains expressing C: 1'- 
\1-214 demonstmrd less actisiv against cefLa7. kbrrbr when 
compared to (1N-\1-15 median zone sire, Cl X-\1-_'4; : Hmm, 
CI1 \I. 13.. Onwn iahk _.. 
AD bl4-ix as harbouring piasmids with the exception of the 
plastid it strain 1A 102"0 wear trancntiscihk with 
high conjuga- 
tinn finurnri s. ranging from 4.84 x 107 to 4. RH x 10' median 
I. SS)K 10 , per donor cell "fable "i. The nxhbdesation of one of 
then 64k-ta harbouring plaatnids was ärrthcr demonstratcd be 
cn njugat .a transfer of the placmid origittalhl 
fnxn S. faaan EG35ti 
(mm an Eire tranwonjutprx hark into a fully suscoptihlc. naise S. 
mmm strain at a sitrtilarh- hitch frrgnrncy. 
DNA sequence analysis of the pEG356 plasmid 
7hr FSBI. encoring grne blat. tx"uM appears to he generally 
restricted to Fiaaoltmterrar in Asia 141,421, with onh- sporadic 
reports of this gene in other locations 143). 
lherrfore, we selected 
the plasntid from isolate EG0356. earr%isg a bitsrix"rj. _v as 
it is 
applral* to this location, sr further charartmsation 
by DNA 
sequencing. 
Nasmid pFk, 356 was found to he a circular replicnn consisting 
of 70.275 nucksttcdrs, similar in size to another blosrjw. N., s 
emending plasmrl from Asp: pKWti. pKW6 was isolated 
from a 
Abdra"üe pwv. ir. ur vain from China in 2002. yet demonstrates 
limited DNA horrnk+gy to pEG356, with exccptnn to the IS81, 
encoding rrgioa 1441. pEG3. i6 was comparadsrly 
GC: neutral 
152.16%; and belonged to iscnn satihiin group F'/ ; on the has of 
the UNA wqurrre hon dogs to the replcation region) ; Figure 3). 
pF. G35h was predicted to contain 104 coding sepwnces. of which 
14 were ennsidered to he prudogenes on the basis of apparrra 
premature stop codtm, fratmhifu or missing start codous. 
the 
drnsiy ofcodng sequencing approached 955 and contained four 
main structural leatures, a reparation region, the ESIII. Rene 
encoding region wilt predicted hnntdo y to an 
ISFsp1 clement, 
an iern ABC transport system and a DNA transfer region : laheUsd 
red, pink, dark- blur and light blue. rrsprctnrty in Figure 'i. - 
pEC;: i: t i encoded the complete s-a gene set encoding a 
ennjttgatisr plus with high srg trice similarly to the transfer 
region from the F plamii sequence from F_ at 
K12 1451 Ac. 
A}kxt1918i 'Ibis is consistent with thew atv data demonstrating 
that this plamii is transmissible into an 
F. rah rrciprnt. 'De InrFl 
replication region was highly imilar to other 
Im-F plasmids, 
including the recently described CI\ \1.17 encoding plasmid 
pEK4'rl ; Ac. Ft l'l5739) isolated 
from an E. uh 025: 114-SI'131 
rpidrmr strait cirrtdating is the United 
Kntistom 146l. 
Additionally. pl'(, 'i% shared another : 10 Khp (psxiion 15,152 
to 4455 in pt. (i: i5sit of high segtrncr similarity with pEK499 
1461 'this region contains muhapk common hypothetical plasmid 
gores of unknown 
function. genes insulted in coniugati%c transfer 
teat( to aafl, plasmi l partitioning and a predicted single stranded 
1)\A binding protein :. ob). L'nlik pE. K499 the nsal- and ha(' post 
segrriptiottal killing genes are missing 
from within the plasmid 
maintenance region 14411. With respect to pEK499 and other 
1.1111. earring plasmids. pEG356 does not cam' mtdtgtle 
antimicrobial resiaanre gents, transposon,.. insertion sequences 
or am additional virulence associated , grrnet 
(4-l, 4ti, 47J; Chen et at. 
2017: Shen et al. Woodford rt al. , 411/<I'-: Chen et al. 2(X)7; 
Shen et aL 2(1(18: Woodford ct al 2.009j. 
In overall srnrrure, but not sizr, pI.: G356 shared the most DNA 
srclurncc similarity with the CoIBM plasmid pAPEC-01 Ac. 
DQ: 38142(1), isolated from an avian parhogrnir E. eoli strain 
j341 
Figure 41k pfG35ti -shared around 811% of the gene content with 
pAPEC: C)l. including the conjugation : trai replication 'r. and a 
putative ATP iron rang-ton system iro). The DO region consisted of 
four crating sequences, which include, a putative perntease. an 
iron hinding protein and an export associated protein. 
The b41x-M. 24 was located on an ISL-pJ lire element. The 
cnerall sequence of te IS&pI variant on pEG356 is 4,7'_'5 hp and 
3. (X11) hp shares 99% DNA homology with an ESBI. gene 
encoding element from an A' rob strait that was isolated in 
China: pOZ174 AF22526221 (48J. The blgrtxar. r4 tarrying 
region is also highh" similar DNA honuilogv to the 
equivalent region in the ptrvirnnh described plasmid, pKl'9fi, 
preluding the 159031) downstream of the War. -IT. M., 4 gene 
:; Figure 4' 1441.11ie ISFp1 element contains two pairs of inverted 
repeat ; Figure 4i the larger intend repeat 31 hp) flanks the 
complete elenetu, inclusive of sic coding sequences. The 'l'end of 
the ISJfpl element contained a ISl: rpl tranTosasc and a small 
hypotletiral coding sequence of untnown function which is 
spanned b% [wet IS1: 380 elements. The hlas. l t , M, tti 
icadjacent to 
two pseudogenes, whit-h wrrr understood to have encoded a 
consercrd hypothetical transposon protein and a maltose-iodur- 
iNe porin precursor. it is not clear what significance, it any. their 
gents are to the overall functionality of the element or the 
plasmid. 
All l*sBl. producing 5ltjge(1a were suhjeeted to I'CR to 
demonarate if all bist 
, 
genes were associated with the IS&pJ 
transposase. Ihe location of the PCR primers Tnp24F and "FnpR 
are highlighted in Figure 4 and were designed to produce an 
amplicon if the bla gene and the adjacent ISA(pl tramposasr were 
in the same location and orientation in strains with a blat: tý-rt"^+" 
A w-condarv forward primer was designed in equivalent location 
for thor strains with ablot, /x-M" 15 1 np 15F). "Iherelore, if bia<.. 1x, 
1.1 24 or the 
l+lßsnr 
-w. ts was ronsistemly adjacent to the 
ISEep/ 
cransposasc it would pro duce an amplicon of 414 lip in all grains. 
All ESBI. positive trains and ('I'X-%1-24) gt"trrand 
a PCR amplicon of the predicted size ; Table 2). Sequencing of all 
PC: R products demonstrated that all the hdtt: tx At-tr> and the 
h/at:, x-M. 24 gene were associated with an ISEpl tramposase, '1`he 
DNA secluerre from all PCR products was identical from within 
the [ranspoca'e gene up to and including the IS1380. 
Discussion 
Menthcr of the hirtrnahn. matrar that carry CITY-M famih 
ESBI-s have been isolatcd from main pans of the world since the 
mid 1919)s 1401. CAN-M gates have been ptrvitusiv identified 
from patho t enir l: nternhatrriacnu circulating in South Last Baia; 
such as Virtnatrt, 'f'hailand. Cambodia and Singapore 16,7,49.501. 
Additionally. our work has shown that ES131s arc conunonly 
found in organisms which constitute the "normal" 
, 
gastrointestinal 
flora it the general population living in 11o Chi Minh City 181. 
Such data predirts that intestinal flora may he a considerable 
rr rsssir of ESI1I. encoding genes and the genetic ek"mena they 
eirrulace on. permitting potential transmission to their pathogenic 
counterparts. 
C'1X-M genes in the , 
Yiqalfae hasr been previously reported in 
Argentina, 
, 
CXX. N, M-2) 1511, Korea ; IX-M-14) 1521 and from a 
traveler returning from India ;CI: Y-11-151 1531. More recently, 
. ý: 
WWwplosMds_or9 
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0 
16,000 
32,000 
f/we IA schewiMk repes. Mellsw Of the bf , as as McOdb Pblaf 
PEG336. ptt, 35t is a 7J275bp Inch plasmsd cauaeung tpi 
amour lraevw a. 1aolntght. d by the wamo s concentnc orclm actordsnq to the annotation of the of the plasmd lac. 
'M ý, ft. cola rd cwtk repetarsts coding seq vales on the forward strand the second circle represents coding sequences on the 
nand 'he coAng seettsences are cold by colour red plasmd replication orange conserved hypothetical. brown pseudogene, dark blue: 
edastaws gr"y sepreytyors tight blue tnrtM Qaeas'transhr light peek transposition 
dark pair degradation resistance and yellow- metabolism. 
'he dsrd come. ttrec cede repeseres the location Of pseesdogenes and the 
fourth circle represents the four main modules of predicted function red 
repkimeou pane transposfuat dark blue. anon transport and 
Igtst blue conluganasal transfer 'he fifth and final coloured circle represents the 
k. mas of the npeae saauract' Ilse pal ey eyntral Papis la repnsenes GC content ran9019 
hiss' high Iblacks to low Igrayý moan 52'r: and the 
serconday cerslnl graph tb' repesertb (a'f GOdrp bias ranging from 
high iblack? to low (grey the Ii[cp1 type element tanylrp the bfa(T  M: m 13 
drssspsrJsed by grev shdn4 
dot t01f 71 puma) pried WDW02 9cXi) 
\=arn w. 1 fk-rtTlrrl a IMArI C IX-M-44 11106d 1mm a 
. hiR4kAs. perm nt. a. 1 r, ith .l . awrr altn rrturninq 
111 1alun 
Inrtn (ism 1: 41 Ihr l mm11r1 . aair. wnlarnl hrrr in 
flit Chi 
Sluth l: iii harlnrrA dr Ai% u Is nMl W 1f u:. Rrn. r. 
I:. rrrtn rbu `"R'lrý" ohm A4ry tf u. v n Irurrl nu ird% in 
Asiat 
141.4: L %r'1 nu% how hrrn trandrmA aw ndrr h. atm. 
14'91. 
SII)* (' 1\-\I- I`, Lrrrº.. nit/ 11 i. rmrrtn( ... lfklwirk a. an 
twtl rtanl luth. iqlr, t . a. wnR h.. rtal-a q. arr. 
1 Inf. lilln. 111 Ihr 
Irtirlwad rwlr. l. 11 
SII)R MrpB. I. Iml. n. r1 .. th ('I \.. \I. I: t/. 
4 
IamtnR I. Ltmd. r. 11. imanrul, r. 
ih irnl. Iralwrn Inr kral 
irrarmrrw rydFN atwi ihr tr. urqu. r4irinn oI ewh lil: nmidi imn 
. whrr rtumvir. a. h. ti l rn iml>Jita. "d it ( : vr. d. t 
I hr mil nut it pF. c: 'i H. t. t irt to It for rr. utarrr6rG ALy: rý ºi 
inqtlr. rh. n ilk h Id. iwmid< m. n Ir t nmm. ut I Jr arr. wnlirw rl 
n. ii"ur .d pF. ('lllf., rtmarAahh high rnnpllatwui trrgtrnn niaý 
rrn. wr . utNard .? ttlLvi. o td thr gnrri .. rgo ai i Iw-. nmr: . t. tlir 
in thr hat irrial ptgwJ. wiiti. 1 hr <implisi'r tim tart- oI pf. (i'Ctn, auh 
a I. rº tt( rldiiwnl. rl rr. i"Iarrr Irtr: tullrw< rhat rhii i; a 
. nnrrrnp. wan rlrnrnr, wih ihr Alg: tý-Ai .. I a reimt :w guictiw. I hr hJi I-, ºI :i Irtr ha< her n 4w atrd on a rrLuirr"h untnrnpli" 
ý 
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ISEcp! -pEG3S6 
Tnp24F----º ,, " f--TnpR 
:i so om 0.4mº , 080 *wo 
1» 
ý« 
, 
ora 
` ý, "i.. cFý I»I ý Iý ýýI 'ý ý -I-- I 
1 174,241 
Flow" lA eclterwdk wpeNiiint. won of ISErphp(G3Si and DNA sequence 
adgnment highlighting correspkondng DNA homology 
taeeweew pIGela and PApfC O1 {e 4 'he MA spumen 
IM Pt", 3i6 and PM I 011 -11M A em . boned .., d c ompard n Art, +nn completion 
rood kA. " "t r. vtv" on ose diagram correspond to ttr re, p"cttve plasmad ytes 
and the black ntegrn highlight 10 Kbp intervals The genetic backbone 
of ow p& . 356 and pM`K 01 ldfat n shove, in yeN7 along wteh 
the various modules red: rw replrotion pink to (transposnon.. dank blue To uron 
uptaie. and Yet t)Lw" tro K)NA tmWer corgtgatbn" 
Areas with NO UNA homology between pk, 3S6 and pA a UI CoItM are shown with grey 
shdieo and Ow pni hack carespords to a nvgn/ed veo of 
lykcp rplk, 35G The ncn+ben on 15Ftp I-pEG356 correspond to the location of the 
element on the ho, t p/ar'd wwh . lagers wp rsentrtg I Kb teervels 
'he geres are kanR OrTAIN coded. pink m (transposition. orange unk iunknown 
ianetaen brows, per p, esadcper, e and dark pe, k ilq . v:. pre. "er 
k carom for the tranposon IKHarr h, a, hght by'np. 4F and 'npl& Ihr location of 
dtr MVCGV da. retrear^ o! the bi4r. u,. n hq U kited 'he repon a 
larded by an inverted repeat lblue trlancjesi and contains an additional inverted 
peat erpkw+, v Sarrlrno the vampov, a, u. -. Lmeypndknq n,,, ttd repeats are 
Inked by arrows 
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\ý º VII F nr .. rrr InrarrA aAjarrs w. a 11fq! . rant+naarr :ý 
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ihr I%t.. p/-61r rlrrnrni, ihr pta. mid. rr the . -irruLitinn r. l h. irrrrial 
. Inr it rrcpmählr Mr ilr inrrrasng rair sit i.. iLiti. m. Ilmirvrr. 
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Nidrh dlwl'milLlird ihnwQhnut awihrm \'irtnam. A. vrinn i4 a 
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ttv. nnrhslcta hsctrTtal padscrn, and owing to the lark of 
rnotwr rd existing sequesre hated mrthnb stich at multi kscun 
atpwtwr nping ISnI. we arr currendv unable to confirm donalip 
atnbncih 4a nor dxn. a, Further cpidemioksgral nsrstiga- 
Dan et(CTX-\1 cmainut waive cnmhirrd wirb a more srnnritr 
sequenced hard methndoksgv. fish as a used for Sdiaaa. la'I %phi 
is rrgt*rrd 15"1. \%r are rurtrnth am-sing the g neck name of 
the swain and the platmdc earning the FSIR genes. 
Our fndngs show a reamer from U% to 75% ceftriacnne 
reswrre it S. , wet owe jua two ycan in the kr% age group I to 
I wars. f duo dsrar, Ik wmpli g across the fin Chi Minh Ciry 
area etwentsg aplwrtimatrI 150 sq b1nmetres of \"ictnam and a 
pttpu4on n of apprmimr rh- IS milt on people we ha. c shown that 
the grneur r, $anattrn kw this fritanre pattern is the 
disrmnstim Pon diners F_SBI genes, of which new is cdtoninarn. 
'Ihsr are the leading Mflarr Of I. 81i in cbtucal SW Ja caws and 
their rapid spread ssggrtts that tart organivns are under stri-mg 
seirenos prefer. 71w use of third gr craion crpbalogxwms. 
mob as coal ertjsn wine and crfhin c in the ccmmuniry is 
common in Vernon, and pans the even she short tens usage of 
erlh"iacane and ocher hrod-slrrtrum crphak sporins in jeopardy. 
, 
SW k #f am capahle of carninc multiple piasmids with an 
array of phcnsnprs nchuding srulrncr and antnskmbeal 
reswsrr (Ib. 181.11r pr wire cif ti; zode in the gastrointestinal 
uracs of bsnsans in an deal etn"rmsrrnt to acquire hoeiznruall' 
vandrnrd grnruc ma rr1. Snail highh transmissible plasmid, 
that inpingr m the fittest a(the hat nvv be rapidh dicrmnacd 
under apprnpriatr conditrms. 
V aematn is a eoumv that in marn' retpt"eu it rrprrsenarisr of 
many pans of use world. 71w \'ruu rww econo". is des ekspnr 
rapidk and the cossrtn' is undergoing trantintn with an nrrrasint 
population urhanaatnn and shifting pancnn of infectrsus 
disearº In the at decade there has been a rraiuk on in species 
(mm S Jieram to S. , mean in the Southrm p roviters of Vietnam. 
Wih this shift has come the rinertTrre of ESBL S . 11aw. 
The, ' 
firrictGs from thr Virtnarnrr population should perhaps srrcc as a 
%arnninq for other rnttntrin encountering the came economic 
Iranvtinn. ihrpm rrssh'cnnlumnofpan-resaantShsv/iamales 
%acrinc dnclopment an incrracinGlh important objective 
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Characterization of rotaviruses causing diarrhoea in 
Vietnamese children 
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Faecal samples from 123 children admitted to the Centre for Tropical Diseases in Ho Chi Minh city, Vietnam, 
with acute watery diarrhoea were screened by negative-stain electron microscopy for vital enteropathogens. In 
addition to the 48 children who were found to be infected with rotavirus only, one had both rota-virus and 
astrovirus, two had adenovirus 40141, and one had astrovirus only. The rota-viruses were subjected to molecular 
analysis by electropherot}ping, G- and P-genotvping (by reverse-transcriptase PCR), and amplicon sequencing. 
By use of newly designed PCR primers, all 40 isolates could be G-genoryped and all but one P-genotyped. Novel 
variants of Gl - G1* - were the most commonly detected 
G-genotype and such variants of P[8] - P[8*] - 
were the second commonest P-genotype. The P[8*] and GI * amplicons were, respectively, only 92%-93.4% and 
88.1%-89% similar to the corresponding sequences from the prototype P[8) GI rotavirus, XT'a. Several unusual 
P- and G-genotype combinations were detected. Four (8%) of the children investigated were each found to be 
co-infected with two different rotasiruses. These data add to our knowledge of the continuing evolution and 
diversity of human rotaviruses, and should help in the rational design of vaccines. 
Diarrhoeal disease is the fourth commonest 
cause of death world-wide (Murray and 
Lopez, 1997). Of the more than 50 patho- 
gens able to cause such disease, rotavirus is 
arguably the most important, and is certainly 
so in infants (Hart er aL, 2002). Globally, 
rotavirus causes an estimated 418,000- 
870,000 deathslyear, rotavirus-attribu table 
mortality among children being markedly 
greater in developing countries than in 
the developed (Anon., 1986; Miller and 
McCann, 2000). 
Rotavirus is a small unenveloped virus 
with an 11-segmented, double-stranded, 
RNA genome. Two viral proteins (VP) 
are expressed on the surface of the virion. 
VP4 is encoded by genome segment 4 and 
must be cleaved proteolytically, to VP5* 
and VPS*, for full viral infectivity. VP7 is 
encoded on genome segment 9 and is a glyco- 
protein. VP4 and VP7 are both involved in 
attachment to, and entry into enterocytes, 
and are the major rotavinis-neutralizing anti- 
gens; antibodies to them confer immunity to 
infection. Epitopes on VP7 define the G (for 
RePr! Dr requests to. C. A. Harr_ 
E-mail: cahmm; pis. ac. uk; f": + 44 (0) 151 706 5805. 
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giycoproteln) types whereas those on VP4 
define the P (for protease) types. So far, 14 
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G-rapes and 20 P-types have been described. 
Infection with one rotavirus G-type does not 
usually confer protection against the other 
G-types (and, similarly, infection with one 
P-type only usually induces immunity to 
that P-type). Originally, rotaviruses were 
categorized, by use of hyper-immune sera and 
monoclonal antibodies, into G- and P-sero- 
types but increasing knowledge of the rota- 
virus genome permitted rotavirus genotyping 
(Gentsch a al., 1996). The G-genotypes 
fortunately coincide with the G-serotypes 
but there are now 20 P-genotypes and only 
12-15 P-serotypes. By convention, P-geno- 
types are designated by a squared bracket, 
and thus the antigenic formula of a rotavirus 
is described as, for example, P[8] GI IA. A 
global survey of rotavirus G-types indicated 
that just four G-types (GI-G4) accounted 
for most infections in humans (Gentsch 
er al., 1996). However, since then it has 
become apparent that things are not so clear- 
cut. G8 rota-viruses have emerged in Africa 
[now being responsible for over a third of 
cases of gastro-enteritis in Malawian infants 
(Cunliffe er al., 2001 b)], G5 has become 
more common in South America (Gouvea 
er al., 1994), and G9 has emerged as a new 
global serotype (Ramachandran er al., 2000; 
Cunliffe er al., 2001a). Rotaviruses show 
tremendous diversity (Cunliffe er al., 2002) 
and alter their genomic and antigenic structure 
by mutation (antigenic drift), re-assortment 
(antigenic shift), and internal re-arrangement 
(Desselberger, 1996; Palombo, 2002). This 
can result in the emergence of novel and 
variant P- and G-types, as well as new 
and G-type combinations. The live rhesus 
re-assortant vaccine that was recently intro- 
duced for routine use against rotavirus in 
the U. S. A. expresses G1-G4 (Lynch er al., 
2000). If novel or variant G-types emerge, the 
efficacy of this vaccine (and others) might 
suffer. The aim of the present study - part of 
a 1-year investigation of the aetiology of acute 
diarrhoea in Vietnamese children - was to 
explore rotavirus diversity in Vietnam, by char- 
acterizing the rotaviruses causing diarrhoeal 
disease in the environs of Ho Chi Minh city. 
SUBJECTS AND METHODS 
On each weekday between 27 September 
and 14 December in the year 2000, samples 
of faeces were collected from the first two, 
three or four young children (aged <5 
years) who were admitted to the Centre for 
Tropical Diseases (CTD) in Ho Chi Minh 
city because they had acute, watery diarrhoea. 
(The CTD is a 500-bed hospital serving all 
those who develop infectious disease in the 
local community. ) Each stool sample was 
frozen at - 20°C and transported to the 
University of Liverpool's Department of 
Medical Microbiology (Liverpool, U. K. ), 
for analysis. Approval for the study was 
granted by the CTD's Scientific and Ethical 
Committee. 
Electron Microscopy 
Faecal suspensions (10°, 4-20%, v/v) were pre- 
pared in phosphate-buffered saline (pH 7.2). 
Copper, electron-microscopy grids (3 mm 
in diameter; 400 mesh) that had been pre- 
coated in polyvinyl formal resin (Formvar©) 
were dipped into the suspension and air-dried. 
The grids were then negatively stained with 
2% (v/v) phosphotungstic acid and then 
viewed on a Philip's 301 electron micro- 
scope at an initial screen magnification of 
x 45,000. 
Extraction of Rotavirus dsRNA 
The faecal suspensions were centrifuged 
in a bench-top microcentrifuge (13,000 xg 
for 10 min). The double-stranded RNA 
(dsRNA) of any rotavirus present was then 
extracted from the supernatant solutions, 
using a guanidine-isothiocyanate-silica- 
glass-powder method (Boom er al., 1990; 
Gentsch et al., 1992). The dsRNA was 
analysed by PAGE and also used for G- 
and P-typing, by reverse-transcriptase PCR 
(see below). 
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PAGE 
PAGE was undertaken in pre-formed, p(1ly- 
acr)lamide gels (10%. vv), each lane being 
loaded with 30 lil of a dsRNA extract which 
had previously been heated to 65 C for 
10 min. Gels were run at 150V fi r 120 min, 
then stained with silver nitrate (Herring 
cr al., 1082) and finally photographed, for 
later analysis. 
P- and G-genotvpiing 
A semi-nested, multiplex, reverse-transcriptase 
PCR (RT-PCR) was used to identify the 
P- and G-genotypes represented in each 
dsRNA sample. The primers used enable the 
detection not only of P14), P[6], P[8], P[Q], 
P1101, Gl, G2, G3, G4, G8 and G9, but 
also of a novel variant of G1 (G 1') that has 
been detected in Malawi and a novel variant 
of P[8] - P[8'] - that has been detected 
in Malawi and the U. K. (Gentsch er al., 
1()92; Das er al., 1994; Gouvea a al., 1999; 
Iturizza-Gomara er al., 2000; Cunliffe er al.. 
2001b). Amplicons were subjected to electro- 
phoresis in 2% (wiv) agarose, stained with 
ethidium bromide and then visualized by 
ultra-violet trans-illumination. Genotypes 
were assigned by comparison of the banding 
patterns with those produced with rLAference 
. ample, t, f kn %vn genotvpe. 
Sequencing 
The variant G 1' and 1118'1 amplicuns were 
cut from the agarose gels, eluted and 
purified using a commercial gel purifi- 
cation kit (Qiagen, Crawley, U. K. ), cloned 
into pGEM-T (Promega, Madison, WI) 
and then transformed into Escherichia cols 
TG2. Plasmid DNA containing the insert 
was isolated from the E. eoli, using 
another commercial kit (Qiagen), and then 
sequenced, using M12 primers, by Lark 
Technologies (Saffron Walden, U. K. ). The 
sequences were compared using the CLUSTAL 
x software package (Institut de Genetique 
et de Biologie Moleculaire et Cellulaire, 
Strasbourg; Thompson er al., 1994) and 
weighted residue tables. 
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RESULTS 
Over the 3-month sampling period, faeces 
were collected from 123 children with 
acute, watery diarrhoea. Electron microscopy 
revealed that 48 (39%) of these children were 
infected with rotavirus alone, two (1.6%, ) 
with adenovirus 40'41, one (0.80x) only with 
astrovirus, and one (0.8%) with both rota- 
virus and astrovirus. Thus, 49 (40%) of 
the children investigated were excreting 
rotavirus in their stools. When subjected to 
PAGE, clear electrophoretic patterns were 
produced from the dsRNA extracted from 
46 of the 49 rotavirus isolates (Fig. ): 17 
(37%) were considered to be of the short 
electropherotype, 27 (59%) of the long, 
and two (T%) shared a mixed pattern. How- 
ever, the `long' and `short' electropherotypes 
34 
000, 
1 I4-oft 
ýi 
ý 
.... -,.. 
I 
FIG. The results of the PAGE of the double-stranded 
RNA from some of the rotavirus isolates, showing 
the short (lane 1) and long (lanes 2,3 and 4) electro- 
phoretic patterns. Lane 4 contained a sample from 
an isolate of the P[8] Gl* genotype whereas lanes 2 
and 3 contained samples from P[8] GI isolates. 
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each formed a broad category, with con- 
TABLE Molecular raping of the Preotarese mrapiruses 
siderable inter-isolate variation within each Isolate Electropherotype P-type G-tvpe 
category. 
The RT-PCR was successful in G-typing DE408 Unclear P[41 G2 
all 49 isolates and in P-typing all but one of DE409 Short P[4] G2 
them (see Table). In addition to the two DE410 Long P[8*1 G1* 
mixed infections detected by PAGE, a DE411 
Long P[8] G1 
further two cases of co-infection (each with DE412 
Long P[8*] G1* 
two rotaviruses) were detected by RT-PCR, 
DE416 Long P[8] G1* 
making a total of four mixed infections (8%) 
DE420 Long P[8*] G1* 
DE421 Short P[4] G2 
and 53 rotaviruses. Overall, the novel G1 * DE422 Long P[8] G1* 
variant (represented by 25, or 47% of the DE426 Short P[4) G2 
viruses) was the commonest G-type, followed DE428 Long P[8*] G4 
by G2 (20 viruses; 38%), and G1 (four DE441 Long P[8) G1* 
viruses; 7.5%) and G4 (four viruses)- 7.5%). 
DE442 Long P18*] G1* 
DE447 Long PIS*] Gl No G3, G8, G9 or G10 rotatiruses were DE448 Long P[8*] Gl* 
detected. In the P-typing, 24 (45%) of the DE454 Long P[8*] G1* 
viruses were found to be P[4], 17 (32%) to DE464 Short P[4] G2 
be the novel variant P[8*], eight (15%) to be DE469 Short P[4] G2 
P[8], three (6%) to be P[6], and one (2%) DE473 Long P[8*] G1* 
to be non-typeable. As expected, almost all 
DE474 Short P[4] G2 
of the short-electropherotype rotaviruses were 
DE476 Short P[4] G2 
Long *] 
P14] G2, but one was found to be P[6] G2 DE491 Short 
DE49 P[41 G2 
P[4] G2 
and another to be P[non-typeable) G2. Most DE492 Long P[8] G1 
of the long-electropherotype rotavirus strains DE495 Long P[4], P[8*] GZG1 
were P[8] (or P[8*]) and G1 (or G1*). DE496 Long P[4]! P[6] Cl' 
However, some unusual combinations - 
DE497 Long x2 P[6]/P[4] G4 
P[6] G1 and P[6] G4 - were detected. 
DE500 Short P[4] G2 
DE506 Long P[8*] G1* 
Finally, it is of note that the G1 strain shared DE507 Long P[8] G1* 
a slightly different but reproducible electro- DE514 Long P[8] G1* 
phoretic pattern from the novel variant G1* DE515 Long P[8*] Cl' 
(see Figure). DE516 Short P[6] G2 
Two of the novel P[8*] amplicons (Of 
DE517 Short P[4] G2 
301 bp) were sequenced and compared with 
DE519 Long P[8*] GI* 
DE520 Short P[4] G2 
the same regions in both the prototype Wa DE527 Short P[4] G2 
P[8] and Malawian P[8*] variant. The two DE531 Long P[8*] G1* 
Vietnamese P[8*] amplicons were 97.7% and DE532 Long P[4] G1* 
98.7% similar to the Malawian P[8*] and 92% DE540 Unclear P[8*] G2 
and 93.4% similar to Wa P[8]. Two novel DE542 
Short P[4] G2 
G1* amplicons (of 118 bp) were sequenced 
DE544 Unclear P[8*] G1* 
DE546 
and compared with the same region of DE547 Long 
P[4] G2 
ng P[4] G1* 
Wa G1 and a novel Malawian G1*. The DE548 Long P[4] G1* 
Vietnamese strains were 99.2% similar to DE550 Long P[4] G1* 
each other and 92.4% and 91.5% similar DE551 Short P14) G2 
to the Malawian G1*. They were very DE552 Short Not typeable G2 
different from the Wa Gi, however, being DE553 Long x2 P[8]/P[41 G1/G1* 
only 89.0% and 88.1% similar over this Long x 2, Two different long electropherotypes were 
small region. observed. 
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DISCUSSION 
Rotavirus was the most important viral 
enteropathogen in this survey of the aetiol- 
ogy of childhood gastro-enteritis in Ho Chi 
Minh city. Vietnam, being responsible for 
40°,, of the cases admitted to hospital. This 
frequency lies within the world-wide range 
reported for hospitalized infants by Hart and 
Cunliffe (1999). and is close to that, of 50%. 
reported both for a rural area close to Ho 
Chi Minh city (for the period 1994- 1996; 
Nishio et aL, 2000) and from four other 
cities in Vietnam (for the period 1995-2000; 
Nguyen u al., 20)01). In a global collection 
of rotaviruses, Gentsch er aL (1996) found 
that four strains - P[81 G1, P[4J G2, P[8J 
G3 and P[8) G4 - predominated, although 
some of their samples were non-typeable. In 
the present study from Vietnam, every strain 
was G-typeable and only one strain was not 
P-t peable. Although P[8] G1 (and variants 
on it) formed the commonest `strain' 
detected in the present study (represented 
by at least 20 isolates), the many G1* and or 
P[8*) viruses would not have been typeable 
had not the newly designed PCR primers, 
which detect these variants (Cunliffe et al., 
2001 b), been employed. The next common- 
est strains were P(4J G2 (confirmed for 16 
isolates) and then, much more rarely, P[4] 
G1* (at least four isolates) and P18*1 G4 
(two isolates); no G3 strains were detected. 
In previous studies of Vietnamese rota- 
viruses (which took no account of the P[8] 
and Gi variants), the results have been 
slightly different. Although Nishio et al. 
(2000), working in a rural area on the 
outskirts of Ho Chi %Ainh city, also found 
G1 to be the most common G-type (29%) 
and G3 to be absent, they observed more 
G4 isolates (27%) than G2 (16%). However, 
28% of their isolates were not G-typeable. 
When Nguyen er al. (2001) analysed a subset 
of the rotaviruses they had collected in four 
Vietnamese cities, they found that G2 pre- 
dominated (53%), with significantly fewer 
isolates typed as GI (13%), G4 (17%) or 
204 
G3 (3.6%); only a small proportion of their 
rotaviruses were not G-typeable using the 
conventional PCR primers but 10% were 
not P-typeable. 
It appears that the G1* and/or P[81* vari- 
ants detected previously in Malawi in 1999 
(both G1* and P[8*]) and the U. K. in 
1995- 1996 (P[8*] only) are also circulating 
in Vietnam. Full confirmation would require 
nucleotide sequence analysis of the VP4 and 
\P7 genes. Four of the patients investigated 
in the present study were each found to be 
co-infected with two different rotaviruses. 
Such co-infection has been observed before, 
predominantly in developing countries such 
as Bangladesh (Tabassum etal., 1994), India 
(Jain er al., 2001) and Vietnam, where 9% of 
the infections investigated by Nguyen er al. 
(2001) were with two different rotaviruses. 
In co-infected individuals, two different 
rotaviruses can infect the same entero- 
cyte, allowing novel viruses to arise by 
re-assortment (Desselberger, 1996; Palombo, 
2002). 
By demonstrating a high prevalence of 
variant GI and P8 rotavirus genotypes and 
the occurrence of unusual G- and P-genotype 
combinations, the present results again reveal 
the tremendous diversity of human rota- 
viruses (Cunliffe er al., 2002). Knowledge of 
this variation is important to those designing 
and using the next generation of rotavirus 
vaccines, since such vaccines may need to 
encompass the recently detected G- and 
P-types, including the variants. At the nucleo- 
tide level, the Vietnamese P[8*] variants 
were > 98% similar to the Malawian P[8*]. 
However the Vietnamese G1* were very 
different from the prototype Wa Gi and only 
92% similar to the Malawian G1*. Whether 
the variant P[8*] and G1* genotypes are 
sufficiently different from the progenitor 
P[8] and G1 strains to allow them to cause 
disease in those immunized with P[8] GI 
virus is not clear. However, it is noteworthy 
that the Malawian P[8*] G4 strains formed 
a cluster, with only 90% homology, at the 
amino-acid level, to other P[81 rotaviruses 
(Cunliffe er al., 2001b). 
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Appendix B: 
Clinical Record Form of The RCT in Chapter Six 
CHILDHOOD SHIGELLOSIS STUDY EG ý 
Name: , 
Hospital ID [SHS]: 
Address: , Ward/Village: 
District: , Province : 
Age (m)[Thäng]: , 
Boy/Girl, Weight: kg, Height: cm 
Date of Admission to Hospital [Ngäy väo vien]: 
Date of Study [Ngäy väo NC]: Time: 
Duration of Present Illness [DA benh bao läu]: hours 
PAST HISTORY [TI EN S Ü]: 
Febrile convulsion [Söt lam kinh]: Co 
Bloody Diarrhea [Tieu dam mau]: Co 
, Khöng 
, Khöng 
Breast feeding [Be cö dä/dang bü me chüt it näo khöng? ]: Co , Khöng 
FAMILY HISTORY : 
Hoc hrc Me [Mom education]: Mü chtr , 
TieuH 
, TrungH , 
CD_DH 
Kinh to [Econ. Status]: rat ngheo , ngheo , trung 
binh 
, 
khä giä 
SO nguäi cling 1 trong nhä [Total people living together] 
Nu6c sinh hoat [Running water]: song-ao , gieng , cö döng ho nuäc 
Di tieu tren söng/ao [Public toilet] , nhä cö cäu tieu rieng [Private toilet]: 
LO7 
Appendices 
HISTORY OF PRESENT ILLNESS [BENH SÜl: 
Day 1 Day 2 Day 3 
Fever (+-A- Söt 
Convulsion (No. ) Co 'ät - So lan 
Vomitting (No. ) [Oi mira - sö Ian 
Abdo. Pain +/- Daubun 
Tenesmus +/- Mot ran 
Wate Dia(No. Tieulön - Sö län/n ä 
MucoidDia(No. Tieu that -So lan/n ä 
Bloody Dia o. [Ti&ic6mki--S61&vhpAyj 
Abd. Distention (4 - Churn bun 
Rect. Prolapse (+/- [Sa truc trän 
Antibiotics used: (r&&lieuKSdädüng/ Khöng 
cö/Khöngbiet) ABWN/U 
Others 
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OBSERVATION SHEET EG 
Name: , Hospital ID: 
Date 
Time 
Study Time 0 6 1 
2 
1 
8 
2 
4 
3 
0 
3 
6 
4 
2 
4 
8 
5 
4 
6 
0 
6 
6 
7 
2 
7 
8 
8 
4 
9 
0 
9 
6 
10 
2 
10 
8 
11 
4 
Drug C/ 
G 
41 
40 
Co 39 
38 
37 
36 
T° (Number) 
Pulse 
M ch 
BP HA 
RR [Nhip thd] 
Dehydration 
[khöng/vira/nin 
Vomitting [6i] 
Seizure [co 
iot 
Ab. Pan [Dakyng] 
Tenesmus [ran] 
RectalProlaps 
e +/- 
Total stools /24 
h 
Time of I" non- 
bloody stool [lieu 
khög ntäu Ian 
däu 
Time of l 
normal stool 
[phin tot Ian 
däu 
Drug Rash 
Stool WBC 
Stool RBC 
WBC [BC] 
Pit [TC] 
Hct 
Glucose 
Bacter [VT] 
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OBSERVATION SHEET EG 
Name: , Hospital 
ID: 
Date 
Time 
Study Time 12 
0 
12 
6 
13 
2 
13 
8 
14 
4 
15 
0 
15 
6 
16 
2 
16 
8 
17 
4 
18 
0 
18 
6 
19 
2 
19 
8 
20 
4 
21 
0 
Drug C/G 
41 
40 
39 
C° 38 
37 
36 
T° (Number) 
Pulse [Mich] 
BP [HA] 
RR [Nhjp thä] 
Dehydration 
[khöng/vira/nang 
Vomitting [oi] 
Seizure [co giät) 
Abd. Pain 
[Daubing] 
Tenesmus [ran] 
Rectal Prolapse 
satrvcträ +/- 
Total stools /24 
h 
Time of Ir non- 
bloody stool [lieu 
khö mau ]an dau 
I' normal stool 
[phän tot Ian 
dau 
Drug Rash 
Stool WBC 
Stool RBC 
WBC [BC] 
Pit [TC] 
Hct 
Glucose 
Bacter [VT] 
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CLINICAL SUMMARY EG 
Name: , Hospital ID: 
Nutrition Status: Overweight / Normal / Malnutrition I/ II / III 
Duration of illness before study: hours 
Fever Clearance Time: hours 
Bloody Diarrhea Stopping Time: hours 
Diarrhea Stopping Time: hours 
Bacteria] Clearance Time: days 
Complications during Study: 
Pathogen: 
Fully sensitive / NaIS / NaIR / MDR / others 
Adverse drug Reaction: rash / drug fever / anaphylaxis 
Outcome: Cure / Clinical Failure / Microbio. Failure / Clinico-microFailure / Relapse 
Doctor: 
FOLLOW-UP 1-2 WEEKS AFTER DISCHARGE 
Date: 
_/_/ 
200 
Healthy: Y/N 
Diarrhea: Y/N; Others: 
Stool / Rectal swap taken: Y/N 
Doctor: 
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EG Shigellosis in Children Study CHECK LIST 
[BANG KIEM NHiUNG VIEC flA LAM XONG 41 
1. CLINICAL DIAGNOSIS OF INVASIVE DIARRHEA: 
" Mucoid-bloody diarrhea [Tieu dam mau] 
" Mucoid diarrhea+AbdPain/tenesm. [Tieu long cö nhöt + dbug/rän] 
2. CONSENT TO TRIAL [Cha me BN ky ding y väo NC] 
3. RANDOMISED [Mä bao thu dung thir to NC] 
4. STOOL/RECTAL SWAB TAKEN FOR CULTURE & EXAM (Dayl) 
[Läy mau phän giri phöng XN khi väo nghien cüu] 
5. BLOOD FOR CBC, BG [Thin CTM, DH] (Day]) 
6. EVERY 6-HOURS TEMPERATURE AND ASSESSMENT 
[Ghi mach nhiet, so Ian di tieu vä tinh chat phän möi 6 gi&] 
7. STOOLS/RECTAL SWAB FOR CULTURE [LAy mau cäy phän möi ngäy]: 
" Day 2 
" Day 3 
" Day 4 
" Day 5 [neu can] 
" Day 6 [neu can] 
8. CLINICAL SUMMARY [Ghi ban töng ket 1äm sang] 
9. ONE WEEK FOLLOW-UP & STOOL/R. SWAB CULTURE 
" [Tai khäm vä Cäy phän sau xuät vien I tuAn] 
Doctor: 
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Appendix C: 
Study Information Sheet and Consent Form 
SCS Y TE TP HÖ CHI MINH CONG HÖA XA HÖI CHO NGHIA VIET NAM 
BENH VIEN BENH NHIET DdI Döc lip - Tu do - Hanh phüc 
(Ho %i talfor Trn pi raº Dbeases) 
190 Him Tv, F. 1 Q. 5 
DT: (84 - 8) 8353704 - 8353804 Ngäy 15 thing 6 näm 2006 Fax: (84 - 8) 8353943 - 8353904 
ttobý 
Dr Hä Vinh 0913 195507 
INFORMATION SHEET 
OXTREC No: 010-06 
An open randomized comparison of Ciprofloxacin 
versus Gatifloxacin for the treatment of shigellosis in 
children 
Introduction to the study 
Your child is being asked to be in a research study on shigellosis. Shigellosis is a 
serious infection and in Viet Nam is now becoming difficult to treat. This study is 
designed to see if we can improve the treatment of shigellosis. 
Stools Tests: 
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Whether or not your child takes part in the study your child will be given the same 
standard of care for her/his illness. If you wish your child to take part in the study we 
will randomize the treatment your child receives to one of two alternatives. We do not 
know which one your child will receive or which is the best treatment. We believe both 
treatments to be effective. We will ask to take stool samples during your child stay in 
hospital and for the next week after your child are discharged from hospital to ensure 
that your child have cleared the infection. This is very important to ensure that your 
family and friends are not at risk of infection. Further tests on these stored samples may 
be undertaken in the future to further the understanding of this disease. 
Confidentiality 
We will keep the information we get from you as private. Your child name will not be 
on your test results-we will use a number instead of your name. These results will be 
under the authority and supervision of the doctor responsible for your child inpatient 
care. The doctor will discuss these results with you. All this information will be kept 
confidential in your child medical records. Your child name will not be mentioned in 
any papers or speeches about the study. 
Risks 
There are very few risks to your child from being in our study. All the drugs being used 
in this study are routinely used in Viet Nam. 
Costs 
There will be no cost to your child. 
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Refusal to participate 
Your child may refuse to be in any parts of the study. If you do not want your child to 
be in the study that decision will not in any way interfere with your child ability to 
receive proper medical care or attention. 
Questions: 
If you have any other questions about the study please ask the doctor on the ward or the 
doctors named at the top of this sheet: Dr. Hä Vinh 0913195507 (This is the doctor you 
see every day. Please ask any nurse or doctor who will help you) 
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TRANG THONG TIN 
OXTREC No: 010-06 
Nghien ciPu so sänh ngäu nhien täc dung giira 21oai 
thuöc Ciprofloxacin vä Gatifloxacin trong dieu tri 
bgnh ly, trtrc trüng tre em 
BS Hä Vinh 0913 195507 
Giöi thigu nghien ciru 
Con (hay chäu) ciia ÖngBä dLrgc de nghi tham gia väo nghien ciru beh ly truc trüng. Li 
trtrc trüng lä möt loai benh nhiem trüng näng & Viet Nam, va hien nay dang tr& nen rät 
^u tri benh ly, truc khö dieu tri. Nghien cüu nay dLrgc thuc hin nhäm cai tin viec die 
trüng. 
Cäc xkt nghigm 
Cho dü benh nhän Co tham gia väo nghien cüu hay khöng thi deu nhän dugc tieu chuän 
dieu tri vä chAm söc nhu nhau. Neu tham gia väo nghien cüu Con (chäu)Ong/Bä se nhän 
dugc dieu tri ngäu nhien theo möt trong 2 cäch. Chüng toi se khöng biet con/chäu ban 
se dugc dieu hi theo phuomg cäch näo cüng nhu each näo 14 tot nhät. Tuy nhien chüng 
töi tin ring cä 2 cäch dieu hi dö deu CO hieu qua. Trong suöt th&i gian con/chäu Ong /Bä 
nim vien, chüng töi se tien hAnh My mau phän de xet nghien tim vi trüng gäy benh. 
Döng thäi sau 1-2 tuAn sau khi xuät vien, chüng toi 1ai 1äy mäu phän nhu tren möt Ian 
nüra de däm bao con/chäu Ong/Bi hoän toän khöng cön bi nhiem trüng nir. M& dieu rät 
quan trong lä phäi chic chin ring nguöi than trong gia dinh va ban be cüa con/chäu 
Öng/Bä khöng cö nguy ca bi nhiem benh. 
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Bäo mät thong tin 
Chung toi se bäo mot nhüng thong tin thu dugc tir benh nhän. Chung toi sa ghi mA so 
thay vi ghi ten cüa benh nhän tren cäc mau xet nghiem, do dö ten cüa con/chäu Ong/Bä 
se khöng the hien tren cäc ket qua xet nghiem. Cäc ket qua nay se dugc kiem soät chot 
the bm Bic si, nguäri duy nhat dugc biet ket qua vä chju träch nhiem dieu tri benh nhän, 
cling nhu thong bäo ket qua den hp. Tat cä thong tin trong qua trinh dieu tri deu dugc 
ghi nhon vä No mot trong ho sa benh An. Ten cüa con/chäu Öng/Bä se khöng dugc de 
cop den trong bat ky bäi bäo hay thäo Won näo ve nghien ciru nay. 
CIc nguy ca 
Se cö rät it nguy ca khi con/chäu Öng/Bä tham gia väo nghien cau nay. Cäc loci thuoc 
dieu tri trong nghien ciru lä nhiing loci thuoc dirgc dung pho bien a Viet Nam. LAy phän 
bang que bong gön cö the gAy khö chju chat dinh. 
Chi phi 
Con chäu ÖngBä tham gia väo nghien ciru se khöng phäi tön bat ky chi phi näo. 
Tir chi tham gin nghien cüu 
Benh nhän cö the tir chi tham gia nghien ciru bat ca phän näo cüa nghien ciru. Cho dü 
con/chäu Öng/Bä khöng tham gia nghien cvu ciang dLrgc dieu tri phü hop Oi benh ly 
cüa minh. 
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Cäc thAc mac ve nghien ciru 
Neu OngiBa Co bat cu thäc mac nao khic ve nghien ciru nay xin vui long lien he v&i 
Bic si tai khoa dieu tri hay Bic si CO ten tren däu trang thong tin nay: BS Ha Vinh 
0913195507. (flay la Bic si ma Ong/Bä/Chiu gap hang ngäy tai khoa. Ong / Ba cling cö 
the höi bat cir Bic si hay Dieu duäng nao trong khoa de dugc giüp dä). 
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CONSENT FORM 
OXTREC No: 010-06: 
An open randomized comparison of Ciprofloxacin 
versus Gatifloxacin for the treatment of shigellosis in 
children 
Consent from patient's parents/caregivers: 
I have been fully informed of the possible risks and benefits of taking part in this study and 
agree to let my child take part. I agree that the samples may be stored and that further tests may 
be undertaken on these samples in the future to further the understanding of this disease. 
Name of patient parents Signature: 
Relationship with patient: Date: 
Name of physician Signature: 
Date 
If the patient's relative give verbal consent to take part in the trial but is unable to sign, 
the physician can record the consent here: 
Name of physician: Signature: 
Date: 
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GUY DONG Y: 
OXTREC No: 010-06: 
Nghien ciru so sänh ngäu nhien täc dung giira 21oai 
thuöc Ciprofloxacin vä Gatifloxacin trong dieu tri 
bgnh ly, trtyc trüng tre em 
Döng cüa cha me hoäc ngtrö'i nuöi du"&ng benh nhän: 
Toi dä dugc nghe Bic sy/ Dieu dung cho biet dieu thu4n Igi vä khöng thuän 1gi cö the xiy ra 
khi tham gia vao nghien ciru nay, vä töi döng y de con toi dugc tham gia. Töi döng y nhirng 
býnh phäm cb the dugc trü tai de ve sau lam cic xet nghiim cän thiet cho su hieu biet ve benh 
My 
. 
Ten cüa Cha mq: Ky ten: 
Quan hý vüi bgnh nhän: Ngäy: 
Ten thäy thuöc Ky ten: 
Ngäy: 
Neu thin nhan benh nhan nöi döng y nhtrng khöng viet chü dirge thi thäy thuöc ghi läi 
döng y vä ky ten diröri day: 
Ten thäy thuöc Ky ten: 
Ngäy: 
220 
Appendices 
Appendix D: 
International Standard Randomised Controlled Trial Number Registration 
T cscarch stmh to nnnpaee wit thxtenaI drugs, gotdloxacm with ciprofloxuciu, for the 
., menu of dvsceten in children 
-titrolird trial of gallfln xa lrl versus ciprofloxaCut 
for the treatment of bacillary 
. ten u. children 
'014, The %orld 11e0h lhgm-atwu (WHO) organised a neetingofexperts voundthe world 
i... recoennended that ciprofloaacui or other fluomquinolones should be used to treat shigellosis 
c luldren as well m adults. However after being used for some years to treat shigellosis, the 
clinical response to rignof oxacin trrahnenl has decreased, strains of Shigella dysenteriae type I 
t. mt to ipn, floxacm were also detected This is why searching 
for alternative regimen is 
it- !s seeded This study will compare the currently recotranendod WHO regimen with a 
ýo ve, affordable and potentially more active fluor uinotone. ie, gidifloxacm. 
:.., s ipprmal r relveil from Oxford I mplcal Research Ethic., 
Committee on the 2(hh hole 2006 
aA: Rf( 01(-O6) 
v-label raidonused contmllcd teal 
et Nero 
.. cells it setters 
Patients aged I) - 14, either sex 
ssmptomatic uncomplicated dysentery 
eves co-lent 
'-sent given 
'11(14 
'in letetl 
ýI emus arc randomised to 
Iptotloxacul It mg kg body weight taken orally every 12 hours 
for a total ofh doses in 3 
or 
1 : wifloxacm 10 mg'kg body weight taken orally every 24 hours for a total .1 73 dosen in 3 days 
will occur for 10 das after disclur a from the hospital 
irre of treatment 
l Pets Went fever at Day 5 
'- Failure to rice corrgNdely the at-ion syrnptorn at Day 5 
Stool culture positive at Day 3 of treatment 
\e,, sl for 'rescue' trcanrcnt with cdlrcixonc 
he development on treatment of any co Ikalion 
eyes elcamncr time, from the start of treatment until axillary teteperature falls to 371°C and 
i. auu at of teiow the, value for greater than 49 hours 
! sloxxfy diarrhoea clearance tune the time to the last stool containing visible blood passed 
>mrrtxea clearance time the time to the first formed ston.. 
Hacterlal clearance tune tune to the last ostlivc stools culture for Shi ellx 
'c Wellcome Trust 161 (grant ref 0613301 
, 
Publish your protocol 
ýý TRIALS 
ooe. Amb J. u"n. i 
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